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1.1 The importance of arginine and of its de novo  synthesis 
 
The amino acid L-arginine is an essential component of all living organisms.  
Its importance resides in the variety of functions that arginine itself, along with 
some intermediary metabolites involved in its de novo synthesis in the cell. Figure 1 
shows the main metabolic interconnections of the de novo biosynthesis of arginine 
and its intermediates. 
 
 
 
Figure 1: Schematic representation of the main metabolic 
interconnections of Arg biosynthesis. Adapted from[1].  Only key 
intermediates are shown. adi: Arg deiminase pathway; ast: Arg 
succinylase pathway; adh: Arg oxidase/dehydrogenase/transaminase 
pathway[2]; arg: arginase pathway; adc: Arg decarboxylase pathway; 
cyd: Orn cyclodeaminase; CP: carbamylphosphate. 
In addition to the above-mentioned important metabolic interconnections, 
Arg has the following essential roles: 
 
• used as building block of many proteins  
• precursor of the energy storage compounds: 
o arginine phosphate, involved in muscle contraction in invertebrates, 
and  
o creatine phosphate, which is stored in muscle and brain in 
vertebrates. 
• intermediate metabolite of the urea cycle. 
• precursor of the signaling molecules nitric oxide (NO), agmatine and 
glutamate in mammals. 
• nitrogen storage compound in plants and cyanobacteria 
 
In many prokaryotes, fungi, and plants the de novo biosynthesis of Arg 
proceeds from glutamate in eight enzymatic steps (Figure 2).  The first committed 
step of this pathway is the N-acetylation of glutamate.  Acetylation of the early 
Introduction 
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precursors of Arg distinguishes them from the analogous intermediates in the 
biosynthesis of proline[3, 4].   
 
 
 
Figure 2: Outline of pathways for the de novo  arginine biosynthesis from L-
glutamate.  Prokaryotic genetic symbols are in small italics, yeast genetic symbols in capital 
italics. EC numbers are indicated. 
The Arg biosynthesis pathway in prokaryotes and lower eukaryotes and the 
mammalian urea cycle share several enzymes and intermediates, leading to the view 
that the urea cycle has evolved from the Arg biosynthesis pathway.  In addition, 
enzymes of the urea cycle and their counterparts in the Arg biosynthetic pathway 
share sequence and structural similarities. 
One of the key steps, the synthesis of the intermediate metabolite ornithine 
can be catalyzed by either of two enzymes (Figure 2) from αN-acetylornithine 
(AOrn): 
 
(i) AOrn deacetylase (AOD, EC 3.5.1.16), also called acetylornithinase 
(AO), or,  
(ii) ornithine acetyltransferase (OAT, EC 2.3.1.35).  
 
Epitomizing the linear and “cyclic” pathways respectively. 
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1.2 The linear pathway of arginine biosynthesis 
 
In the linear arginine biosynthetic pathway, the flow of acetylated 
precursors, which, in most cases, starts with the acetylation of glutamate by the 
enzyme N-acetyl-L-glutamate synthase (NAGS), leads to the formation of AOrn 
(Figure 2).  AOrn is then deacetylated to form ornithine by the enzyme 
acetylornithine deacetylase (AOD) the product of the gene ArgE (in bacteria). 
In the last part of the pathway, Arg is synthesized in three additional steps 
from ornithine.  The first of them involves the carbamylation of Orn to form L-
citrulline (Cit).  In most organisms studied until now, Orn is carbamylated to Cit by 
the enzyme ornithine transcarbamylase (OTC, EC 2.1.3.3).  Escherichia coli was 
found to contain two paralogous genes, argF and argI whose products can form 
hybrid trimeric forms of OTC[5].  
The second substrate of the reaction catalyzed by OTC is carbamylphosphate 
(CP).  In most microorganisms CP is synthesized from HCO3-, ATP, and glutamine 
by the enzyme carbamylphosphate synthetase (CPS, EC 6.3.5.5).  CP can be 
synthesized by a single CPS or by two distinct enzymes.  The single-CPS situation is 
typical of Gram-negative bacteria such as E. coli and Pseudomonas aeruginosa[6, 7].  
The double-CPS situation has been found in some Gram-positive bacteria, 
represented by Bacillus subtilis, and in fungi[8].  In those organisms devoid of CPS, 
CP may be generated from Arg by the catabolic arginine deiminase (ADI) 
pathway[9], or, perhaps in the hyperthermophilic archaeon Pyrococcus furiosus[10, 
11] by a carbamate kinase using ATP and carbamate as substrates. 
The intermediate citrulline is converted by the enzyme argininosuccinate 
synthase (ASS, EC 6.3.4.5) into argininosuccinate (AS), which is then split into Arg 
and fumarate by the enzyme argininosuccinate lyase (ASL, EC 4.3.2.1) in the last 
step of the Arg biosynthetic pathway (Figure 2). 
 
 
1.3 Variant of the classical pathway of arginine 
biosynthesis and its occurrence 
 
Glutamate can be acetylated in the presence of OAT from AOrn in the “cyclic” 
pathway (Figure 2), to form Orn and N-acetyl-L-glutamate (NAG). This enzyme was 
discovered in Micrococcus glutamicus as a substitute for AOD[12] while studying the 
fermentation of Orn in this microorganism.  
In some cases, OAT is able to synthesize NAG de novo from AcCoA and 
glutamate, however, there are no detectable similarities between these bifunctional 
OATs and the classical NAGS[13].  Since its discovery in the late 50’s, OAT has been 
found encoded in the genome of 3531 organisms (Table 1). In most cases the 
corresponding gene product have been annotated as bifunctional (that is, 
transacetylase as well as NAGS) on the sole basis of sequence similarity, but only a 
small subset of these gene products have been experimentally characterized to 
confirm whether they are indeed mono- or bifunctional OATs[13]. 
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The presence of a mono- or bifunctional OAT does not necessarily exclude the 
presence of NAGS, since in some instances both genes are present in the same 
microorganism[13]. In those organisms with a monofunctional OAT, NAGS is 
supposed to play an anaplerotic role by priming the acetyl cycle with the first 
molecule of NAG.  Most intriguing is the functional redundancy in those organisms 
with bifunctional OAT, which also contain NAGS; In these organisms the AOrn-
dependent transacetylation is believed to be quantitatively the most important 
reaction for NAG production[13], although no data has been reported that confirm 
this hypothesis. 
 
Table 1: Occurrence of OAT in sequenced genomes. The sequences 
in the database at the National Center for Biotechnology Information 
(NCBI) (http://www.ncbi.nlm.nih.gov/protein) were searched using 
“ornithine acetyltransferase” as query.  The first figure is the number of 
hits, whereas the second number in each pair is the number of sequenced 
genomes at the time of the search. 
Bacteria (3148/173101)  
 Proteobacteria (1378/75698) 
  α-proteobacteria (458) 
  β-proteobacteria (433) 
  γ-proteobacteria (340) 
  Others (147) 
 Firmicutes (848/26944)  
  Bacillales (477) 
  Others (371) 
 Actinobacteria (524/27861) 
  Actinomycetales (460) 
  Others (64) 
 Cyanobacteria (136/6916) 
 GNS bacteria (42)  
 Spirochaetes (27/1446)  
 Green sulfur bacteria (26) 
 Others (167)  
Eukaryotes (291/291145)   
 Fungi (205/62076)  
 Green plants (65/113035)  
 Others (21)  
Archaea (88/5220)  
 Euryarchaeotes (87/3201)  
 Others (1)  
Unclassified 
(2/55) 
  
Viruses 
(2/63967) 
  
   
 
This “cyclic” pathway has been referred frequently to as “more evolved” than 
the linear pathway, but biochemical and phylogenetic analyses suggest that the loss 
of OAT could have been one of the reasons for the recruitment of AOD in the 
pathway of arginine biosynthesis[13]. 
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The fact that there are a few organisms in which the NAGS gene is absent 
while an apparently bifunctional OAT is present leads to the conclusion that these 
organisms rely on a bifunctional OAT for NAG synthesis and therefore for Arg 
biosynthesis. 
Recent studies have revealed that there are other alternatives to OAT for the 
catalysis of the first committed step of the arginine biosynthesis pathway. 
 
 
1.4 The catalyst of the first committed step of the pathway 
 
As stated before, the first committed step of the de novo Arg biosynthetic 
pathway is the αN-acetylation of L-glutamate.  In prokaryotes, several enzymes can 
catalyze this reaction:  
(i) Classical NAGS, first characterized in E. coli, and present also in 
those animals that synthesize arginine. 
(ii) Bifunctional OAT, able to use AcCoA to acetylate glutamate and also 
utilizing AOrn for transacetylation of glutamate.  Present in Bacteria, 
Archaea and many Eukaryotes (Table 1). 
(iii) Short NAGS of the GCN5-related N-acetyltransferase (GNAT) family, 
either independent or fused with the ArgH protein (argininosuccinase) 
The first two enzymes on this list have already been discussed in the 
preceding sections. 
Genetic studies of Campylobacter jejuni and Moritella abyssi and Moritella 
profunda provided the first evidences of the existence of substitutes of classical 
NAGS that are not OATs[14, 15]; These substitutes were able to complement E. coli 
argA mutants.  They could be found in two forms in the genome of the organisms 
that contain them: fused to the ASL gene or as independent genes[15]. 
In some organisms like Thermus thermophilus, Streptomyces coelicolor or 
Mycobacterium tuberculosis, the lack of argE and argA and the possibility that their 
OATs are monofunctional probably makes them rely on S-NAGS for Arg 
synthesis[13].  S-NAGS has been characterized in M. tuberculosis[16].  This enzyme 
shows an extremely high Km for glutamate (>600mM) which suggest that another 
enzyme could provide an efficient glutamate binding site, such as NAG kinase 
(NAGK), that would form an effective active acetylating complex as it appears to be 
the case in Saccharomyces cerevisiae[17], although in this organism NAGS is of the 
classical type except for the presence of a C-terminal extension of ~150 residues[18]. 
Acetylation of glutamate appears to control the “in vivo” flow of acetylated 
precursors that lead to Orn in those organisms that use AOD instead of OAT, and 
therefore that have a linear pathway.  Classical NAGS activity is controlled through 
feedback inhibition by Arg[19], as well as is the case of S-NAGS[16].  The control of 
the activity of mono- and bifunctional OATs by arginine has not been fully proven, 
but Orn behaves as a competitive inhibitor[20] controlling the activity of these 
enzymes.  Although significant progress has been achieved in the determination of 
the mechanism by which Arg inhibits classical NAGS and NAGK (see next section), 
such mechanism remains elusive for S-NAGSs. 
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1.5 Catalysts of the second or kinase step of the arginine 
biosynthetic pathway 
 
The second step of the Arg biosynthetic pathway is the phosphorylation of 
NAG by the enzyme NAGK (Figure 2).  In contrast with the first committed step of 
the pathway, this second step can only be catalyzed by NAGK, highlighting the 
importance of this enzyme and its regulation in the homeostatic control of the Arg 
pool in the organisms. 
In some organisms NAGK is Arg-insensitive (E. coli and Microbacterium 
lacticum, among others[12, 21]), therefore NAGS becomes the most important point 
of control of the pathway, but in those microorganisms in which NAG is formed by 
transacetylation and therefore have a “cyclic” Arg biosynthetic pathway, NAGK is a 
crucial metabolic flow control point of the pathway[9]. 
One of the most frequent ways to control NAGK activity is through inhibition 
by the end product of the pathway Arg.  The structural bases of such inhibition have 
been described by the group of Rubio[22] for the NAGKs from Thermotoga maritima 
and P. aeruginosa.  Upon binding of Arg to the enzyme a conformational change 
occurs that stabilize NAGK in a more “open” state (T-state), in which the active site 
is enlarged consequently increasing the distance between the nucleotide and NAG, 
thus rendering a much less active NAGK (Figure 3). 
 
 
Figure 3: Conformational changes induced by the binding of Arg to 
hexameric NAGK. Adapted from Ramón-Maiques et al 2006[22].  Schematic 
representation of the R- to T-state transition induced by Arg upon binding to NAGK. 
Since classical NAGS consists of a domain that is homologous to NAGK and a 
C-terminal smaller domain belonging to the GNAT family, the similarities of NAGK 
with the NAGK-like, or amino acid kinase (AAK) domain of NAGS led to the 
identification in classical NAGS of the Arg binding site, corresponding to that 
observed in NAGK, suggesting that the same inhibitory mechanism is operative for 
NAGK and NAGS.  Recent studies from the same group involving site directed 
mutagenesis on P. aeruginosa NAGS, supported this hypothesis[23, 24]. 
In plants and photosynthetic microorganisms the control of NAGK activity is 
exerted not only by arginine, but also by the nitrogen abundance-signaling protein 
PII[25].  In this case PII binds NAGK reducing its sensitivity for Arg and allowing 
this amino acid to be synthesized continuously when nitrogen carbon and ATP are 
abundant, and to be stored in arginine-rich proteins, as in seeds, or in arginine-rich 
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polymers like cyanophycins, as in some cyanobacteria[26]. 
In ascomycetes (including, for example, yeast and Neurospora crassa) NAGS 
and NAGK are associated into a complex whose integrity has been proven to be 
essential for NAGS building as a stable protein, as well as for NAGS activity and 
effective inhibition by Arg[17]. 
 
 
1.6 The role of transcarbamylation in arginine synthesis 
and catabolism 
 
Until now only the first two steps of the Arg biosynthetic pathway have been 
discussed. Although each and every step of the pathway is essential for its 
completion, transcarbamylation of Orn to produce Cit (Figure 2) represents yet 
another crucial step in the pathway (Figure 1). 
The reaction catalyzed by OTC can participate in either the anabolism or the 
catabolism of Arg. While the carbamylation of Orn, yielding Cit, is involved in the 
biosynthetic sequence; the reverse reaction, the phosphorolysis of Cit, is the second 
step of the arginine deiminase (ADI) pathway (Figure 4).  ADI, OTC and carbamate 
kinase (CK) convert Arg to Orn, ammonia and CO2 in three steps producing ATP, 
which makes the ADI pathway a major source of energy for several organisms under 
anaerobic conditions[27-31].   
 
 
Figure 4: Schematic representation of the ADI 
pathway.  Arg is converted to Orn, ammonia and CO2 
in three consecutive steps by ADI (arginine 
deiminase), COTC (catabolic ornithine 
transcarbamylase) and CK (carbamate kinase), 
generating 1 mol of ATP per mol of Arg that enters the 
pathway. 
cOTC 
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Organisms that carry out both, arginine synthesis and ADI-pathway 
mediated arginine catabolism, generally have distinct anabolic and catabolic 
OTCases like it is the case of Pseudomonads[32-35].  Both OTCases (anabolic and 
catabolic) have been studied in detail in P. aeruginosa.  In this organism anabolic 
OTCase, encoded by the gene argF, is repressed by Arg[36], while the catabolic 
enzyme, encoded by the arcB gene, which belongs to the arcDABC operon, is induced 
by Arg[37]. The two enzymes share ~52%[36] identity at the nucleotide sequence 
level.  Despite their sequence similarities, the active form of ArgF is a homotrimer of 
approximately 100kDa while ArcB forms dodecameric tetramers of trimers of 
456kDa[36, 38].  These differences in quaternary structure can apply also to other 
OTCases found in different organisms containing both anabolic and catabolic 
enzymes[33].  Catabolic OTC (COTC) is supposed to be the limiting step in the ADI 
pathway[39], due to the irreversibility of the reaction catalyzed by ADI and the 
significant favor towards the formation of ATP of the CK reaction.  In fact, of the 
enzymes of the ADI pathway of P. aeruginosa only catabolic OTC appears to be 
under regulation at the level of enzyme activity[40]. 
Anabolic OTC is widespread throughout phyla and is considered an essential 
arginine biosynthetic enzyme.  Absence of the OTC gene or enzyme deficiency due to 
mutations causes Arg auxotrophy[5] in microorganisms and is lethal in ureotelic 
animals[41].  Among microorganisms, only a few obligate parasitic bacteria lack the 
OTC gene[42]. 
 
 
1.7 Transcarbamylation across phyla 
 
The transcarbamylases family of enzymes belongs to the carboxyl- and 
carbamoyltransferases group, EC 2.1.3, a family that comprises enzymes that 
catalyze the transfer of a carbamoyl group from CP to an amino or oxygen group of a 
second substrate. 
Members of the transcarbamylase family can be identified based on sequence 
identities in the N-terminal or CP-binding domain as all the members of this family 
share common residues involved in the binding of CP to the enzyme[43].  The most 
widely studied members of the transcarbamylases family are ornithine 
transcarbamylase (OTC) and aspartate transcarbamylase (ATC). 
OTC and ATCase catalyze analogous reactions, and, as already indicated for 
OTC, are quite universally distributed[42].  While OTC utilizes Orn and CP, ATCase 
catalyzes the reaction between aspartate and CP that is the second step in the 
pathway of pyrimidine biosynthesis[44].   
In 1999 Labedan and others[42], studied the evolutionary history of 
transcarbamylases using a limited number of sequences representing the three 
domains of life (44 OTCases and 33 ATCases).  The results obtained from that work 
could not establish the actual order of organismal descent due to the complex 
topology of the composite rooted phylogenetic tree.  The authors explained such 
complexity by assuming the occurrence of four subfamilies, two per group of 
enzymes; OTC α and OTC β and ATC I and ATC II, based on unique sequence 
signatures. 
These studies on the evolution of the transcarbamylases indicated the 
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presence of such activity in the Last Universal Common Ancestor (LUCA), and ruled 
out the possibility of an evolutionary mechanism of fusion of independent modules.  
Despite the increasing number of sequences available, the robustness of the 
evolutionary tree constructed was confirmed by studies performed with ATC by the 
same laboratory[45] using quaternary structures to assess the evolutionary history 
of proteins.  The general tree topology was not modified, simply the ATC I and ATC 
II groups were enlarged by the addition of new sequences but not dislodged[45]. 
The two groups of OTCases (OTC α and β) identified by Labedan et al.[42] 
were also confirmed by a more recent evolutionary study focused on OTC[46].  In 
their work, Naumoff et al.[46] highlighted the existence of sequences in the public 
databases, annotated as OTC that either did not catalyzed the transcarbamylation 
of Orn to form Cit (like the Bacteroides fragilis transcabamylase-like enzyme, 
previously crystallized by our group[47], therefore annotated as unknown 
transcarbamylase or UTC), or did catalyze the transcarbamylation of a substrate 
other than Orn (like the case of putrescine transcarbamylase, PTC).  The 
evolutionary tree of transcarbamylases constructed by Naumoff et al.[46] using the 
245 sequences for OTCases available at the moment of making the tree shown in 
Figure 5. 
 
 
Figure 5: Evolutionary tree of transcarbamylases.  Adapted from Naumoff et al. 2004[46].  
A few paralogous ATCases belonging to either family ATC I or ATC II were used to root the tree.  A 
black dot indicates the root.  OTC families are schematized as triangles.  The homologous 
transcarbamylases that are branching far from these ATC or OTC families are labeled as unknown 
(UTC).  The few UTC sequences annotated as transcarbamylase-like are enclosed in ovals. 
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The functional assignment of proteins identified in genome sequencing 
projects is a major problem in post-genomic biology, as highlighted in the works of 
Naumoff et al.[46] and Sekowska et al.[48] among others[49-51].  Putative amino 
acid sequences have, in many cases, been annotated uniquely by a two-step process:  
 
1. - Detection of a homologous relationship by a pairwise sequence similarity 
search at the level of primary structure 
2. - Inference of functional similarity from this detected homology. 
 
The work of Naumoff and others[46] was centered in the case of the PTC 
family of proteins that has been erroneously annotated as OTC and that form a 
distinctive branch from both ATC and OTC families (Figure 5).  As Figure 5 shows, 
next to the branch formed by the YgeW protein from E. coli and Clostridium 
botulinum there is another branch that contains the sequence of a protein that has 
been reported to be essential for arginine biosynthesis in Xanthomonads and 
Bacteroides[47]. 
 
 
1.8 Sequence/structure traits and the substrate 
specificities of transcarbamylases 
 
Transcarbamylases, as stated before, share a common functional domain, the 
CP-binding domain located in the N-terminal moiety[43] with significant proportions 
of identical or similar residues.  The highest conservation across the 
transcarbamylase superfamily involves three regions: the SxRT, the HPxQ and the 
HxLP motifs[52].  All of them are involved in direct interactions with the common 
substrate for all the members of the family, CP.  These homologies in the CP-binding 
domain have been used for the identification of the members of this family. 
Furthermore comparison of the structures of OTC and ATC allowed 
identification in the CP-binding domains of both enzymes of residues involved in 
binding CP[53, 54].  In both active centers the STRT motif binds the phosphate 
oxygens of CP[55], and the active site also contains one R and one H residues (Arg106 
and His136 in the human OCTase), which bind the carbonyl oxygen of CP[56].  In 
both families, at least one residue of the CP site is contributed by an adjacent 
subunit, in the case of E. coli ATCase, Ser 80 and Lys 84 of the adjacent subunit 
participate in the CP site, while in E. coli OTCase Gln 82 is the residue belonging to 
an adjacent subunit[56] (Figure 6). 
Despite the structural similarities between the C-terminal moieties of OTC 
and ATC[57, 58], the sequence of this domain is more divergent than that of the N-
domain, due to the variety of substrates that can be carbamylated[56].  Figure 6 
illustrates the different interactions and residues involved in the binding of Orn and 
aspartate to OTC and ATC respectively. 
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Figure 6: Schematic representation of the interactions between 
the substrates and the active site in E. coli  ATC and OTC.  
Adapted from Allewell et al. 1999[56]. A) Interactions of the bisubstrate 
analog Nδ-Phosphonoacetyl-L-Aspartate (PALA) with E. coli ATC.  B) 
Interactions of the bisubstrate analog Nδ-Phosphonoacetyl-L-Ornithine 
(PALO) with E. coli OTC.  Residues from an adjacent subunit are labeled 
with an asterisk (*).  
The reaction catalyzed by transcarbamylases involves the nucleophilic attack 
of the carbonyl C of CP by an amino group.  Catalysis of this attack involves 
interactions mediated by the highly conserved HCLP motif of OTCases or the HPLP 
motif of ATCases.  The difference between these two conserved motifs has to do with 
the charges of each of the substrates utilized by these enzymes[56].  This HCLP 
motif was thought to be a signature for Orn binding to OTC but the same motif is 
also present in PTCases[46]. 
Another sequence signature associated with transcarbamylases can be found 
in the so-called 240’s loop (residues 236 to 259, E. coli OTC numbering) DxxxSMG in 
OTCases and RxQxER in ATCases.  This loop is flexible and is an important 
ornithine or aspartate binding element[52].  The flexibility of this loop is essential 
for such binding since it requires a conformational change to create an induced-fit 
pocket in which the substrate is located. 
The catalytic mechanism of both OTC and ATCases involves a tetrahedral 
intermediate.  Glutamine 136 (Gln136) in the case of E. coli OTC fulfills the role of 
stabilizing this intermediate, while Gln137 plays the same role in E. coli ATC.  The 
region surrounding this glutamine in both OTC and ATC is strongly conserved; 
NxLxxxxHxxQxxD for OTCases and NxGDGxxxHxxQxxD in ATCases[56]. 
All the evolutionary conserved motifs present in the transcarbamylase family 
have led to the erroneous annotation of a large, yet increasing, number of genes as 
OTCases without experimental confirmation of such activity as has been mentioned 
before in this introduction and it has been highlighted by the studies of Labedan and 
collaborators[45, 46, 59].  The case of the transcarbamylase-like gene found in B. 
fragilis illustrates this statement. 
A 
B 
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1.9 Implication of a transcarbamylase-like gene with no 
OTC activity from Bacteroides fragilis  in the de novo  
arginine biosynthesis in this organism. 
 
While studying the arginine biosynthetic pathway in the anaerobe B. fragilis, 
using transposon-mediated mutagenesis Dr. Malamy, discovered the presence of a 
transcarbamylase-like (BfargF’) gene essential for the biosynthesis of arginine in this 
organism (unpublished results). 
In 2002, Shi et al.[47] described the crystal structure of this 
transcarbamylase-like protein from B. fragilis strain TM4000.  The general fold of 
this protein (Figure 7) shared a high degree of structural similarities with anabolic 
OTCases and ATCases.  However, there were several striking differences in some of 
the regions of the active site between the BfArgF’ and OTC and ATC[47]  
 
Figure 7: Ribbon diagram representation of the monomer 
structure of the transcarbamylase-like protein from B. fragilis .   
The 80’s loop is shown in blue, the 120’s loop in red, β-sheet B4 and α-helix 
H4 in orange, the 240’s loop in purple and the proline-rich loop in cyan. 
The 80’s loop (residues 70-92, shown in blue in Figure 7) is 12 amino acids 
longer than that of OTCase or ATCase, and contains two short parallel strands 
(residues 77-78 and 91-92) that are unique to this protein.  The 120’s loop (residues 
111-124, shown in red in Figure 7), which links B4 and H4 (shown in orange) near 
the active site, is ten residues longer than the respective loop in OTCase and 
ATCase.  As a result, this loop extends further along the active site and is able to 
interact with the 240’s loop (residues 236-259, shown in purple in Figure 7).  The 
240’s loop, which is involved in recognizing the second substrate in OTCase and 
ATCase, and in triggering conformational changes upon binding of such substrate, 
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lacks the characteristic motifs DxxxSMG or RxQxER of OTCase and ATCase 
respectively, and has a different three-dimensional structure[47]. 
Even more surprising is the presence of a proline-rich loop (residues 173-183, 
shown in cyan in Figure 7) that links B6 and H6 and is located between the active 
site and the 240’s loop[47]. Because of the number of prolines, this loop is not mobile, 
and would be expected to prevent movement of the 240’s loop towards the active site 
when the second substrate binds.  Although the structure of BfArgF’ was solved, its 
enzymatic activity could not be detected. 
According to the authors there were at least three possible ways in which this 
protein could be involved in producing citrulline that would explain why its activity 
has not been detected: 
 
1. The enzyme requires an unidentified cofactor to bind the protein to 
become active. 
2. The enzyme, within the cell, is part of a complex with other proteins 
and the disruption of this complex eliminates its activity. 
3. The enzyme converts a substrate other than ornithine into an 
unknown intermediate that is subsequently converted to citrulline. 
 
 
1.10 Identification of misannotated transcarbamylases 
 
The fact that the transcarbamylase-like gene from B. fragilis was implicated 
in the de novo arginine biosynthesis in this organism, and the fact that the three-
dimensional structure of the protein coded by BfargF’ was very similar to that of OTC 
and ATCases, increased the interest of our laboratory to study the transcarbamylase 
activity of this protein.  Unfortunately initial attempts to elucidate such activity 
were unsuccessful[47]. 
Screening of the, at the time, available genomes using the BfargF’ sequence as 
a query allowed the identification of a similar gene in Xylella fastidiosa.  Both genes 
shared a high degree of sequence similarity (52%) and homology (38%) and both 
genes lack the OTC and ATC signature sequences (DxxxSMG and RxQxER 
respectively)[47] (Figure 8).  The predicted three-dimensional structure of the 
protein identified in X. fastidiosa was very similar to that of the BfArgF’ indicating a 
similar function in the arginine biosynthetic pathway in this organism. 
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Figure 8: Amino acid sequence alignment of B. fragilis  and X. fastidiosa  
transcarbamylase-like proteins and human OTC and E. coli  ATC.  Adapted from Shi et al. 
2002.  Structural elements are indicated by colored boxes above the sequence; green: β-sheets and red: 
α-helices.  Red letters represents the residues conserved in all known transcarbamylases.  Blue box 
highlights the region where the sequence signatures for both OTC and ATC can be found, which are not 
present in these other transcarbamylases of unknown activity. 
Dr. Morizono carried out the initial bioinformatics analyses on the genes 
annotated as OTCases in the public protein database NCBI 
(www.ncbi.nlm.nih.gov/protein) to identify other members of this group of 
transcarbamylase-like proteins that lack the essential DxxxSMG motif.   
A query using the keyword 2.1.3.3 (the E.C. number for OTCase) with NCBI 
Entrez returned 474 protein sequences (nowadays using the same keyword the 
search would return 3513 sequences of genes annotated as OTCases); those that 
appeared truncated or incomplete were discarded.  The remaining genes were then 
screened for the presence or absence of the SMG motif using the EMBOSS module 
fuzzpro.  Of the 474 sequences annotated as OTCase, 56 did not contain the SMG 
motif.  These were aligned using pileup and the cluster associated with B. fragilis 
was used for further analysis. Figure 9 shows the sequence logo representation 
generated using WebLogo[60] (http://weblogo.berkeley.edu/), from the alignments of 
the C-terminal domain of those protein sequences that lacks the SMG motif 
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compared to the alignment of known OTC sequences.  Among the argF’ genes 
identified that lacked the SMG motif and annotated as potential transcarbamylases 
were those of Bacteroides thetaiotaomicron, Cytophaga hutchinsonii, several 
pathovars: Xylella fastidiosa, Xanthomonas campestris, Xanthomonas axonopodis, 
Prevotella ruminicola, and Tannerella forsythus[61]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9: Representation of the alignment of known OTCases and 
transcarbamylase-like proteins identified in the initial bioinformatics 
analyses.  In this figure the size of the letters is related to the degree of conservation 
among the sequences aligned and the color the type of residue.  The motifs conserved in both 
groups are highlighted with red boxes.  OTCase signature motif, present in all known 
OTCases and absent in the transcarbamylase-like proteins, is highlighted with a blue box. 
These analyses showed the widespread distribution of these 
transcarbamylases of unknown activity among bacteria.  In an effort to identify the 
activity of these transcarbamylase-like proteins, several argF’ genes from these 
organisms were cloned, including: Xylella fastidiosa, Cytophaga hutchinsonii, 
Xanthomonas campestris and B. fragilis argF’. 
Complementation studies carried out by Dr. Malamy, showed that Xa. 
campestris, Xy. fastidiosa and C. hutchinsonii argF’ genes were able to revert the 
arginine auxotrophy of E. coli C6.1 (a K12 strain lacking both OTC genes argF and 
argI) when introduced by transformation into these cells and induced with IPTG.  
Thus, the ArgF’ protein from these organisms functions in E. coli and provides a 
reaction product that can be used for arginine biosynthesis.  However, when OTCase 
activity of these proteins was assayed with CP and ornithine as substrates no 
significant citrulline production was detected (data not shown). 
The ability of all these proteins to complement E. coli C6.1 arginine 
auxotrophy suggested that the activity of these enzymes should be located upstream 
the reaction catalyzed by OTC in the pathway (Figure 2). 
The first enzymatic activity discovered among these proteins was the N-
acetylornithine transcarbamylase (AOTC) activity of Xa. campestris ArgF’.  Which  
was elucidated using a coupled assay in which the lysate from E. coli C6.1 cells 
expressing XcArgF’ was incubated with each of the substrates of the enzymes CK, 
CPS, AOD and OTC  
A) OTCases 
B) Transcarbamylase-like proteins 
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1.11 The specific context of this Thesis and of its objectives 
 
The present thesis work is focused in the case of two families of misannotated 
microbial transcarbamylases that have been identified as essential for arginine 
biosynthesis, but which lacked the ability to catalyze the conversion of Orn into Cit. 
The objectives of the present thesis work are the biochemical and molecular 
characterization of the AOTC activity of XcArgF’ as well as the elucidation of the 
enzymatic activity of BfArgF’ and its biochemical and molecular characterization.  
We show that Xanthomonads and Bacteroidetes use novel pathways for the 
de novo arginine biosynthesis mediated by acetyl- and succinyl-ornithine 
transcarbamylases, we identify a recognition motif for these enzymes and we provide 
evidence supporting the view that the existence of succinyl-ornithine 
transcarbamylase requires that the first five steps of the arginine biosynthesis 
pathway use succinylated rather than acetylated intermediates. 
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The objectives of the present PhD thesis are: 
 
1. Biochemical characterization of ArgF’ from 
Xanthomonas campestris. 
 
• The specificity of the reaction will be investigated. 
• The reaction products will be identified. 
• The kinetics parameters will be determined 
• The kinetic behavior of the enzyme in the presence of different specific 
inhibitors will be studied. 
 
2. Design and synthesis of possible substrates as well as 
inhibitory compounds 
 
• Possible substrates for the ArgF’ enzyme from B. fragilis will be 
synthesized based on the data provided by the quaternary structure of 
the protein, as well as possible substrates for other enzymes implicated 
in the de novo arginine biosynthesis in these organisms. 
• Inhibitory compounds will be synthesized based on the catalytic 
activity of the ArgF’ enzymes from X. campestris and B. fragilis. 
 
3. Identification and partial characterization of the 
activity of the enzyme codified by the argF’ gene in Bacteroides 
fragilis. 
 
• The activity of Bacteroides fragilis ArgF’ will be identified. 
• The activity of Bacteroides fragilis ArgF’ will be partially 
characterized. 
 
4. Determination of the implications of the presence of 
these transcarbamylases on the arginine biosynthetic pathway 
of the organisms that possess them. 
 
• The logical metabolic flow of intermediates in the arginine biosynthetic 
pathway of X. campestris will be investigated. 
• The initial steps of the arginine biosynthetic pathway from B. fragilis, 
leading to the intermediate metabolite that the ArgF’ enzyme from this 
organism utilize will be investigated. 
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Some results described in this work have been published in the following 
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2.1 Xanthomonas campestris pv campestris  
 
Xanthomonas is a genus that includes several plant pathogens.  X. 
campestris pv campestris is a Gram-negative rod that attacks a variety of 
economically important crucifers, such as Brassica and Arabidopsis, causing black 
rot, which can appear on plants at any growth stage.   
Disease control usually consists of using resistant cultivars, certified seeds, 
hot-water treatments of seeds followed by application of antibiotics of protecting 
fungicides, crop rotation, control of weeds and insects, and destruction of infected 
plants and debris in the field. Nowadays, the use of resistant cultivars is the most 
economical method of control[62]. 
X. campestris has also a commercial use since it is grown to produce the 
exopolysaccharide xanthan gum, which is used to control viscosity and as a 
stabilizing agent in many industries. 
Phylogenetic analyses locate the Xanthomonas genus at the base of the g-
subdivision of proteobacteria, within the same clade as Xylella fastidiosa.  When its 
genome was sequenced only 64.91% of the genes were assigned a role category, the 
rest (35.01%) were either genes with not assigned role category (10.16%), conserved 
hypothetical genes (11.88%) and hypothetical genes (13.03%).   
Essentially all the putative arginine biosynthesis genes in X. campestris and 
X. axonopodis can be identified by homology to known arg genes from various 
organisms; however, the sequences of their putative argF genes differ significantly 
from the canonical argF genes that encode OTCase enzymes[63].  These novel argF’ 
genes are very similar to BfargF’ that is essential for arginine biosynthesis[47] as 
described in the Introduction. 
 
As stated before in the Introduction the enzymatic activity of XcArgF’ has 
been identified to be that of N-acetylornithine transcarbamylase, a new member of 
the transcarbamylases family of proteins. 
 
In this chapter I will present the results obtained for the Biochemical 
Characterization of the AOTCase activity of XcArgF’. 
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2.2 Identification of the product of the transcarbamylase 
reaction catalyzed by XcArgF’ 
 
2.2.1 Preliminary identification using an amino acid analyzer of 
ACit as the product of the reaction catalyzed by XcArgF’ 
 
Previously described results indicated that the enzyme could use AOrn rather 
than ornithine and generates either ACit or citrulline.  In the initial assay, XcArgF’ 
activity was measured with a colorimetric method described by Pastra-Landis et 
al.[64] using known amounts of citrulline as standard.   
This method detects the ureido group common to the side chains of both 
citrulline and ACit (Figure 10) and therefore could not discriminate between both of 
them, thus different approaches were necessary for the correct identification of the 
product of the reaction catalyzed by XcArgF’. 
 
 
Figure 10: Schematic representation of the chemical 
structure of L-citrulline and N-acetyl-L-citrulline.  Dashed 
red boxes show the ureido group and dashed blue boxes show the a-
amino group in both compounds. 
Ninhydrin is a compound that preferentially reacts with free amines and 
therefore, would react strongly with citrulline but weekly with ACit, which has a 
blocked α-amino group (Figure 10).   
With the use of a Beckman amino acid analyzer (as described in Materials 
and Methods), the reaction of chemically and enzymatically synthesized ACit with 
ninhydrin was studied.  Citrulline and AOrn have easily distinguishable different 
elution times (Figure 11), while ACit elutes near phosphoethanolamine and has a 
markedly reduced absorption coefficient at 570nm[65] (Figure 11), reflected on a 
lower absorbance at 570nm compared with similar amounts of citrulline. 
 
Citrulline N-acetyl-L-Citrulline 
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Figure 11: Representative amino acid analyzer chromatogram.  For this assay 10µg 
of purified XcArgF’ were incubated at 25°C in 1ml of 50mM Tris-HCl buffer pH 8.3 containing 
5mM AOrn and 4.8mM CP.  After 10 minutes 100µl of the reaction solution were diluted to 
500µl with H2O and the reaction terminated with 500µl of 7% sulfosalicilic acid.  900µl of the 
color reagent (Materials and Methods: Colorimetric OTC activity assay) were added to the 
remaining 900µl of reaction solution for quantification of the product formed using the 
Colorimetric OTC activity assay. Based on the colorimetric assay, 136nmols of product were 
formed during the incubation.  Thin line corresponds to the chromatogram generated by a 
solution of 110mM Cit (purchased from Sigma).   The products of the reaction catalyzed by 
XcArgF’ are represented with a thick line.  For clarification of the figure thin lines are 
vertically offset for about 0.05 absorbance units. 
If citrulline was the product of the reaction catalyzed by XcArgF’ the 
chromatogram (thick line, Figure 11) should have shown a peak at the same 
retention time as the chemically synthesized citrulline (thin line, Figure 11), 
instead, it shows a peak with a retention time similar to that of 
phosphoethanolamine which is consistent with the expected results for ACit. 
Although these results indicated that citrulline is not the product of the 
reaction catalyzed by XcArgF’, they could only suggest that ACit is indeed the 
product formed from AOrn and CP in the presence of XcArgF’ since no information 
about the chemical nature of the product of the reaction could be extracted from 
them. 
We used liquid chromatography coupled with mass spectrometry (LC-MS) 
and nuclear magnetic resonance (NMR) to gather information about the chemical 
structure of the product of the reaction catalyzed by XcArgF’. 
 
 
  
N-acetyl-L-citrulline 
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2.2.2 LC-MS and NMR analysis confirmed that the product of the 
reaction catalyzed by XcArgF’ is N-acetyl-L-citrulline 
 
Using the results of the colorimetric detection method described by Pastra-
Landis et al.[64] to measure OTC activity as an estimate approximately equal 
amounts of both enzymatically and chemically synthesized ACit (commercially 
available) were analyzed by LC-MS (Materials and Methods).   
Analysis of these samples revealed the presence of a peak with a mass equal 
to that of ACit in a protonated state (218.1 m/z) in both samples (Figure 12), 
citrulline in the same state would have been detected as an ion of 176.1 m/z and a 
different retention time.  Boiled enzyme used as a control did not show this peak, 
neither the control without the enzyme (Figure 12). 
 
 
Figure 12: LC-MS analysis of the products of the reaction catalyzed by XcArgF’.  For 
these analyses 2µg of purified XcArgF’ were incubated for 5 minutes at 25°C in 1ml of 50mM Tris-
HCl containing 1mM CP and 5mM AOrn.  After the incubation time, 1ml of 30% tri-chloroacetic 
acid (TCA) was added to stop the reaction and precipitate the protein.  Samples were then 
centrifuged and the supernatant was loaded onto the instrument without further purification 
(Materials and Methods). The chromatograms represented in the figure are those of the single 
ions corresponding to each of the compounds extracted from the total ions detected by the 
instrument during the run (Materials and Methods). Dashed lines: pure compounds (AOrn and 
ACit). Thick lines: enzymatically synthesized products by XcArgF’. 
These results showed the presence of a compound with the same m/z and 
retention time than those of purified ACit among the products of the reaction 
catalyzed by XcArgF’, which in conjunction with the previous results from the 
colorimetric assay and ninhydrin reactivity suggested that ACit is most likely to be 
the product of the reaction. 
Final confirmation about the nature of the product of the reaction catalyzed 
by XcArgF’ was obtained by NMR analyses (Materials and Methods). 
Figure 13 shows the results obtained for the COSY-NMR (top) and two-
dimensional COSY-NMR (bottom) spectra of both, chemically and enzymatically 
synthesized ACit. 
 
 Boiled enzyme 
Purified enzyme 
Pure compounds 
218 m/z 175 m/z 
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Figure 13:  NMR analyses of the products synthesized by XcArgF’ compared 
to the chemically synthesized compounds.  COSY-NMR spectra show the 
enzymatically generated compound to be N-acetylcitrulline. (Top) The chemical 
structure of ACit with the protons seen in the labeled NMR spectra.  1H-NMR 
comparison of chemically and enzymatically synthesized ACit, AOrn, and CP. (Bottom) 
Two-dimensional COSY-NMR of the enzymatically synthesized ACit sample. The self-
correlation peaks can be seen on the diagonal from lower left to upper right. Coupled 
peaks are seen off the diagonal. Protons that are coupled are identified by tracing 
horizontally and vertically off a point on the diagonal to a coupled peak and then 
returning vertically or horizontally to a new peak on the diagonal. The peaks between 
3.5 and 3.8 ppm are not coupled to any other groups in N-acetylcitrulline and are likely 
due to a contaminant from the enzyme preparation 
Both NMR analyses identified the product of the reaction catalyzed by 
XcArgF’ as N-acetyl-L-citrulline thus supporting the previous results obtained by the 
different techniques presented in this section. 
 
The data presented in this section provide evidence that the activity of 
XcArgF’ is indeed that of a N-acetyl-L-ornithine transcarbamylase (AOTCase) and 
that the product of such activity is ACit. The reaction catalyzed by XcArgF’ would be 
described by the following equation: 
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carbamoyl phosphate + N-acetyl-L-ornithine N-acetyl-L-citrulline + Pi 
 
  Therefore, herein it will be designated as XcAOTCase. 
 
 
2.3 Characterization of the AOTCase activity of XcArgF’ 
 
2.3.1 Purification of ArgF’ from X. campestris pv campestris 
(XcAOTCase) 
 
XcArgF’ was purified as described by Shi et al. [63] using an AKTA FPLC by 
nickel affinity. This enzyme was purified to homogeneity with >96.5% purity.   
Figure 14 shows a representative SDS-PAGE of the proteins presents in the 
fractions collected during the purification of this enzyme.  
   
 
Figure 14:  Representative gel showing the 
different stages of the purification of 
XcAOTCase.  MK: Size marker (BenchMark Ladder), 
Sup: Supernatant (after cell lysis and membranes 
precipitation), FT: Flow through (unbounded proteins), 
Wash: weakly bounded proteins eluted with mild 
stringent buffer, Ni: fractions collected after elution of 
the protein bonded to the nickel column, DEAE: 
fractions collected after elution of the protein bind to 
DEAE column. 
The molecular weight determined experimentally differs from that calculated 
from the 339 amino acids polypeptide encoded by the XcargF’ gene (37.8 KDa).  Such 
difference can be explained by the addition of a poly-histidine tag when cloning the 
gene. 
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For these studies XcAOTCase was purified using an FPLC by nickel affinity, as 
described in Materials and Methods.  We were able to purify the enzyme to homogeneity 
with >96.5% purity.  Figur  14 shows a representative SDS-PAGE of the proteins 
p esents in the fractions collected during the purif cation of this enzyme.  
 
 
Figure 14:  Representative gel showing the different 
stages of the purification of XcAOTCase.  MK: Size 
marker (BenchMark Ladder), Sup: Supernatant (after 
cell lysis and membranes precipitation), FT: Flow 
through (unbounded proteins), Wash: weakly bounded 
proteins eluted with mild stringent buffer, Ni: fractions 
collected after elution of the protein bonded to the nickel 
column, DEAE: fractions collected after elution of the 
protein bind to DEAE column. 
The molecular weight determined experimentally differs from that calculated 
fro  the 339 amino acids polypeptide encoded by the XcargF’ gene (37.8 KDa).  Such 
difference can be explained by the addition of a poly-histidine tag when cloning the gene. 
After purification, all fractions containing the purified XcAOTCase protein were 
pooled and dialyzed in storage buffer (Materials and Methods) prior to its use for 
enzymatic assays. 
Purified XcAOTCase was quantified using the Bradford method as described in 
Materials and Methods using bovine serum albumin (BSA) as standard. 
 
 
 
 
XcArgF’ 
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After purification, all fractions containing the purified XcAOTCase protein 
were pooled and dialyzed in storage buffer (Materials and Methods) prior to its use 
for enzymatic assays. 
Purified XcAOTCase was quantified using the Bradford method as described 
in Materials and Methods. 
 
2.3.2 Specificity of the reaction catalyzed by XcAOTCase 
 
To determine the specificity of the reaction catalyzed by XcAOTCase as well as 
to elucidate if the AOTCase activity could be assigned to any of the other 
transcarbamylases identified in this study, ornithine and AOrn were used as 
substrates for the transcarbamylase assay. 
In this experiment, 2µg of purified XcAOTCase were assayed along with 2µg of 
purified ArgF’ proteins from C. hutchinsonii (ChArgF), B. fragilis (BfArgF) and human 
OTCase (hOTCase), using the standard conditions for OTCase assay[41], that is: 5 
mM ornithine or AOrn and 4.8 mM CP (Figure 15).  Boiled enzymes were used as 
negative controls and the product formation was quantified using known amounts of 
citrulline as standard. 
 
 
Figure 15:  Comparison of the ability of different ArgF’ enzymes to utilize 
ornithine or AOrn as substrates.  2µg of purified ArgF’ from X. campestris, C. 
hutchinsonii, B. fragilis and H. sapiens were assayed in 1ml of 50mM Tris-HCl pH 8.3 in the 
presence of 5mM of ornithine or AOrn and 4.8mM CP.  Incubations were carried out at 25°C in 
a water bath for 5 minutes.  After 5 minutes 1ml of fresh color reagent (Materials and 
Methods) was added to stop the reaction.  Tubes containing the samples were incubated over 
night at room temperature with constant shaking at 125rpm in the dark.  The following day 
tubes containing the samples assayed were incubated at 45°C for 25 minutes for final color 
development.  Sample absorbance was then measured spectrophotometrically at 466nm. 
The results shown in Figure 15 suggest that the reaction catalyzed by 
XcAOTCase is highly specific for AOrn, and that it must play a crucial role in the 
arginine biosynthetic pathways in this organism since no other transcabamylase-
like gene can be found in the genome of X. campestris. 
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In addition, these results prove that the AOTCase activity might be restricted 
to members of the Xanthomonads family of microorganisms and is not broadly 
distributed among the phyla identified in the initial bioinformatics analyses. 
 
2.3.3 AOTCase assay conditions optimization 
 
Salt concentration 
 
High concentrations of salt (KCl, 200mM) has been proven to stabilize 
Pirococcus furiosus OTCase by preventing the dissociation, at high temperatures, of 
the dodecameric active estate of the protein[66], thus the effects that several 
concentrations of NaCl and KCl could have on the activity of XcAOTCase were tested. 
As shown in Figure 16, both salts, even at concentrations of 200 mM, have 
very little or no effect on the activity of XcAOTCase under the experimental 
conditions tested (Materials and Methods).   
 
 
 
Figure 16: Effects of various concentrations of NaCl and KCl on 
XcAOTCase activity.  2µg of purified XcAOTCase were assayed in the 
colorimetric assay, in 1ml of 50mM Tris-HCl pH 8.3 containing 1mM AOrn, 4.8mM 
CP and either NaCl or KCl at different concentrations, at 25°C for 5 minutes. 
Percentages of activity were calculated using the activity measured in the absence 
of each salt, as reference. 
These results show that the activity of XcAOTCase is not dependent on the 
presence or absence of neither NaCl nor KCl, therefore, based on these results no 
salts were added to the experimental conditions to assay the activity of XcAOTCase. 
 
Enzyme concentration and time of reaction; Detecting enzyme inactivation 
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Determination of the optimal enzyme concentration as well as time of 
reaction are crucial in order to obtain reliable and reproducible results since certain 
enzymes that are stable under optimized conditions of long-term storage will 
inactivate during the course of an activity assay.   
This behavior is characterized by progress curves that plateau early, before 
significant substrate loss has occurred.  Enzyme inactivation commonly occurs for 
two reasons:  
 
• the active conformation of the enzyme may not be stable under the 
specific conditions used in the assay and  
• spontaneous enzyme inactivation that results from catalytic turnover.  
For some enzymes, the chemistry associated with turnover can lead to 
inactivation of the enzyme by covalent adduct formation, of by 
destruction of a key active site amino acid residue or cofactor. 
 
Enzyme inactivation during the course of the time of reaction can be detected 
using the Selwyn test[67].  To perform this test, the reaction progress has to be 
measured at several different concentrations of enzyme.  If the enzyme is not 
inactivated during the course of the reaction, plots of p (concentration of product 
after time) against e0t (e0: total enzyme concentration, t: time) should be 
superimposable 
We performed the Selwyn test for XcAOTCase as described in Materials and 
Methods and the results obtained are shown in Figure 17.  
 
 
 
Figure 17:  Detecting enzyme inactivation during the course of the reaction 
catalyzed by XcAOTCase.  Different amounts of purified XcAOTCase were assayed as described 
before in 1ml of 50mM Tris-HCl pH 8.3 in the presence of 5mM AOrn at 25°C.  The reaction was 
stopped by addition of fresh color reagent (Materials and Methods) at 3, 5, 7.5, 10 and 15 minutes 
after addition of 0.5mM CP to the reaction mixture.  Linear regression fitting was performed 
using all the data obtained in this experiment. 
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These results demonstrate that the rate of product formation is linear with 
respect to time and independent of the amount of enzyme used in the assay. 
 
2.3.4 Determination of the kinetic parameters that characterize 
the activity of XcAOTCase 
 
To characterize the reaction catalyzed by XcAOTCase, the Michaelis constant 
(Km) and the maximum velocity (Vmax) were determined using saturation curves for 
both substrates (AOrn and CP) as described in Materials and Methods.   
 
AOrn saturation curve 
 
The AOrn saturation curve for XcAOTCase was performed in the presence of 
4.8mM of CP while varying the AOrn concentration from 0 to 5mM as Figure 18 
shows. The reaction was carried out for 5 minutes at 25°C.  
 
 
 
Figure 18:  Determination of the kinetics parameters Km and Vmax 
for AOrn of XcAOTCase.  0.3µg of purified XcAOTCase were incubated as 
described before, in the presence of a constant amount of 4.8mM CP while 
varying the AOrn concentration.  After 5 minutes the reaction was stopped and 
the product formation was quantified using ACit as standard.  Data were fitted 
to the Michaelis-Menten equation for enzyme kinetics and the values 
determined for Km and Vmax were 1.05±0.23 mM and 65.08±4.77 µmols/min/µg 
respectively. 
The reaction catalyzed by XcAOTCase follows a Michaelis-Menten type of 
kinetics for AOrn (Figure 18). Km and Vmax were: 1.05 ± 0.23 mM and 65.28 ± 4.77 
µmols min-1µg-1 respectively, as determined by non-linear fitting of the experimental 
data to the following equation: 
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using the program GNUPLOT (by Williams & Kelley, 2004). 
These values are on the range of those obtained for other members of the 
OTCase family.  In general, OTCases from other organisms have a lower affinity for 
ornithine than XcAOTCase has for AOrn, with the exception of the human and S. 
cerevisiae enzymes in these cases the affinity for ornithine is 10 and 2 times greater 
respectively[41, 68]). 
 
CP saturation curve 
 
Km for AOrn (1.05mM) calculated as described in the previous section was 
used as a reference for the determination of the kinetic parameters for CP.  In this 
case the AOrn concentration was kept constant at 5mM (about 5 times the Km), 
while the CP concentration was varied from 0 to 1mM. 
As determined for AOrn, the reaction follows a Michaelis-Menten type of 
kinetic (Figure 19) although in this case the affinity for CP of XcAOTCase is much 
higher than that for AOrn. 
 
 
Figure 19:  Determination of the kinetic parameters Km and Vmax for 
CP of XcAOTCase. 0.3µg of purified XcAOTCase were incubated as described 
before, in the presence of a constant amount of 5mM AOrn while varying the CP 
concentration.  After 5 minutes the reaction was stopped and the product 
formation was quantified using ACit as standard.  Data were fitted to the 
Michaelis-Menten equation for enzyme kinetics and the values determined for 
Km and Vmax were 0.01±0.0007mM and 50.68±0.48 µmols/min/µg respectively. 
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The kinetic parameters for CP were calculated as described in the previous 
section using the GNUPLOT software. The Km value for CP of XcAOTCase is 
0.01mM, such affinity is the greatest compared to that of other members of the 
OTCases family for the same substrate, only S. cerevisiae OTCase possess an 
equivalent value (0.019 mM[68]).  E. coli and human OTCases have an affinity 20 
and 5 times lower[41, 69], respectively, while the difference with P. aeruginosa and 
N. crassa enzymes is 100 and 250 times lower respectively[70, 71]. 
 
The lack of activity of XcAOTCase using ornithine as a substrate (Figure 15) 
suggest that acetylation of the aN-group must be necessary not only for the 
substrate of the reaction catalyzed by this enzyme but, as well, for potential 
inhibitors to be able to exert any kind of effect over XcAOTCase. 
The following section covers the study of the inhibitory effects of the 
acetylated forms of some of the most effective inhibitors of OTCases. 
 
 
2.4 Inhibition studies on XcAOTCase 
 
2.4.1 Substrate inhibition  
 
XcAOTCase has shown a kinetic behavior analogous to other previously 
characterized OTCases.  One of the characteristics common to several OTCases as 
well as ATCases is the inhibition by the reaction substrates ornithine or aspartate 
respectively[41, 72-74].  Sometimes like in the case of human OTC the inhibition is 
very pronounced even at concentrations above 1 mM of ornithine[41].   
Since XcAOTCase has a Km for AOrn similar to that of other OTCases for 
ornithine we expected the same kinetic behavior thus we assayed the AOTCase 
activity of XcArgF’ in the presence of high concentrations of AOrn while maintaining 
the CP concentration constant 10 times above the determined Km (0.01mM) (Figure 
20). 
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Figure 20: Studies on the inhibition of XcAOTCase by the reaction 
substrate AOrn.  The effects of high concentrations of AOrn on the activity of 
XcAOTCase were studied using 2µg of purified enzyme in the presence of a constant 
concentration of 0.1mM CP while varying the AOrn concentration from 0 to 50mM.  
Assays were carried out at 25°C for 5 minutes in 50mM Tris-HCl pH 8.3 and the 
product formation was quantified using ACit as standard.  Every assay was done 
in triplicate and each point represents the average and the standard deviation 
obtained for each condition. 
 
Although not very pronounced, XcAOTCase shows a slight deviation from 
Michaelis-Menten kinetics at high AOrn concentrations (up to 50 mM) (Figure 20).  
The results shown in Figure 20 were fitted to a model of substrate inhibition 
described by the following equation: 
 
  
 
Where Vmax is the maximum enzyme velocity if the substrate didn’t inhibit 
enzyme activity, Km is the Michaelis-Menten constant and Ksi is the dissociation 
constant for substrate binding and represent the substrate concentration at which 
the velocity of the reaction is half the Vmax. 
The dissociation constant calculated for AOrn in the case of XcAOTCase is 
231mM, which is about 10 times higher than the equivalent value for ornithine 
inhibition of human OTCase[41].  These results emphasize the differences between 
this new member of the transcarbamylases family and the well known OTC and 
ATCases, highlighting the discrepancies between nucleotide sequence homologies 
and enzyme activity. 
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2.4.2 Substrates analogs inhibition studies  
 
It has been shown that ornithine analogs such as L-norvaline (Norv) or L-
serine (Ser) can inhibit the reaction catalyzed by E. coli OTCase[69], therefore 
structural analogs of AOrn are expected to behave as inhibitors of XcAOTCase.   
In this section I will present the results obtained from the study on the 
effects of N-acetyl-L-norvaline (ANorv) and pyrophosphate (PP), compounds that are 
structural analogs of AOrn and CP respectively. 
 
N-acetyl-L-norvaline effects on XcAOTCase activity 
 
Norvaline is an structural analog of ornithine that behaves as a competitive 
inhibitor of OTCase with a Ki of 5.8 µM at pH 7.9[72].  Due to the high specificity for 
AOrn of XcAOTCase, norvaline was expected to have very little, if any, effect on its 
activity.   
Inhibition studies in the presence of 5mM norvaline confirmed this 
hypothesis.  This compound reduced the activity of XcAOTCase only by 13% (Figure 
21).   
 
 
 
Figure 21: Inhibitory effects of norvaline on XcAOTCase activity. 
XcAOTCase activity was assayed in the presence of 0 or 5mM (blue and red bars 
respectively).  Data represent the % of reduction of the Vmax and Km.  
 
Therefore, the acetylated derivative of norvaline, ANorv, would be expected 
to inhibit XcAOTCase in a similar way as norvaline inhibits OTCase. 
To confirm this hypothesis, 2µg of purified XcAOTCase were assayed as 
described in Materials and Methods using AOrn saturation curves, in the presence 
of different concentrations of ANorv, ranging from 0.125 to 1mM (Figure 22) 
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Figure 22:  Studies on the inhibition of XcAOTCase activity by the structural 
analog ANorv.  2µg of XcAOTCase were assayed in 1ml of 50mM Tris-HCl pH 8.3 with a 
constant concentration of 0.1mM CP while varying the concentration of AOrn in the presence 
of different concentrations of ANorv ranging from 0 to 1mM.  Lineweaver-Burk 
representation was chosen to more clearly illustrate the kinetic behavior.  The trend lines 
were produced using the apparent Vmax and Km values derived from direct nonlinear least 
squares regression of the data.  Each point shows the average and standard deviation of three 
independent assays. 
The results obtained in this experiment showed that ANorv behaves as a 
competitive inhibitor of XcAOTCase as we hypothesized previously. 
The calculated Ki for ANorv with respect to AOrn is 0.3 mM, a value much 
higher than that of norvaline against E. coli OTCase.  This difference can be 
explained by different interactions of the inhibitors to the respective enzyme.  
 
Pyrophosphate effects on XcAOTCase activity 
 
CP is the common substrate to all the members of the transcarbamylases 
family, therefore compounds that attach to the CP binding site of the proteins are 
expected to affect the enzymatic activity of these proteins.  Pyrophosphate (PP) a 
structural analogue of CP, is able to competitively inhibit ATCase and OTCases 
activity and thus it was expected to inhibit XcAOTCase as well. 
XcAOTCase activity was assayed using 2µg of purified enzyme in the presence 
of different amounts of PP (0, 0.63, 1.25, 2.5 and 5mM) as described in Materials and 
Methods, maintaining constant the CP concentration while varying the AOrn 
concentration. 
Chapter 2 
40 
Figure 23 shows the effects of PP on XcAOTCase activity expressed in 
variation of the kinetic parameters Vmax and Km. 
 
   
 
Figure 23:  Effects of PP over XcAOTCase activity.  Data represent the % of 
reduction of the Vmax (Blue bars, primary vertical axe) in the presence of 0.63, 1.25, 2.5 
and 5mM PP compared to the Vmax in the absence of inhibitor, and the effects exerted 
on the Km at the same concentrations of PP (Red squares, secondary vertical axe). 
Because of the results obtained under these conditions were not conclusive; 
the inhibitory mechanism of PP towards XcAOTCase could not be determined. 
 
 
2.4.3 Synthesis of acetylated PALO derivative α-N-acetyl-δ-
phosphonoacetyl-L-ornithine (PALAO) and study of its effects on 
XcAOTCase activity.  
 
δ-N-phosphonoacetyl-L-ornithine (PALO) is an stable transition-state 
analogue (for CP and ornithine) and a potent inhibitor of OTCase (the Ki for E. coli 
OTCase is 0.77 µM[75]).  As in the case of norvaline and ANorv, we hypothesized 
that the acetylated-PALO derivative, α-N-acetyl-δ-N-phosphonoacetyl-L-ornithine 
(PALAO) would effectively inhibit the activity of XcAOTCase while PALO should 
have no effects. 
 
Synthesis of PALAO 
 
To test our hypothesis, we needed to synthesize PALAO from PALO.   
As described in Materials and Methods, 5.1mg (0.02mmols) of PALO were 
dissolved in 200µl of water and incubated with 0.2mmols of acetic anhydride for 2 
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hours at room temperature with constant stirring.  After incubation the solution was 
neutralized with 2ml of 1% (w/v) KOH. 
Chemically synthesized PALAO was tested for purity by LC-MS and its 
concentration was estimated based on the amount of un-reacted PALO remaining in 
the sample, quantified by LC-MS using PALO as standard (Figure 24). 
 
 
 
Figure 24: LC-MS analysis of chemically synthesized PALAO.  The ions with 
an m/z corresponding to that of PALO (255m/z, Red line) and PALAO (297m/z, Blue 
line) were analyzed for quantification purposes.  The amount of PALAO synthesized 
was quantified based on the amount of unreacted PALO present in the sample using 
known amounts of PALO as standard. 
 
Using LC-MS analyses, the concentration of PALAO in the sample was 
estimated to be 9mM.   
Although the purity of the chemically synthesized PALAO was not optimal 
we tested its ability to inhibit XcAOTCase activity as presented in the next section. 
 
Chemically synthesized PALAO inhibits XcAOTCase activity 
 
Chemically synthesized PALAO was assayed without further purification.  In 
order to discriminate between the effects of PALAO and the rest of the components 
of the reaction, each compound was tested at the higher concentration used in the 
synthesis. 
For comparison purposes, PALO was assayed at similar concentrations as 
estimated for PALAO (Figure 24) 
 None of the components of the chemical reaction affected the enzymatic 
activity of XcAOTCase under the conditions of the assay (data not shown) except for 
PALAO (Figure 24), thus proving that as hypothesized, PALO, due to the lack of 
acetylation at the aN-group has no effect on XcAOTCase activity, while PALAO 
behaves as a potent inhibitor. 
  Based on these results the estimated half-maximal inhibition was calculated 
to occur at 22.4nM of PALAO. 
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Figure 24: Effects of unpurified PALAO on XcAOTCase activity.  The 
effects of PALAO on XcAOTCase activity were tested using 2µg of purified enzyme 
assayed in 50mM Tris-HCl pH 8.3 buffer containing 0.1mM CP and 5mM AOrn in 
the presence of different concentrations of PALAO and PALO at 25°C. The 
reactions were stopped after 5 minutes incubation with fresh color reagent 
(Materials and Methods). Average of three measurements and standard deviations 
for each point are shown. 
To further characterize the inhibitory effects of PALAO, this compound was 
chemically synthesized and purified by IMI TAMI Institute for Research and 
Development, Ltd. (Haifa, Israel). 
 
Inhibition studies using purified PALAO 
 
The effects of purified PALAO, at 0, 0.0075, 0.01 and 0.0125mM on 
XcAOTCase activity were tested in the presence of constant amount of CP (1mM) 
while the concentration of AOrn was varied from 0 to 5mM (Materials and Methods).  
Although the Vmax was only slightly affected by the presence of PALAO 
(Figure 25, panel A), the biggest effect was detected at the Km level (Figure 25, panel 
B).   
The inhibition constant (Ki) calculated for PALAO was 18.23 µM (about 23-
fold less efficient than PALO for E. coli OTCase[75]). 
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Figure 25: Effects of purified PALAO on the Vmax and Km 
of the AOTCase activity of XcArgF’.  The inhibitory effects of 
purified PALAO were studied using 2µg of purified XcAOTCase as 
described in the text.  Panel A shows the effects on the Vmax of the 
reaction relative to absence of PALAO. Panel B shows the effects on 
the Km in the absence and presence of PALAO.  From these results 
we determined that the Ki of PALAO for XcAOTCase was 18.23µM. 
The Ki of PALAO for XcAOTCase obtained using purified PALAO, is in 
concordance with the estimated Ki calculated using unpurified PALAO chemically 
synthesized in our laboratory, 22.4µM (Figure 24), probing the high purity of the 
compound synthesized as well as the accurate estimation of the concentration. 
 
 
2.4.4 Can polyamines affect XcAOTCase activity?  
 
There are other sources of ornithine and arginine in the cells but the 
implication of the arginine biosynthetic pathway as a provider of precursors for 
polyamines biosynthesis is evident (Figure 1). Since the arginine biosynthetic 
pathway is feedback controlled by the end product, it would be expected that 
polyamines might exert some effect over the enzymes that controls the key steps in 
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arginine biosynthesis, in fact P. aeruginosa NAGS is inhibited synergistically by 
polyamines[76], another examples is the catabolic OTCase from P. aeruginosa which 
is inhibited by spermidine[40, 77].   
To test if XcAOTCase activity could be controlled by polyamines we measured 
it in the presence of the polyamines putrescine and spermidine.  We used AOrn 
saturation curves for the study of the effects of these polyamines on XcAOTCase 
activity (Table 2). 
 
Table 2: Effects of polyamines on XcAOTCase activity.  2µg of 
purified XcAOTCase were assayed in 50mM Tris-HCl pH 8.3 as 
described in Materials and Methods in the presence of several 
concentrations of the polyamine in study maintaining constant the CP 
concentration at 0.1mM while varying the AOrn concentration.  Data 
were fitted to the Michaelis-Menten equation for enzyme kinetics for 
each concentration of polyamine assayed.  and  represent the 
Vmax and the Km respectively in the presence of the polyamine at each 
concentration  
Polyamine Concentration (mM)   
Putrescine    
 0 1.00 1.00 
 0.1 1.01 1.04 
 1 0.95 1.01 
 5 0.94 0.97 
    
Spermidine    
 0 1.00 1.00 
 0.1 0.85 0.72 
 1 0.91 0.72 
 5 0.93 0.60 
 
As Table 2 shows, putrescine, under the conditions of the assay did not affect 
the kinetic parameters of XcAOTCase and therefore its activity.  
Contrary to what we were expecting, spermidine did not behave as an 
inhibitor, but as an activator by increasing XcAOTCase affinity for AOrn.   
Probably, by reducing the Km for AOrn the polyamines biosynthetic pathway 
can be somehow controlled since AOrn is transcarbamylated more efficiently than 
deacetylated therefore regulating the availability of the precursor ornithine.  
Although these effects are not that significant when compared to those of arginine 
on NAGS activity[19].  Therefore there should be another mechanism by which the 
availability of precursors of polyamines is controlled in those organisms that posses 
an AOTCase instead of OTCase. 
 
2.5 N-acetyl-L-citrulline continues the arginine 
biosynthetic pathway by means of XcArgE. 
 
The fact that XcArgF’ is indeed an AOTCase and therefore the product of the 
reaction catalyzed by this enzyme is N-acetyl-L-citrulline as demonstrated before, 
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raises a question of biological importance: Can N-acetyl-L-citrulline continue the 
arginine biosynthetic pathway? 
Initial complementation studies performed by Dr. Malamy suggested that N-
acetyl-L-citrulline could be deacetylated to form citrulline thus continuing the 
arginine biosynthetic pathway as described by the following equation: 
 
N-acetylcitrulline + H2O             L-citrulline + acetate 
 
This reaction should be catalyzed by XcArgE.  To test this hypothesis we used 
purified XcArgE (AOD, Figure 2) generously provided by Dr. Daniel Shi and we 
assayed its activity in the presence of AOrn and ACit. 
In this case, 20.6µg of purified XcArgE were incubated for 10 minutes at 37°C 
in 80mM potassium phosphate buffer pH 7.0 containing 0.02mM CoCl2, 0.08mM 
glutathione (reduced) and either AOrn or ACit in a final volume of 500µl.  After 10 
minutes the reaction was stopped by addition of 500µl of 7% sulfosalicylic acid.  
After protein precipitation by centrifugation samples were loaded in an amino acid 
analyzer (Beckman) for its quantification using citrulline and ornithine as 
standards. The results obtained are represented in Figure 26. 
 
 
 
Figure 26:  Deacetylation of AOrn and ACit catalyzed by XcArgE.  The 
activity of XcArgE to deacetylate either AOrn or ACit was assayed using 20.6µg of 
purified enzyme in 80mM potassium phosphate buffer pH 7.0 in the presence of 
0.02mM CoCl2, 0.08mM glutathione (reduced) and either AOrn or ACit in a final 
volume of 500µl.  After an incubation of 10 minutes at 37°C the reaction was stopped 
with 500µl of 7% sulfosalicylic acid and the samples were loaded in a Beckman amino 
acid analyzer after protein precipitation (by centrifugation).  Activity is expressed as 
nmols of citrulline (red squares) or ornithine (blue diamonds) per minute and per µg 
of protein for each concentration assayed. 
 
These results support the hypothesis that ACit continues the arginine 
biosynthetic pathway in Xanthomonads through deacetylation catalyzed by ArgE.  
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Furthermore, these results provided key information to elucidate the arginine 
biosynthetic pathway in these organisms. 
The fact that XcArgE is able to catalyze the deacetylation of AOrn as well as 
ACit can be used by these organisms (those provided with an AOTCase instead of an 
OTCase) to regulate the levels of ornithine thus controlling the arginine and the 
polyamines biosynthetic pathways. 
The characterization of XcArgE and the possible regulatory mechanisms that 
control its activity is an interesting continuation of this work, unfortunately is 
beyond the scope of the present Thesis work and therefore has not been studied. 
 
 
2.6 Summary 
 
The results presented in this chapter: Functional characterization of a 
novel type of transcarbamylase that uses acetylornithine, identified in 
Xanthomonas campestris pv campestris , demonstrates for the first time that 
there is a new member of the transcarbamylases family of enzymes which catalyzes 
the carbamylation of N-acetylornithine to produce N-acetylcitrulline and therefore 
denominated acetylornithine transcarbamylase (AOTCase). 
In the first part of this chapter I have provided conclusive evidences proving 
the substrates of the reaction catalyzed by XcArgF’ to be carbamylphosphate and aN-
acetyl-L-ornithine, and that the product of the reaction is aN-acetyl-L-citrulline. 
The specificity of the reaction has been demonstrated and AOrn is the only 
substrate that XcAOTCase can utilize.  Additionally the optimal conditions for the 
assay of the activity of XcAOTCase have been determined. 
The kinetics parameters of the activity catalyzed by XcAOTCase have been 
determined using saturation curves for both substrates (CP and AOrn) and are 
summarized in Table 3. 
 
Table 3: Kinetic parameters determined for XcAOTCase.  
Summary of the kinetic parameters determined for the AOTCase 
from X. campestris pv campestris. 
Substrate Km (mM) Vmax (µmols/min*µg) 
CP 0.01 ± 0.0007 50.68 ± 0.48 
AOrn 1.05 ± 0.23 65.05 ± 4.77 
 
Although the kinetic parameters shown in Table 3 that characterizes the 
activity of XcAOTCase are on the range of those calculated for other OTCases[41, 68-
71], the affinity of XcAOTCase for CP is unusually high, being comparable only to 
that of S. cerevisiae OTC[68] (0.019mM).   
On the contrary to other members of the transcarbamylases family like OTC 
and ATC that are inhibited by their substrates, ornithine and aspartate 
respectively[41, 72-74], XcAOTCase is not inhibited by the substrate AOrn, even at 
concentrations as high as 50mM (Figure 21).  This fact lead us to think that 
XcAOTCase is not a crucial point of control for the metabolic flow of intermediates in 
the arginine biosynthetic pathway, although the lack of this activity renders 
arginine auxotrophy, highlighting the importance of the reaction catalyzed by 
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XcAOTCase.   
As indicated before (Section 2.5), regulation of XcArgE, both at the 
transcriptional and enzymatic levels could be the mechanism by which, the 
organisms that possess an AOTCase, controls the metabolic flow of intermediates 
between arginine and polyamines biosynthesis. 
The results of the studies with polyamines showed very little or no effect on 
XcAOTCase activity, corroborating the hypothesis that XcArgE is a most likely point 
of control for the arginine and polyamines biosynthetic pathways. 
In this chapter I have also proven that acetylation of the aN-group is not only 
necessary for substrate recognition but that is also necessary for certain compounds 
to exert an inhibitory effect on XcAOTCase activity.  This has been demonstrated not 
only by the lack of enzymatic activity when ornithine was used as substrate but by 
the lack of inhibition when XcAOTCase was assayed in the presence of norvaline or 
PALO while the acetylated versions of each of these compounds were able to inhibit 
the enzymatic activity of XcAOTCase. 
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3.1 Bacteroides fragilis 
 
Bacteroidetes is one of the major lineages of bacteria that arose early during 
the evolutionary process.  Bacteroides species are anaerobic, bile-resistant, non-
spore-forming, Gram-negative rods.  Its taxonomy has undergone major revisions in 
the last decades and contains >20 species, many of these were isolated as single 
strains from human feces[78].  The numbers of B. fragilis isolates are 10 to 100-fold 
lower than those of other intestinal Bacteroides species, yet B. fragilis is the most 
frequent isolate from clinical specimens and is regarded as the most virulent 
Bacteroides species. 
Recent genomic and proteomic advances have greatly facilitated our 
understanding of the uniquely adaptive nature of Bacteroides species.  Thus far (at 
the time of writing the present work) the genomes of B. fragilis, B. thetaiotaomicron, 
B. vulgatus and Parabacteroides distasonis have been sequenced and an increasing 
number is in the process of being completed.  The first to be sequenced were B. 
fragilis and B. thetaiotaomicron.  Both genomes share a few interesting facts; there 
is an unusually low gene content for their genome size, which reflects a large 
number of proteins containing >1000 amino acids, many of these predicted proteins 
were assigned putative functions based on homology with known bacterial proteins 
(~60% in B. thetaiotaomicron).  A second common feature in both species is the 
presence of extensive DNA inversions that may control the expression of a large 
number of genes.  Also, both species exhibit multiple paralogous groups of genes, i.e., 
genes that seem to have derived from a common ancestral gene and have since 
diverged from the parent copy by mutation and selection of drift[78]. 
Bacteroides species has established throughout the evolution a relationship 
that can be considered mutualism since both the bacteria and the human host 
experience increased fitness as a result of the relationship[79].  Is when the 
Bacteroides organisms escape the gut, usually resulting from rupture of the 
gastrointestinal tract of intestinal surgery, they can cause significant pathology[78] 
with high morbidity and mortality rates.   
Although B. fragilis accounts for only 0.5% of the human colonic flora[80], it 
is the most commonly isolated anaerobic pathogen, due in part to its potent 
virulence factors[78], which make this a very clinically important microorganism. 
Arginine is an essential amino acid for the survival of B. fragilis as shown by 
Dr. Malamy using transposon-mediated mutagenesis.  As indicated in the 
Introduction the lack of argF’ in B. fragilis rendered arginine auxotrophy 
highlighting the importance of this gene in the arginine biosynthetic pathway for 
these organisms.  
Even though the crystal structure of the protein encoded by BfargF’ was 
solved[47], its activity remained unknown. 
In this chapter I will present evidences proving that BfArgF’ catalyze the 
transcarbamylation of N-Succinyl-L-ornithine and therefore is a new member of the 
transcarbamylases family. 
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3.2 Identification of potential substrates of BfArgF’  
 
The identification of the AOTCase activity of XcArgF’ implied the possibility 
that, at least, some of the transcarbamylases of unknown activity identified in the 
studies that preceded this thesis could use different derivatives of ornithine as 
substrates for the reaction, since, in contrast to the CP-binding site, that is 
structurally conserved across XcAOTCase, BfArgF’, in human OTCase and E. coli 
ATCase[63], the putative binding site for the second substrate is strikingly different 
from that of other known transcarbamylases[47] (Figure 27). 
 
 
Figure 27: Comparison of the ornithine binding domain in human OTCase 
and the putative ornithine-binding domain in BfArgF’.  Schematic 
representation of the ornithine binding domains in human OTCase (left) and BfArgF’ 
(right).  Residues involved in substrate recognition are indicated by single letter code 
and residue ID number. Putative localization of ornithine in the BfArgF’ protein is 
represented in shadows (left). 
As shown in Figure 15 BfArgF’ lacks the ability to transcabamylate AOrn to 
produce ACit, therefore presenting a new challenge; If this enzyme is required for 
the de novo arginine biosynthesis in B. fragilis but can not use neither ornithine nor 
acetyl ornithine, what it is the substrate of the reaction that can continue the 
pathway? 
 
Could it be N-Succinyl-L-ornithine? 
 
N2-succinyl-L-ornithine (SOrn) is one of the intermediates in the catabolic 
arginine succinyltransferase pathway but the enzyme that utilizes this intermediary 
(astC) has very little similarities with BfArgF’ (13% identity and 21.7% similarity).  
Based on these similarities there is no evidence that SOrn could be the substrate for 
BfArgF’. 
Human 
OTCase 
BfArgF’ 
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Although when the structures of L-ornithine, AOrn and SOrn are compared 
(Figure 28) it seems to be a good candidate since its structure is more voluminous 
than that of AOrn and could potentially fit the binding pocket for the second 
substrate in BfArgF’. 
 
 
Figure 28: Schematic representation of the substrates for OTCase, AOTCase and the 
putative substrate for BfArgF’.  Ornithine, the substrate of OTCase is shown on the left panel of 
the figure, acetylornithine, the substrate of AOTCase is shown in the middle panel and 
succinylornithine is shown on the right panel of the figure.  These schematic representations illustrate 
the structural differences between these compounds. 
 
 
3.3 Chemical synthesis of the potential substrate N-
Succinly-L-ornithine and initial activity assays  
 
To test this hypothesis I synthesized SOrn chemically as follows: 
Initially, 1.076mmols of t-Boc-Ornithine (ornithine with the α-amino group 
temporarily protected by a tert-butyloxycarbonyl group) were dissolved in 5ml of 
water. The pH of the reaction was kept neutral with 40% (w/v) NaOH while 
1.076mmols of succinic anhydride were added. Once the addition of succinic 
anhydride was completed and the pH was neutral the reaction was considered 
finalized. 
Without further analyses the product of the reaction (presumably SOrn in its 
majority) was tested as a substrate of BfArgF’. 
 
Initial activity assays to test SOrn 
 
To determine whether or not BfArgF’ could utilize SOrn as substrate we used 
the chemically synthesized SOrn.   
In this experiment, E. coli C6.1 cells containing the plasmid pTrc99a-BfArgF-
His were induced with IPTG to over express BfArgF’ as indicated in Materials and 
Methods and then lysed in Ni-column purification buffer A (Materials and Methods), 
were assayed using the colorimetric method for OTC and AOTCase activities. 
The cells lysate was assayed without further purification in 50mM Tris-HCl 
pH 8.3 buffer containing 4.8mM CP and an unknown amount of SOrn (a ½ dilution 
Orn AOrn SOrn 
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of the chemically synthesized SOrn without further purification) (Figure 29).  Boiled 
cells lysate and AOrn were used as negative controls. 
 
Figure 29:  First attempt to elucidate the nature of the second 
substrate of the reaction catalyzed by BfArgF’.  20µl of cells lysate 
were assayed in 50mM Tris-HCl pH 8.3 buffer in the presence of 4.8mM CP 
and an unknown amount of SOrn or 5mM AOrn, for 5 minutes at 25°C. (*) 
Sample absorbance was above the detection limit of the instrument 
(spectrophotometer). 
Although the amount of color obtained for the sample assayed with SOrn was 
over the detection limit of the spectrophotometer used for the quantification (≥3 
units of absorbance) and, therefore, the result was not accurate, this experiment 
showed for the first time, that the activity of BfArgF’ seems to be that of N-succinyl-
L-ornithine transcarbamylase (SOTCase). 
In this experiment the cell lysate contained some activity with AOrn that 
could be explained by the presence of other enzymes in the sample assayed. 
While we could not rule out the possibility of an artifact in the SOTCase 
activity obtained due to the induction of undesired pathways and proteins when 
inducing the expression of BfArgF’, the boiled enzyme control showed that the sample 
did not contain a component that could be responsible for the absorbance and thus 
the compound formed when using SOrn as substrate is most likely the product of the 
activity of the over expressed BfArgF’. 
To confirm that BfArgF’ indeed, catalyzes the conversion of SOrn to SCit in 
the presence of CP, BfArgF’ was purified to homogeneity as described in Materials 
and Methods and assayed in the presence of CP and chemically synthesized SOrn. 
The SOTCase activity was tracked through the purification process to 
identify the fraction that contained such activity (Figure 30).  For this experiment 2 
µg of protein from each fraction were assayed in the presence of 1 mM CP and a ½ 
dilution of the chemically synthesized SOrn for 10 minutes using the 1 hr OTCase 
assay as described in Materials and Methods. 
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Figure 30: SOTCase activity levels in the fractions collected during the 
purification of BfArgF’.  2µg of protein from each of the fractions collected during the 
purification of BfArgF’ were assayed for SOTCase activity.  The fractions were: Crude Lysate: 
cells lysated in Ni-column purification buffer A prior to be loaded in the column; Flowthrough: 
fraction collected after the cells lysate has been loaded onto the column, containing a mixture of 
proteins that do not bind the Ni-column; Wash: fraction containing proteins eluted using mild 
stringent conditions (80% buffer A, 25% buffer B, Materials and Methods); Ni-column purified: 
containing purified BfArgF’ after elution from the column using stringent conditions (50% 
buffer B). Measurements were performed in duplicate for each fraction and the average is 
represented in the graph. 
This experiment shows that the activity is restricted to the fractions that 
contains the over expressed protein, that is the crude lysate and the Ni-column 
purified fractions, proving that BfArgF’ catalyzes the transcarbamylation of SOrn to 
produce SCit in the presence of CP. 
 
 
3.4  Identification of N-succinyl-L-Citrulline as the 
product of the reaction catalyzed by BfArgF’ 
 
Although the experiments described in the previous sections demonstrate 
that the substrate of the reaction catalyzed by BfArgF’ is SOrn, they only indicate 
that the product of such reaction contains an ureido group as described in section 
2.2.1, Chapter 2. It is expected that being CP and SOrn the substrates of the 
reaction, the product should be SCit, which contains an ureido group and through 
de-succinylation can continue the arginine biosynthetic pathway in these organisms. 
In order to prove this hypothesis both, chemically and enzymatically 
synthesized SCit were analyzed by NMR and LC-MS (Figure 31) as specified in 
Materials and Methods. 
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Figure 31:  NMR and LC-MS analysis of the product of the reaction catalyzed 
by BfArgF’. A, proton NMR of chemically synthesized N-succinyl-L-ornithine and N-
succinyl-L-citrulline are shown compared with the products formed using CP and SOrn 
incubated with either BfArgF’ or heat inactivated BfArgF’. B, The enzymatic product of the 
SOTCase reaction (dashed blue line) analyzed using LC-MS has the same retention time 
and m/z as the chemically synthesized SCit (dashed red line).  Ions corresponding to SOrn 
and SCit were extracted from the total spectra of chemically synthesized compounds and 
the enzymatic reaction, and then plotted.  Heat inactivated BfArgF’ used as negative 
control.  Base lines have been offset vertically for clarity. 
 
The peaks seen in the proton NMR spectra of the enzymatically-generated 
product have chemical shifts that are identical to those of the chemically synthesized 
SCit (Figure 31 panel A). 
Thick lines in Figure 31, panel B, represent SOrn and dashed lines SCit.  In 
red are shown the extracted m/z ions for a concentration of 5 mM of both compounds 
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chemically synthesized run independently. In blue lines the extracted m/z ions for 
both compounds after incubation of BfArgF’ in the presence of 5 mM SOrn and 1 mM 
CP, both peaks are present but the one corresponding to SOrn has decreased with 
respect to the initial concentration (same as in the chemically synthesized run), 
indicating that this substrate has been consumed during the reaction.  And in green 
lines the same ions extracted from a sample in which BfArgF’ has been heat 
inactivated and incubated as the native sample, where only the peak for SOrn is 
present and therefore, no SCit is formed, as expected.  As this Figure 31 shows, the 
retention times and the m/z of the enzymatically-synthesized product are identical to 
those of the chemically synthesized SCit. 
The results obtained by these two techniques confirmed that the product of 
the reaction catalyzed by BfArgF’ is N-succinyl-L-citrulline.   
Based on the results presented in the previous sections we concluded that the 
activity of BfArgF’ is that of N-succinyl-L-ornithine transcarbamylase (SOTCase) and 
would be described by the following equation: 
 
carbamoyl phosphate + N-succinyl-L-ornithine        N-succinyl-L-citrulline + Pi 
 
This SOTCase activity has not been described previously and therefore 
BfSOTCase can be added as a new member of the transcarbamylases family. 
 
 
3.5 Determination of the extinction coefficients for 
citrulline, acetylcitrulline and succinylcitrulline 
 
Due to the lack of chemically synthesized and purified SCit, thus far we used 
ACit as standard for the quantification of the product formed by BfSOTCase.   
We observed that the same concentration of Cit and ACit produce different 
amount of color under the same conditions, therefore we expected that replacing the 
acetyl group for the succinyl group would have similar effects on the extinction 
coefficient. 
In order to accurately characterize the SOTCase activity of BfArgF’, SOrn and 
SCit were synthesized and purified by Chiral Quest Co. (Monmouth Junction, NJ). 
We used purified ACit and SCit to determine the extinction coefficients for 
each compound.  
We used a colorimetric assay that detects the ureido group present in all 
three compounds, to determine the extinction coefficients.  Samples containing 0, 5, 
10, 25, 50, 75 and 100 nmols of either Cit, ACit or SCit in 1ml of 50mM Tris-HCl pH 
8.3 were treated with 1ml of fresh color reagent (Materials and Methods) and 
incubated at room temperature over night under constant shaking (100rpm) and 
protected from the light.  Following the over night incubation at room temperature, 
samples were incubated at 42°C in a water bath under light for color development 
completion.  After that samples were placed on ice water and the absorbance was 
measured at 466nm using a spectrophotometer. 
We applied the Beer-Lambert law that is characterized by the equation, to 
determine the extinction coefficients: 
 
BfArgF’ 
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where A represents the absorbance at any given wavelength, e represents the 
molar absorptivity or extinction coefficient; l is the cell path length and c the analyte 
concentration. 
The results obtained in this experiment are shown in Figure 32. 
 
 
 
Figure 32: Determination of the extinction coefficients for citrulline, 
acetylcitrulline and succinylcitrulline.  Each concentration was measured in 
independent duplicates. Both measurements for each concentration are shown in 
the graph to highlight the accuracy of the determination.  Extinction coefficients 
can easily be calculated from the slopes of these representations when using linear 
regression fitting of the data 
 
The extinction coefficients calculated from these results were: 0.0215, 0.0196 
and 0.0063 L mol-1 cm-1 for Cit, ACit and SCit respectively. These extinction 
coefficients are quite different highlighting the importance of the use of the 
appropriate reference compound when determine enzyme activity and calculating 
kinetic parameters. 
Purified SCit and SOrn were used as reference and substrate respectively, to 
accurately determine the kinetic parameters of BfSOTCase. 
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3.6 Initial characterization of the SOTCase activity of 
BfArgF’ 
 
 
SOrn saturation curve 
 
For the determination of the Km for SOrn and the Vmax of BfSOTCase, 0.2µg of 
purified enzyme were assayed in 50mM Tris-HCl buffer pH 8.3 in the presence of a 
constant amount of 4.8 mM CP while the SOrn concentration was varied from 0 to 
25mM, in a final volume of 1ml (Materials and Methods). After 5 minutes incubation 
at 25°C the reaction was stopped by the addition of freshly made color reagent 
(Materials and Methods).  Each point of the saturation curve was measured in 
triplicate (Figure 33). 
 
 
 
Figure 33: Determination of the kinetics parameters Km and Vmax for 
SOrn of BfSOTCase.  0.2µg of purified BfSOTCase were assayed in 50mM Tris-
HCl pH8.3 buffer in the presence of 4.8mM CP while varying the SOrn 
concentration between 0 and 25mM in a final volume of 1ml. After 5 minutes 
incubation at 25°C the reaction was stopped and the product formation was 
quantified using SCit as standard. Data showed slight substrate inhibition above 
15mM of SOrn.  The Km and Vmax values determined using the substrate inhibition 
equation to fit the data were: 12.5±1.5mM and 370.6±32.6µmols min-1mg-1 
respectively, while the calculated Ksi was 20.4±3.3mM. 
 
Under these conditions the enzyme shows a slight substrate inhibition at 
concentrations of SOrn above 15mM. Data were fitted to the substrate inhibition 
equation (described in section 3.7.1). 
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The kinetic parameters calculated for SOrn in this experiment were: 
 Vmax= 370.6 ± 32.6 µmol min-1mg-1 
 Km= 12.5 ± 1.5 mM 
 Ksi= 20.4 ± 3.3 mM 
The Km of BfSOTCase for the substrate SOrn is the highest compared to other 
members of the transcarbamylase family, especially when compared with human 
and S. cerevisiae OTCases[41, 68]). 
 
CP saturation curve 
 
The kinetics parameters Km and Vmax of BfSOTCase for the substrate CP were 
determined using 0.2µg of purified enzyme as previously described.  BfSOTCase was 
assayed in 50mM Tris-HCl buffer pH 8.3 in the presence of a constant amount of 
20mM SOrn (approximately 2 times the previously calculated Km, since higher 
concentrations would inhibit the enzyme) while varying the concentration of CP 
from 0 to 2mM.  Figure 34 shows the CP saturation curve obtained under these 
conditions. 
 
 
 
Figure 34: Determination of the kinetic parameters Km and Vmax for CP 
of BfSOTCase.  0.2µg of purified BfSOTCase were assayed in 50mM Tris-HCl buffer 
pH 8.3 containing a constant amount of SOrn of 20mM while varying the CP 
concentration from 0 to 2mM. After 5 minutes incubation at 25°C the reaction was 
stopped and the product formation was quantified using SCit as standard. Data were 
fitted to the Michaelis-Menten equation for enzyme activity using the program 
GNUPLOT (by Williams & Kelley, 2004), and the Km and Vmax were determined to be 
0.025 ± 0.003mM and 141.7 ± 3 µmol min-1mg-1 respectively. 
 
Data were fitted to the Michaelis-Menten equation for enzyme kinetics using 
the software GNUPLOT and the kinetic parameters Km and Vmax were determined to 
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be 0.025 ± 0.003mM and 141.7 ± 3 µmol min-1mg-1 respectively. 
The affinity of BfSOTCase for CP is quite high as in the case of the affinity of 
XcAOTCase[61] for CP and is only comparable to that of S. cerevisiae OTCase[68]. 
These results show that BfSOTCase behaves as other members of the 
transcarbamylases family previously described and s in the case of XcAOTCase, 
BfSOTCase is a highly specific enzyme unable to catalyze the transcarbamylation of 
any substrate other than SOrn as demonstrated before (Figures 15 and 29).  
As demonstrated for XcAOTCase, the acetyl group was required both for 
activity as well as for inhibition (Figures 15, 22, and 24), therefore it was expected 
that the succinylated version of compounds such as PALO would exert inhibitory 
effects over BfSOTCase since PALO and PALAO are two of the most potent inhibitors 
of OTCase and AOTCase respectively[61, 75]. 
 
To test this hypothesis I chemically synthesized the succinylated derivative of 
PALO: αN-succinyl-δN-phosphonoacetyl-L-ornithine (PALSO). 
 
 
3.7 Chemical synthesis of the potential BfSOTCase 
inhibitor αN-succinyl-δN-phosphonoacetyl-L-ornithine 
(PALSO). 
 
For the chemical synthesis of PALSO 5.1mg (0.02mmols) of PALO were 
dissolved in 200µl of water. The pH of the solution was kept neutral with 40% (w/v) 
NaOH while 0.2mmols of succinic anhydride were added at room temperature with 
constant stirring. Once the pH stabilized the reaction was considered completed. 
The amount of PALSO chemically synthesized was estimated by LC-MS, 
using PALO as standard, based on the amount of un-reacted PALO present in the 
sample once the reaction was stopped. The amount of un-reacted PALO was 
estimated based on both the area and the height of the ion 296 m/z when extracted 
from the LC-MS results (Figure 35). 
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Parameter Measurement 
Remaining PALO 
concentration 
(mM) 
Estimated 
PALSO 
concentration 
(mM) 
Estimated % of 
conversion 
Area 184406 0.177 6.708 97.4% 
Height 33411.3 0.222 6.663 96.8% 
     
Figure 35: Estimation of the concentration of chemically synthesized PALSO.  The 
amount of PALSO was calculated by LC-MS based on the remaining un-reacted PALO present in 
the sample after the chemical reaction was stopped. Quantification was determined by 
measuring both the area and the height of the peak corresponding to the PALO ion (296.1 m/z).  
Bottom table shows the results obtained for the un-reacted PALO present in the sample of the 
chemically synthesized PALSO as well as the estimated PALSO concentration and the % of 
conversion from PALO to PALSO. 
As shown in Figure 35, the degree of conversion was near 100%.  Although 
both measurements (area under the peak and peak height) provided similar results 
for the estimation of the amount of PALSO present in the sample, we used the 
estimation based on the area under the peak parameter for our assays. 
Chemically synthesized PALSO was used without further purification to 
study its effects on BfSOTCase activity. 
 
 
3.8 Study of the effects of PALSO on BfSOTCase 
activity 
 
For these assays 0.2µg of purified BfSOTCase were assayed in 50mM Tris-HCl 
buffer pH 8.3 and 5mM SOrn and 0.1mM CP in the presence of different amounts of 
PALSO (ranging from 0 to 670.8µM). After 5 minutes incubation at 25°C, the 
reaction was stopped with fresh color reagent (Materials and Methods) and the 
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product was quantified using SCit as standard (Figure 36). 
 
 
 
Figure 36: Inhibitory effects of PALSO on BfSOTCase activity measured 
at saturating conditions.  0.2µg of purified BfSOTCase were assayed in 50mM 
Tris-HCl buffer pH 8.3 containing 5mM SOrn and 0.1mM CP in the presence of 
different amounts of PALSO (ranging from 0 to 670.8µM).  Reactions were carried 
out for 5 minutes at 25°C and product formation was quantified using SCit as 
standard. 
 
Data were fitted to the four parameter logistic model (4PL), also called the 
Hill-Slope model, described by the following equation: 
 
 
 
where y is the percent activity and x is the corresponding concentration. The fitted 
IC50 parameter is the relative IC50, and is defined as the concentration giving a 
response half way between the fitted top and bottom of the curve 
(http://www.ncgc.nih.gov/guidance/section3.html). 
As shown in the Figure 36, PALSO is a very potent inhibitor of BfSOTCase 
with a calculated IC50 of 0.45 ± 0.05 µM. 
The effects of un-purified PALSO on BfSOTCase activity are comparable to 
those of PALAO on XcAOTCase activity[61] (Figure 24) and PALO on EcOTCase 
activity[75], although the calculated IC50 is higher in the case of PALSO.  These 
differences could be explained by different interactions of each bisubstrate analog to 
the corresponding enzyme. 
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3.9 Summary 
 
In this Chapter 3: “Demonstration that a structurally obvious 
transcarbamylase from Bacteroides fragilis ,  of previously unknown 
activity catalyzes the transcarbamylation of succinylornithine. 
Functional characterization of this transcarbamylase” I have provided 
evidences probing that the activity of the enzyme codified by the gene argF’ in B. 
fragilis is that of an N-succinyl-L-ornithine transcarbamylase (SOTCase). 
BfArgF’ specifically catalyzes the transcarbamylation of succinylornithine in 
the presence of CP as the specificity tests performed shown in this, as well as, in the 
previous chapter have demonstrated.  NMR and LC-MS analyses confirmed that the 
product of the reaction catalyzed by BfArgF’ is N-succinylcitrulline. 
In this chapter the initial characterization of the reaction catalyzed by 
BfSOTCase is presented.  The kinetics parameters (Km and Vmax) obtained for each of 
the substrates of this enzyme are summarized in Table 4. 
 
Table 4: Initial characterization parameters determined 
for BfSOTCase.  The enzyme showed slight substrate inhibition 
for SOrn but not with CP, under the conditions of the assay. 
 SOrn CP 
Km (mM) 12.5 ± 1.5 0.025 ± 0.003 
Vmax (µmol min-1mg-1) 370.6 ± 32.6 141.7 ± 3 
Ksi (mM) 20.4 ± 3.3 n/a 
 
BfSOTCase showed substrate inhibition by SOrn, that was not detected in 
XcAOTCase, although it is much less pronounced than in other members of the 
transcarbamylases family[41, 72-74]. 
Based on the specificity of the reaction catalyzed by BfSOTCase I have 
synthesized the bisubstrate analog PALSO from PALO and characterized its 
inhibitory effects on BfSOTCase.  Using PALSO chemically synthesized (97.4% pure), 
the IC50 was determined to be 0.45µM probing that PALSO is a potent inhibitor of 
BfSOTCase activity, although its behavior is still undetermined since no purified 
source of PALSO is available.  These results suggest that the succinylated 
derivatives of common inhibitors of OTCase, like norvaline, should inhibit the 
activity of BfSOTCase, as the acetylated derivatives inhibit the XcAOTCase activity. 
The discovery of the SOTCase activity of BfArgF’ described here, 
demonstrates the presence of a succinylated intermediate in the arginine 
biosynthetic pathway in this organism since the lack of argF’ renders arginine 
auxotrophy.  The fact that succinylornithine is an obligate intermediate in the 
arginine biosynthetic pathway implies that the initial part of this pathway utilizes 
succinylated precursors. 
To probe this hypothesis I will elucidate the activity of the initial enzymes in 
the arginine biosynthetic pathway of B. fragilis, that is ArgA and ArgB. 
The results obtained from these studies are presented in the following 
Chapter 4. 
 
 
    
 
  

     
 
Chapter 4. The use of N-succinyl-L-
glutamate as substrate by ArgB of 
Bacteroides fragilis supports the 
existence in this organism of an arginine 
biosynthetic pathway using N-
succinylated intermediates. 
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4.1 The context of this chapter 
 
As stated in the introduction, in the classical arginine biosynthetic pathway, 
known until now, the flow of acetylated precursors leads to the formation of AOrn 
(Figure 2).   
In the majority of organisms, AOrn is then deacetylated to form ornithine by 
the enzyme acetylornithine deacetylase (AOD), also called acetylornithinase (AO, 
E.C. 3.5.1.16), to continue the pathway.  
In chapter 2 I presented results showing that in Xanthomonads AOrn is 
transcarbamylated by AOTCase producing ACit that is then deacetylated by the 
product of the gene argE to continue the arginine biosynthetic pathway in these 
organisms. 
The discovery of the SOTCase activity of BfArgF’ lead us to think that there 
are other possible pathways for the de novo arginine biosynthesis that doesn’t occur 
through acetylated intermediates.  In the case of B. fragilis (and concomitantly the 
Bacteroidetes family) the arginine biosynthetic pathway would involve succinylated 
intermediates, something never described before. 
In this chapter I am going to present evidences that support this hypothesis 
and that let us conclude that in the Bacteroidetes family of microorganisms the de 
novo biosynthesis of arginine occurs through succinylated intermediates instead of 
acetylated intermediates, a novel pathway for the biosynthesis of arginine. 
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4.2 Initial attempts to assay the first enzyme of the 
arginine biosynthetic pathway in B. fragilis  
 
Recent advances in the sequencing of the genomic DNA of several members of 
the family Bacteroidetes has made possible the localization of the distribution of the 
genes involved in the arginine biosynthetic pathway on these organisms (Figure 37). 
 
 
 
 
 
 
 
Figure 37: Schematic representation of the distribution of genes involved in the 
arginine biosynthetic pathway common to the Bacteroidetes  family of 
microorganisms.  The gene annotated as “argX?” highlighted with a red box is supposed to 
participate in the arginine biosynthetic pathway in these organisms.  Sequence analyses using 
the BLASTX from NCBI returned no similarities between argX and any of the genes known to 
be involved in the arginine biosynthetic pathway in E. coli.  
 
Located between the genes identified as argR and argG there was found an 
open reading frame (ORF), argX that codifies for a protein supposedly involved in 
the arginine biosynthetic pathway.  Sequences analyses revealed that the protein 
encoded by the gene denominated argX does not share any homologies or similarities 
to any of the genes of the arginine biosynthetic pathway in other organisms. 
The lack of similarities with other known genes of the arginine biosynthetic 
pathway could be explained by the fact that Bacteroidetes apparently uses an 
arginine biosynthetic pathway different from the rest of the organisms described 
until now as hypothesized before. 
To test if BfargX is indeed the first gene involved in the arginine biosynthetic 
pathway in B. fragilis, we cloned argX from B. fragilis TM4000 using the primers: 
BfargXXhoIFW and BfargXNdeIRV as described in Materials and Methods 
generating the expression vector pET21b-BfArgX.  Should this be true the reaction 
catalyzed by BfArgX would be described by the following equation: 
 
succinyl-CoA + L-glutamate              CoASH + N-succinyl-L-glutamate 
 
In an attempt to elucidate the nature of the reaction catalyzed by BfArgX, 
lysates of cells over-expressing the enzyme were assayed in the presence of Succinyl-
CoA (SucCoA) and glutamate using the assay described by Caldovic et al.[81].  
Monitorization of the product (N-succinyl-L-glutamate, NSG), formed as well as 
substrate consumed produced similar results.  Unfortunately, the rate of product 
formation in the presence of the lysate was indistinguishable from that of the 
spontaneous reaction of the substrates (Figure 38) and consequently we could not 
conclude that BfArgX has N-succinylglutamate synthase (NSGS) activity. 
 
 
argB? argE argF argH 
argD, argC, argG, argX?, argR 
BfArgX 
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Figure 38: Initial attempts to assay the activity of BfArgX.  E. coli BL21 
(DE3) cells over expressing BfArgX were disrupted in 50mM KPi3 pH 7.5 buffer 
containing 200mM KCl, 20% glycerol, 10mM β-ME, 0.0006% Triton X-100 and 1% 
acetone.  A total of 193.6µg of total protein were assayed in 100µl of 50mM MES 
buffer pH 6.0 containing 50mM glutamate and 2.5mM SucCoA. The reaction was 
stopped by adding 100µl of 30% TCA and after centrifugation, samples were loaded 
onto the LC-MS instrument. Product formation was quantified using glutamate as 
standard and measuring the amount of substrate consumed. 
 
 
4.3 Can the spontaneous formation of NSG be reduced so 
the activity of BfArgX could be measured? 
 
In order to be able to assay the supposed NSGS activity of BfArgX I monitored 
the rate of spontaneous NSG formation from glutamate and SucCoA under different 
conditions to determine the conditions at which such formation is minimal and 
therefore more easily distinguishable from the enzymatically catalyzed reaction. 
 
Effect of pH on the spontaneous formation of NSG 
 
The spontaneous formation of NSG was measured at different pH using MES 
buffer.  The conditions for the assay were the same as described in the previous 
section with the only difference of the pH of the solution in which the compounds 
were mixed. 
Figure 39 shows that, under the conditions tested, the spontaneous formation 
of NSG from glutamate and SucCoA is maximal at pH 7.5 while minimal at pH 6.0. 
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Figure 39: pH effects on the rate of spontaneous formation of NSG.  The pH 
effects on the spontaneous formation of NSG were tested using 50mM MES 
buffer at different pH (ranging from 6 to 8.5).  Product formation was determined 
by the presence of the ion whose m/z corresponded to that of NSG (248.1 m/z) on 
each sample measured by LC-MS. 
Based on these results our first approach to elucidate the enzymatic activity 
of BfArgX was performed at a pH (pH 6) at which the spontaneous formation of NSG 
is minimal compared to higher pH.  The fact that the NSG formation in the presence 
of the cells lysate containing BfArgX was indistinguishable from that in the absence 
of the lysate lead us to think that the buffer composition for the assay of this enzyme 
was not appropriate, therefore we tested the spontaneous formation of NSG in 
different buffers at pH 6.0 and 6.5. 
 
Effect of buffer composition on the spontaneous formation of NSG at pH 6 
and 6.5 
 
The spontaneous formation of NSG in MES and Bis-Tris buffers was tested at 
pH 6 and 6.5 in an attempt to optimize the conditions of the assay for the enzymatic 
activity of BfArgX. 
Figure 40 shows that the rate of spontaneous formation of NSG from 
glutamate and SucCoA is minimal in MES pH 6.0 compare to MES pH 6.5 and Bis-
Tris pH 6.0 and 6.5. 
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Figure 40: Determination of the rate of spontaneous formation of NSG 
in MES and Bis-Tris buffers at pH 6.0 and 6.5. The buffer composition 
effects on the spontaneous formation of NSG were tested using 50mM MES or Bis-
Tris buffers at pH 6.0 and 6.5.  Product formation was determined by the presence of 
the ion whose m/z corresponded to that of NSG (248.1 m/z) on each sample measured 
by LC-MS. 
The results shown in Figure 40 demonstrate that the conditions in which the 
initial assays to elucidate the activity of BfArgX were performed were optimal in 
terms of minimal spontaneous formation of NSG from glutamate and SucCoA. 
The lack of similarities between BfargX and any known gene involved in the 
arginine biosynthetic pathway, and the fact that we couldn’t assay the activity of the 
enzyme encoded by it, forced us to move to the following reaction involved in the 
arginine biosynthetic pathway (Figure 2): the ATP-dependent phosphorylation of 
NAG (in the case of Bacteroidetes, NSG), in order to prove that the arginine 
biosynthetic pathway in B. fragilis indeed occurs through succinylated intermediates 
as hypothesized before. 
 
 
4.4 Synthesis of the putative substrate of the reaction 
catalyzed by BfArgB 
 
The second step of the arginine biosynthetic pathway, the ATP-dependent 
phosphorylation of NAG (Figure 2), is catalyzed, in most organisms[9], by N-acetyl-
L-glutamate kinase (ArgB, NAGK, EC 2.7.2.8).  
This enzyme becomes the point of control of the metabolic flow of the arginine 
biosynthetic pathway in those organisms with a “cyclic pathway” (those that have an 
argJ gene).  Since no other genes similar to argJ can be found in the B. fragilis 
genome it is expected that the control of the metabolic flow of intermediates to be 
exerted therefore at the level of the synthesis of NSG catalyzed by ArgA.   
So far we have unsuccessfully attempted to elucidate the enzymatic activity 
of the enzyme encoded by the gene denominated argX in B. fragilis as shown in the 
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previous epigraphs and therefore we could not determine if this protein is 
responsible for the control of the metabolic flow of intermediates in the arginine 
biosynthetic pathway of B. fragilis. 
The B. fragilis argB gene (Figure 35) has 45.8% similarity with its E. coli 
ortholog, and it has been identified as essential for arginine biosynthesis in this 
organism (Dr. Malamy, transposon mediated mutagenesis experiments, personal 
communication). 
If the hypothesis of a succinylated initial part of the pathway is correct, the 
reaction catalyzed by the product of the gene argB in B. fragilis, should be the ATP-
dependent phosphorylation of NSG to produce N-succinylglutamyl phosphate 
(NSGP) to continue the arginine biosynthetic pathway. This reaction is described by 
the following equation: 
 
N-acetyl-L-glutamate + ATP          N-acetyl-L-glutamate 5-phosphate + ADP 
 
To test this hypothesis the putative substrate of BfArgB, NSG had to be 
chemically synthesized since it is not commercially available. NSG was chemically 
synthesized from succinic anhydride and glutamate. 
0.025 moles of glutamic acid (monosodium salt) were dissolved in 25ml of 
water.  NaOH was added until fully dissolved.  The solution was then incubated 
with 0.025 moles of succinic anhydride for 24 hours at around 50°C with constant 
stirring.  Quantification of the product formation was obtained by measuring the 
depletion of peaks corresponding to unreacted glutamic acid (148 m/z) using known 
concentrations of glutamic acid as a standard curve by LC-MS (Figure 41) 
 
 
 
Figure 41: Glutamate standard curve used for the quantification of 
NSG. Chemically synthesized NSG was quantified based on the amount of 
unreacted glutamate present in the sample after the reaction was considered 
finished. LC-MS analysis tracking the ion corresponding to glutamate (148.1 m/z). 
Blue squares represent the area measured under the peak of the 148.1 m/z ion and 
red squares represent the height of the peak. Both measurements shows a good 
correlation but for quantification purposes I used the area results. 
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Both glutamate and aspartate are structurally very similar; therefore, in 
order to test the specificity of the enzymatic reaction catalyzed by BfArgB, assuming 
we could detect and quantify it, N-succinyl-L-aspartate (NSA) was also chemically 
synthesized from succinic anhydride and L-aspartate following the same procedure 
used for the synthesis of NSG. 
LC-MS and ninhydrin reactivity (measured in an amino acid analyzer) 
techniques were used for the quantification of the product formed in each reaction, 
as indicated in Materials and Methods.  Quantifications were done based on the 
amount of free, un-reacted, glutamate and aspartate present in each sample after 
the reactions were considered to be complete.  The results were very similar using 
both techniques and we obtained a 99.95% and 86.8% conversion for NSG and NSA 
respectively yielding a concentration of 679.7 and 590.3mM respectively. 
These chemically synthesized compounds were used in the enzymatic activity 
assays without further purification. 
 
 
4.5 Demonstration that enzyme codified by BfargB  catalyzes 
the ATP-dependent phosphorylation of NSG 
 
The gene argB from B. fragilis was cloned as described in Materials and 
Methods using the primers BfargABNdeIFW and BfragABXhoI into the expression 
vector pET28a, and over-expressed in BL21 cells. 
 
Lysates assays to test the activity of BfArgB 
 
In a first approach to identify the activity of BfArgB, cells over expressing the 
protein were disrupted by sonication in Ni-column buffer A as indicated in Materials 
and Methods, and the lysate assayed without further purification as described by Qu 
et al. 2007[82]. 
Cells lysates were assayed for 30 minutes at 37°C in 100mM Tris buffer, pH 
7.4 containing 400mM ATP, 100mM MgCl2 and 400mM hydroxylamine in the 
presence of 8mM NAG, glutamate or aspartate or 54.4mM NSG or 52.1mM NSA.  
H2O and boiled cells lysate were used as negative controls of the reaction (Figure 
42).  Product formation was quantified using glutamyl hydroxamate as standard. 
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Figure 42: Initial attempt to assay the activity of BfArgB using chemically 
synthesized NSG.  Cells over-expressing BfArgB were lysated in Ni-column buffer A (Materials 
and Methods) and assayed for kinase activity without further purification. Each sample contained 
610.2µg of total lysate (boiled or non boiled) in 100mM Tris buffer, pH 7.4 containing 400mM ATP, 
100mM MgCl2 and 400mM hydroxylamine and 8mM NAG, glutamate or aspartate or 54.4mM NSG 
or 52.1mM NSA in a final volume of 500µl.  After 30 minutes at 37°C the reaction was terminated 
by addition of 500µl of ferric chloride solution (5% FeCl3, 8% TCA and 0.3 M HCl). Product 
formation was estimated using glutamyl hydroxamate as standard. (*) indicates that the sample 
absorbance was over the limit of detection of the spectrophotometer used and therefore should only 
be considered as a reference for the presence of the kinase activity on the cells lysate and not as an 
accurate quantification of such activity. 
The results obtained in this experiment showed for the first time that BfArgB 
has N-succinylglutamate kinase (NSGK) activity. 
To confirm that BfArgB has NSGK activity and that the results presented in 
the previous figure were not an artifact due to the complexity of the sample assayed 
(cells over-expressing BfArgB lysate), the assay was performed with the purified 
enzyme. 
 
Purified BfArgB activity confirmed that this enzyme is in fact a N-
succinylglutamate kinase 
 
BfArgB was purified using Ni affinity as described in Materials and Methods 
with purity higher than 95%. 
To test the specificity of the reaction catalyzed by BfArgB, 10µg of purified 
enzyme were assayed in 100mM Tris buffer pH 6.0 containing 400mM ATP, 100mM 
MgCl2 and 400mM hydroxylamine and 8mM NAG, glutamate or aspartate or 
54.4mM NSG or 52.1 NSA in a final volume of 100µl.  After 20 minutes incubation at 
-5 
45 
95 
145 
195 
245 
295 
345 
Succinyl 
Glutamate 
Acetyl 
Glutamate 
Glutamate Succinyl 
Aspartate 
Aspartate H2O 
SG
H
 (n
m
ol
s/
30
m
in
) 
Lysate Boiled lysate Buffer H2O 
*
    Chapter 4 
77 
37°C the reaction was stopped with 100µl of ferric chloride solution (Materials and 
Methods). Product formation was quantified using glutamyl hydroxamate as 
standard.  Heat-inactivated enzyme (10µg of purified BfArgB boiled for 10 minutes) 
was used as negative control for the experiment (Figure 43). 
 
 
 
Figure 43: Confirmation that BfArgB catalyzes the ATP-dependent phosphorylation of 
succinylglutamate.  10µg of purified BfArgB were assayed for NSGK activity in 100mM Tris buffer 
pH 7.4 containing 400mM ATP, 100mM MgCl2 and 400mM hydroxylamine and 8mM NAG, glutamate 
or aspartate or 54.4mM NSG or 52.1 NSA in a final volume of 100µl. The reaction was carried out for 
20 minutes at 37°C and stopped with 100µl of ferric chloride solution (Materials and Methods).  Each 
assay was performed in triplicate and the graph shows the average and standard deviation for each 
condition. 
These results prove that BfArgB has NSGK activity and highlight its 
specificity, being able to catalyze only the ATP-dependent phosphorylation of NSG 
but not of any of the other substrates tested (NAG, glutamate, NAS or aspartate). 
 
 These results confirmed the initial hypothesis of an arginine biosynthetic 
pathway in B. fragilis that utilizes succinylated instead of acetylated intermediates, 
which has never been described before.   
 
 
4.6 Initial characterization of the NSGK activity of BfArgB 
 
As in the case of the enzymes described previously in this thesis work, I did 
an initial characterization of the reaction catalyzed by BfArgB and studied the 
putative inhibitory effects of arginine to elucidate if BfArgB controls the arginine 
biosynthetic pathway flow. 
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Test for enzyme inactivation and linearity of the reaction catalyzed by BfArgB 
 
The linearity of the reaction catalyzed by BfArgB was tested using 2 and 2.5µg 
of purified enzyme.  This test was also used to determine if enzyme inactivation 
occurs during the time of the reaction.  BfArgB was assayed in 100mM Tris buffer pH 
6.0 containing 20mM ATP, 100mM MgCl2 and 400mM hydroxylamine and 8mM 
NSG for 1, 2.5, 5, 7.5 and 10 minutes at 37°C. 
The results showed that the reaction catalyzed by BfArgB is linear with 
respect to the time and that there is no detectable enzyme inactivation in the course 
of the reaction when either 2 or 2.5µg of purified BfArgB are used for the assay 
(Figure 44).  
 
 
 
Figure 44: Test for enzyme inactivation (Selwyn’s test) and linearity of 
the reaction catalyzed by BfArgB.  2 and 2.5µg of purified BfArgB were assayed in 
100mM Tris buffer pH 6.0 containing 20mM ATP, 100mM MgCl2 and 400mM 
hydroxylamine and 8mM NSG for 1, 2.5, 5, 7.5 and 10 minutes at 37°C.  In this graph 
the results are presented as nmols of succinylglutamate hydroxymate against e0t (time 
of reaction x enzyme concentration).  These results prove that the reaction catalyzed by 
BfArgB is linear and that there is no detectable enzyme inactivation when either 2 or 
2.5µg are used for the assay. 
Based on these results we decided to use 2.5µg of enzyme for the 
characterization of the activity of BfArgB. 
 
Determination of the kinetics parameters Km and Vmax for NSG of BfArgB 
 
To determine the Km and Vmax for NSG of BfArgB, 2.5µg of purified enzyme 
were assayed in 100mM Tris buffer pH 6.0 containing 100mM MgCl2, 400mM 
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hydroxylamine in the presence of a constant ATP concentration of 20mM while 
varying the NSG concentration from 0 to 20mM (Figure 45).  After 10 minutes 
incubation at 37°C the reaction was stopped by adding fresh ferric chloride solution 
(Materials and Methods). 
 
 
 
Figure 45:  Determination of the kinetics parameters for NSG of BfArgB.  
2.5µg of purified BfArgB were assayed in 100µl of 100mM Tris buffer pH 6.0 containing 
100mM MgCl2, 400mM hydroxylamine in the presence of a constant ATP concentration of 
20mM while varying the NSG concentration from 0 to 20mM.  The reaction was carried 
out at 37°C and after 10 minutes stopped by the addition of 100µl of fresh ferric chloride 
solution.  Data were fitted to the Michaelis-Menten equation for enzyme activity using 
the program GNUPLOT.  Each data represents the average and standard deviation of 3 
independent assays per condition.  Product formation was quantified using glutamyl 
hydroxamate as standard. 
As Figure 45 shows the NSG saturation curve for BfArgB follows a hyperbolic 
of Michaelis-Menten kinetic.  Experimental data were fitted to the corresponding 
equation using non-linear fitting using the program GNUPLOT.  The kinetic 
parameters determined for NSG in this experiment were: 
 
 Km: 7.3 ± 0.44mM and 
 Vmax: 52.1 ± 1.4µmol min-1 mg-1 
 
The Km for NSG of BfNSGK is much higher with respect to other NAGKs for 
NAG (200 µM for the E. coli enzyme[83]), only P. aeruginosa NAGK has a similar Km 
being only 3 times lower[84]. 
 
Determination of the kinetic parameters Km and Vmax for ATP of BfArgB 
 
For the experimental determination of the kinetic parameters Km and Vmax 
for ATP of BfArgB we used 2.5µg of purified enzyme as described in the previous 
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epigraph.  In this experiment the concentration of NSG was kept constant at 40mM 
while the ATP concentration was varied from 0 to 20mM.  The Mg2+ concentration 
was kept 10mM higher than that of the ATP at each condition assayed. 
The ATP saturation curve follows a Michaelis-Menten kinetic as shown in 
Figure 46.  And the calculated kinetic parameters are: 
 
 Km: 4.6 ± 0.25mM and 
 Vmax: 54.7 ± 1.1 µmol min-1 mg-1 
 
 
 
 
Figure 46: Determination of the kinetic parameters Km and Vmax for ATP of 
BfArgB.  2.5µg of purified BfArgB were assayed at 37°C in 100µl of 100mM Tris buffer 
pH 6.0 containing 400mM hydroxylamine in the presence of a constant NSG 
concentration of 40mM while varying the ATP concentration from 0 to 20mM.  Mg2+ 
concentration was kept 10mM higher than the ATP concentration throughout the 
experiment. After 10 minutes the reaction was stopped by the addition of 100µl of fresh 
ferric chloride solution (Materials and Methods).  Data were fitted to the Michaelis-
Menten equation for enzyme kinetic using non-linear fitting with the software 
GNUPLOT. 
In this case the Km for ATP is also higher than that of the E. coli enzyme (300 
µM[83]), but not that different from P. aeruginosa NAGK (3 mM[84]). 
 
The Km calculated for both substrates of BfArgB are among the highest 
compared to other ArgB enzymes from organisms that posses an acetylated pathway 
for arginine biosynthesis.  It is possible that BfArgB forms a complex with ArgA’ or 
N-succinylglutamate synthase or the enzyme responsible for NSG synthesis to 
compensate for the low affinity of the substrates.  It is also possible that BfArgB 
interacts with other proteins in order to be more effective. 
Since the activity of the enzyme that we thought could be the first enzyme of 
the arginine biosynthesis pathway in B. fragilis (ArgX) could not be assayed it made 
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impossible to investigate the possible regulatory effects that arginine may have on 
it.  Therefore we decided to study the effects that arginine may have on the activity 
of BfArgB to determine whether or not this enzyme could be a point of control in the 
arginine biosynthetic pathway in the Bacteroidetes family of microorganisms. 
 
Study of the arginine effect on the activity of BfArgB 
 
To study the possible effects of arginine on the activity of BfArgB we assayed 
2.5µg of purified enzyme using the assay described before (Materials and Methods) 
at saturating conditions (40mM NSG, 40mM ATP), Km conditions (NSG 10mM, ATP 
6mM) and half Km conditions (NSG 3.6mM, ATP 2.3mM) in the presence of several 
arginine concentrations ranging from 0 to 50mM (Figure 47).  The Mg2+ 
concentration was kept 10mM higher than that of ATP at all times. 
 
 
 
Figure 47: Study of the effects of arginine on BfArgB activity.  2.5µg of purified 
BfArgB were assayed in 100µl of 100mM Tris buffer pH 6.0 containing 400mM 
hydroxylamine in the presence of several arginine concentrations ranging from 0 to 50mM 
at saturating conditions (40mM NSG and 40mM ATP), Km conditions (10mM NSG and 
6mM ATP) and half Km conditions (3.6mM NSG and 2.3mM ATP) for 10 minutes at 37°C. 
Mg2+ concentration was kept 10mM higher than the ATP concentration.  Product formation 
was quantified using glutamyl hydroxamate as standard.  Logarithmic scale was used only 
for representation purposes only. 
The results obtained in these assays shown in Figure 47 demonstrate that 
arginine has no effect whatsoever on the activity of BfArgB. 
The lack of inhibitory effects of arginine on the activity of BfArgB suggest that 
in the organisms which posses a succinylated arginine biosynthetic pathway the 
metabolic flow of intermediates is controlled at the level of NSG synthesis, which 
also suggest a linear non-classic pathway rather than a cyclic pathway.  This 
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hypothesis is supported also by the fact that in the genome of the members of the 
Bacteroidetes family the gene that codifies for an enzyme similar to OAT could not 
be found. 
 
 
4.6 Summary 
 
In this Chapter 5: “The use of N-succinyl-L-glutamate as substrate 
by ArgB of Bacteroides fragilis  supports the existence in this organism 
of an arginine biosynthetic pathway using N-succinylated 
intermediates”, I have presented further evidences that support the hypothesis, 
developed from the discovery of the SOTCase activity of the argF’-encoded protein in 
B. fragilis, of the existence of an arginine biosynthetic pathway in the Bacteroidetes 
family of microorganisms that uses N-succinylated instead of N-acetylated 
intermediates. 
Unfortunately the activity of the, hypothesized, first enzyme of the pathway 
(ArgX, Figure 35) could not be assayed due to the high rate of spontaneous 
succinylation of L-glutamate in the presence of SucCoA.  It is possible that the 
enzyme requires the interaction with other members of the arginine biosynthesis 
pathway (like ArgB), or the presence of certain cofactors in order to catalyze the first 
reaction of the pathway.  Determination of the means by which N-succinylglutamate 
enters the arginine biosynthesis pathway in these organisms could provide relevant 
information about the regulation and control of the metabolic flow in this pathway. 
Although I could not assay the very first reaction involved in the arginine 
biosynthetic pathway in B. fragilis, I was able to demonstrate that the argB’-encoded 
protein from this organism catalyzes the phosphorylation of NSG, probing that the 
biosynthesis or arginine is mediated by succinylated intermediates as hypothesized 
after the discovery of the SOTCase activity of BfArgF’. 
BfArgB has been partially characterized as a result of the present thesis work 
and the kinetic parameters Km and Vmax determined for the two substrates of the 
enzyme, NSG and ATP (Table 5). 
 
Table 5: Summary of the kinetic parameters determined for 
BfArgB. 
 Km (mM) Vmax (µmols min-1 mg-1) 
NSG 7.3 ± 0.44 52.1 ± 1.4 
ATP 4.6 ± 0.25 54.7 ± 1.1 
 
The affinity of the enzyme for the two substrates is low compared to NAGSs 
from other microorganisms that use acetylated intermediates[83, 84].  Proximity of 
the substrates would help to compensate for the low affinity of BfArgB for them, 
therefore it is possible that ArgB and ArgX in B. fragilis interact with each other in 
such a way that ArgX becomes active and the substrates are easily available to ArgB 
to continue the arginine biosynthesis pathway as is the case of the S. cerevisiae and 
N. crassa enzymes[17]. 
The absence of an OAT-like gene in the genome of B. fragilis led us to 
hypothesize that the arginine biosynthetic pathway in this organism is linear rather 
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than cyclic.  Further confirmation of the linear nature of the arginine biosynthetic 
pathway in B. fragilis was provided by the study of the arginine effects on BfArgB 
activity.  As shown in Figure 45, arginine has no effects on the activity of BfArgB 
probing that this reaction is not regulated by the final product of the pathway and 
therefore the arginine biosynthetic pathway in these organisms is most likely to be 
linear instead of cyclic. 
 
 

     
 
Resumen en Español 
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Resumen de la tesis 
 
 
El amino ácido L-arginina es un componente esencial de todos los organismos 
vivos. Su importancia reside en la gran variedad the funciones que la arginina, así 
como los intermediarios involucrados en su síntesis, tienen en las células, como 
muestra la Figura 1. 
Entre las principales funciones de la arginina en la célula se encuentran: 
 
• forma parte de la composición amino acídica de muchas proteínas 
• precursor de los siguientes compuestos usados por las células para 
almacenar energía 
o fosfato de arginina, usado en la contracción muscular en 
invertebrados y 
o fosfato de creatina, que se encuentra almacenado en el músculo 
y el cerebro en vertebrados 
• metabolito intermediario en el ciclo de la urea 
• precursor de las moléculas de señalización: oxido nítrico, agmatina y 
glutamato en mamíferos 
• y es usada como compuesto de almacenamiento de nitrógeno en 
plantas y cianobacterias 
En numerosos procariotas, hongos y plantas la síntesis de novo de la arginina 
ocurre a partir the glutamato en ocho pasos enzimáticos como se describe en la 
Figura 2. La acetilación de los precursores iniciales en la biosíntesis de arginina 
permite la separación de ésta ruta metabólica de la biosíntesis de prolina. 
De todos los pasos implicados en la ruta biosintética de la arginina, la 
acetilación de glutamato y su fosforilación han sido los más estudiados dada su 
importancia en la regulación del flujo de metabolitos en ésta ruta. 
Sin embargo, la transcarbamilación de la ornitina constituye otra reacción 
crucial en la ruta de biosíntesis y biodegradación de la arginina como muestra la 
Figura 4. 
En la ruta de biosíntesis, ornitina es transcarbamilada por la enzima ornitina 
transcarbamilasa (OTC, EC 3.2.1.1). OTC pertenece a la familia de las 
transcarbamilasas cuyos miembros son identificados fácilmente basándose 
únicamente en las homologías a nivel de las secuencias peptídicas que presentan 
todos ellos ya que todos comparten el motivo de unión al fosfato de carbamilo, que es 
un sustrato común a todos los miembros de la familia. Los miembros más estudiados 
de la familia de las transcarbamilasas son OTC y aspartato transcarbamilasa (ATC). 
Los estudios sobre la evolución de las transcarbamilasas realizados por 
Labedan y colaboradores revelaron la presencia de ésta actividad en el último 
ancestro común universal (Last Universal Common Ancestor, LUCA), destacando la 
importancia de la reacciones catalizadas por las transcarbamilasas. 
Más recientemente, Naumoff y colaboradores, entre otros, han puesto de 
manifiesto cuán inexacta es la asignación de ciertas actividades enzimáticas 
basándose exclusivamente en las similitudes entre nuevas secuencias genómicas y 
las estudiadas bioquímicamente previamente. El trabajo de Naumoff y colaboradores 
se centró en el caso particular de las transcarbamilasas de putrescina (PTC), 
miembros de la familia de las transcarbamilasas erróneamente anotadas como OTC. 
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La topología del árbol evolutivo generado por Naumoff y colaboradores usando las 
245 secuencias disponibles en el momento (Figura 5) no difiere de la del árbol 
presentado por Labedan y colaboradores anteriormente.  En su análisis, Naumoff y 
colaboradores introdujeron dos nuevos grupos de transcarbamilasas (PTC and UTC, 
o transcarbamilasas de actividad desconociada). El grupo de las UTC está formado 
por las transcarbamilasas anotadas como OTCasas pero que carecen de la capacidad 
para usar ornitina como sustrato, como es el caso de la enzima, potencialmente 
transcarbamilasa, presente en el organismo Bacteroides fragilis. 
El Dr. Malamy, usando mutagenesis mediada por transposon, demostró que 
en B. fragilis el gen que codifica para la putativa ornithina transcarbamilasa está 
directamente involucrado en la biosíntesis de arginina dado que cuando dicho gen no 
estaba presente en el genoma, el organismo se volvía auxotrofo para la arginina. 
El gen BfargF´ fue clonado y la proteína purificada y cristalizada por el Dr. 
Shi (Figura 7). La estructura tridimensional de la enzima presenta grandes 
similitudes con las estructuras de OTC y ATC, desafortunadamente la actividad de 
esta enzima no pudo ser identificada dado que no cataliza la transcarbamilación de 
la ornitina. 
Usando como referencia la secuencia aminoacídica de la proteína de B. 
fragilis se pudieron identificar proteínas similares a ésta en los genomas de varios 
organismos entre los que se encuentran Xylella fastidiosa, Cytophaga hutchinsonii, 
Xanthomonas campestris, Prevotella ruminicola y Tannerella forsythus. Todas estas 
proteínas identificadas compartían con la de B. fragilis la ausencia del motivo de 
unión a ornitina: SMG, presente en todas las OTCasas. Asímismo, ninguno de los 
genes identificados en estos organismos pudo complementar los mutantes de E. coli 
(argF-, argI-) que carecen de OTCasa. 
La primera actividad que se descubrió de entre las anteriormente 
mencionadas transcarbamilasas de actividad desconocida fue la de X. campestris 
ArgF´. Dr. Morizono descubrió que la actividad de XcArgF´ era la de una nueva 
transcarbamilasa: acetilornitina transcarbamilasa (AOTCasa). 
La presente tesis se centra en la caracterización bioquímica de la actividad de 
la enzima XcArgF´ así como en la identificación y caracterización de la actividad 
catalítica de la enzima BfArgF´ y en las implicaciones que la presencia de estas dos 
enzimas tienen para la ruta de biosíntesis de la arginina en los organismos que las 
poseen. 
A continuación presento el sumario de los resultados obtenidos durante la 
realización del presente proyecto de tesis: “Discovery of novel pathways of microbial 
arginine biosynthesis”. 
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Capitulo 2: “Functional characterization of a novel type 
of transcarbmylase that uses acetylornithine, identified in 
Xanthomonas campestris pv campestris” 
 
En este capitulo se han presentado pruebas concluyentes demostrando que la 
actividad catalizada por la enzima XcArgF´ es la de una acetilornitina 
transcarbamilasa (AOTCasa) mediante la identificación tanto de los sustratos como 
de los productos de la reacción. 
La especificidad de la reacción catalizada por la XcAOTCasa ha sido 
demostrada indicando que acetilornitina es el único compuesto que junto con 
carbamilfosfato puede ser transcarbamilado para formar acetilcitrulina. Asimismo 
se han optimizado las condiciones para el ensayo de esta nueva actividad AOTCasa. 
Los parámetros cinéticos (Km y Vmax) han sido determinados para ambos 
sustratos (AOrn y CP, Tabla 3). 
Al contrario que ocurre con otros miembros de la familia de las 
transcarbamilasas, XcAOTCasa no es inhibida por el sustrato de la reacción (AOrn), 
incluso a concentraciones tan elevadas como 50mM (Figura 21). Estos resultados 
parecen indicar que la reacción catalizada por XcAOTCasa no es crucial en el control 
de la ruta biosintética de la arginina, sin embargo el hecho de que la ausencia de 
este gen confiera auxotrofía para la arginina hace resaltar su importancia en la 
mencionada ruta de biosíntesis. 
Asimismo en este capitulo se ha demostrado que la acetilación del grupo alfa-
amino no sólo es necesaria para el reconocimiento del sustrato sino que también es 
un requerimiento para los inhibidores, como muestran los resultados obtenidos en 
los estudios de inhibición por norvalina y acetilnorvalina presentados en las figuras 
21 y 22, así como en los estudios con PALO y PALAO presentados en las figuras 25 y 
26. 
 
 
Capitulo 3: “Demonstration that a structurally obvious 
transcarbamylase from Bacteroides fragilis ,  of previously 
unknown activity catalyzaes the transcarbamylation of 
succinylornithine. Funtional characterization of this 
transcarbamylase” 
 
En este capitulo se han presentado los resultados que prueban que la 
actividad enzimática de la proteína codificada por el gen argF´ de B. fragilis es la de 
una succinilornitina transcarbamilasa (SOTCasa). 
Los análisis por NMR y LC-MS confirmaron que el producto de la reacción 
catalizada por BfSOTCasa en presencia de carbamilfosfato y succinilornitina es 
succinilcitrullina. 
Así mismo se han presentado los resultados de la caracterización inicial de la 
enzima BfSOTCasa y se han determinado los parámetros cinéticos para ambos 
sustratos de la reacción (Tabla 4). 
Al contrario que la XcAOTCasa, BfSOTCasa muestra inhibición por sustrato 
(Figura 33) aunque dicha inhibición es mucho menos pronunciada comparada con 
otros miembros de la familia de las transcarbamilasas. 
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Al igual que ocurría con XcAOTCasa, la BfSOTCasa requiere la presencia del 
grupo succinilo unido al extremo alfa-amino tanto para el reconocimiento del 
sustrato (succinilornitina), como de los inhibidores. Esto ha sido demostrado 
mediante estudios de inhibición por PALO y PALSO (sintetizado químicamente). 
El descubrimiento de la actividad SOTCasa de la enzima BfArgF´ unido al 
echo de que la ausencia del gen argF´ en B. fragilis transforma este organismo en 
auxotrofo para la arginina indica que tanto succinilornitina como succinilcitrulina 
son intermediarios en la ruta de biosíntesis de la arginina en Bacteroidetes.  
Lo expuesto en el anterior párrafo implica que la parte inicial de la ruta de 
biosíntesis de la arginina en los organismos que poseen actividad SOTCasa 
transcurre a través de intermediarios succinilados y no acetilados como ocurre en el 
resto de los organismos descritos hasta el momento. 
Esta hipótesis es el punto de partida para los resultados expuestos en el 
siguiente capitulo. 
 
 
Capitulo 4: “The use of N-succinyl-Lglutamate as substrate 
by ArgB of Bacteroides fragilis  supports the existence in this 
organism o fan arginine biosynthetic pathway using N-
succinylated intermediates” 
 
En este capitulo se presentan los datos obtenidos en el estudio de la actividad 
enzimática de los dos primeros genes supuestamente involucrados en al biosíntesis 
de la arginina en B. fragilis (argX and argB, Figura 37). 
Ambos genes fueron clonados y las respectivas proteínas expresadas y 
purificadas, desafortunadamente la actividad enzimática de la proteína que 
hipotéticamente catalizaría el primer paso de la ruta, la succinilización del 
glutamato, no pudo ser ensayada dado que la velocidad de la reacción espontánea 
era similar o superior a la de la reacción en presencia de la proteína codificada por el 
gen BfargX (Figura 38). Posiblemente la enzima necesite unas condiciones diferentes 
a las ensayadas para ser activa, como por ejemplo algún cofactor desconocido de 
momento, o la interacción con otras proteínas. 
Por consiguiente los esfuerzos se concentraron en el ensayo de la posible 
actividad succinilglutamato kinasa de la proteína codificada por el gen argB de B. 
fragilis. Para poder ensayar esta actividad, el potencial sustrato succinilglutamato, 
fue sintetizado químicamente y dada el alto porcentaje de conversión (Figura 41), 
usado sin posterior purificación en los ensayos enzimáticos. 
Como se muestra en las figuras 42 y 43, sólo el succinilglutamato puede ser 
utilizado como sustrato por la enzima BfArgB, lo cual demuestra que la biosíntesis de 
la arginina en B. fragilis transcurre a través de intermediarios succinilados y no 
acetilados tal y como se había hipotetizado tras el descubrimiento de la actividad 
SOTCasa de BfArgF´. 
Usando el succinilglutamato sintetizado químicamente en el laboratorio, la 
actividad NSGK de BfArgB ha sido caracterizada y se han calculado los parámetros 
cinéticos (Km y Vmax, Tabla 5). 
 
A continuación procederé a la discusión de los resultados presentados en los 
anteriores capítulos de la presente tesis. 
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The study of the arginine biosynthetic pathway has mainly focused, for the 
last years, in the regulation and control of the flow of its metabolites.  As a 
consequence new genes that codifies for different enzymes that are able to initiate 
and/or regulate the arginine biosynthetic pathway have been discovered (shorter 
NAGS of the Gcn5-related N-acetyltransferase (GNAT) family, either independent or 
fused with the ArgH protein (argininosuccinase), bifunctional ornithine 
acetyltransferase (OAT), that is able to acetylate glutamate with both AcCoA and 
AOrn[1]). 
Due to the focus on the initial component of the arginine biosynthetic 
pathway other aspects of this pathway have been neglected, in part also because of 
the belief that the biosynthesis of arginine uses a canonical pathway either linear (or 
classic) or cyclic (Figure 2). 
Recent advantages in the sequencing of the genome of an increasing number 
of organisms have revealed the existence of, among many other genes, different 
versions of OTCase.  Nevertheless these versions have been erroneously annotated 
as OTCases based on pairwise sequence similarities at the level of the primary 
structure, as the work of Naumoff et al.[46] and Sekowska et al.[48], among 
others[49-51] highlighted. 
The work leading to the present Thesis started with the study of the arginine 
biosynthetic pathway in the anaerobe B. fragilis with the objective of creating an 
organism able to overproduce arginine for its use in urea cycle and other related 
disorders patients to treat hyperammonemia.  While studying the arginine 
biosynthesis in B. fragilis, Dr. Malamy identified a gene (BfargF’) that codified for an 
OTC-like protein that was essential for the synthesis of arginine in this organism.  
Although the crystal structure of the BfArgF’ protein was solved showing a high 
degree of similarity with that of OTC from other organisms, the enzymatic activity 
could not be determined and remained a mystery until recently[85]. 
As stated in the introduction to Chapter 2, the genomic sequence of BfargF’ 
was used to identify several other genes in different organisms in which the 
sequence signatures of OTC were modified (Figures 8 and 9).  Among these newly 
identified genes were those of Xanthomonas campestris pv campestris and 
Cytophaga hutchinsonii which played a key role in the identification of the 
enzymatic activity of some of these OTC-like proteins and that constituted the basis 
over which the present Thesis work was developed. 
We have discovered two new members of the transcarbamylases family of 
enzymes: N-acetylornithine and N-succinylornithine transcarbamylase.  These two 
new transcarbamylases had expanded our view of the, until now, “canonical” argF 
gene involved in the arginine biosynthetic pathway.  The objective of this project was 
to describe these two members of the transcarbamylases family and study the 
arginine biosynthetic pathway in the organisms that contains them to first, extend 
our knowledge of the pathway and second, provide some of the basis for developing 
new strategies against the pathogenic effects of such microorganisms. 
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Characterization of the AOTCase activity of XcArgF’ 
 
Before the present thesis project started, acetylornithine had been identified 
as the substrate of XcArgF’ by Dr. Morizono. 
Dr. Morizono’s experiments proved that XcArgF’ was able to catalyze the 
transcarbamylation of acetylornithine to produce a compound with an ureido group 
on its formulation, most likely acetylcitrulline. 
I studied the chemical nature of the products of the reaction catalyzed by 
XcArgF’ as well as characterized its kinetic behavior in the presence of both 
substrates (CP and AOrn) and inhibitors.  I have also synthesized and assayed the 
effects of two potential inhibitors of XcArgF’: acetylnorvaline and PALAO. 
The results obtained using an amino acid analyzer and LC-MS (Figures 11 
and 12 respectively) indicated that the product of the reaction catalyzed by XcArgF’ 
contained an ureido group that interferes with the free amine reaction with 
ninhydrin (Figure 11) and that the retention time and m/z matches that of the 
purified chemically synthesized ACit (Figure 12).  Further confirmation that the 
product of the reaction was ACit was obtained from the NMR analyses performed 
using COSY-NMR (Figure 13).  All these experiments along with the identification 
of acetylornithine as the substrate of XcArgF’ allowed us to catalog this enzyme as a 
new member of the transcarbamylases family: N-acetyl-L-ornithine 
transcarbamylase (AOTC). 
Once that XcArgF’ was proven to be an AOTCase I proceeded to characterize 
its activity.  I was able to isolate XcAOTCase with a high degree of purity (Figure 14) 
in order to use it for enzyme activity assays. 
The transcarbamylation reaction catalyzed by XcAOTC is highly specific for 
acetylornithine as Figure 15 shows and follows a Michaelis-Menten type of kinetic 
for both substrates, AOrn and CP (Figures 18 and 19) described by the kinetic 
parameters summarized in Table 3.  The affinity of XcAOTCase for its substrates is 
among the highest compared to other members of the family[41, 68-71], which could 
be explained by the differences in the orientation of the binding of AOrn compared to 
the orientation of PALO or norvaline to OTC[86].  In XcAOTC the carboxyl group of 
AOrn is rotated approximately 120° between the Cγ-Cδ bond relative to the carboxy 
group of ornithine in OTC structures.  The slightly higher energy of this 
conformation is probably one of the reasons for the lower affinity of AOrn to XcAOTC 
compared to Orn for OTC[86]. 
XcAOTC shows only slight substrate inhibition when AOrn concentrations 
were as high as 50mM (Figure 20), with a calculated Ksi of 231mM, while in the case 
of human OTCase this value is 2.5mM[41].  The lack of substrate inhibition can be 
explained by the random binding mechanism of the reaction of XcAOTC[86] 
compared to the ordered mechanism of the reactions catalyzed by ATC and 
OTCases[52, 69, 87, 88].  The high Ksi for AOrn could be explained by the fact that 
the AOrn binding pocket seems to be preformed before and not upon AOrn 
binding[86] in contrast to ATC and OTCases in which the second-substrate binding 
pocket is an induced-fit pocket, where binding of the second substrate induces a 
conformational change and brings the flexible 240’s loop in the active site to interact 
with the second substrate[89, 90].  In XcAOTC movement of the 240’s loop and 
domain closure seem to be restrained by the stronger domain-domain interactions 
provided by the extended 120’s and 240’s loops[86]. 
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The high specificity of XcAOTC for AOrn led us to hypothesize that αN-
acetylation is necessary not only for substrate recognition but for inhibitors to bind 
the active site of the enzyme.  To corroborate this hypothesis I tested the acetylated 
versions of two known OTC inhibitors: norvaline and PALO.  The results showed 
that ANorv behaves as a competitive inhibitor of XcAOTCase (Figure 22), while Norv 
had a very small effect on the Vmax at a much higher concentration (Figure 21).  The 
calculated Ki of ANorv for XcAOTC (0.3mM) is much higher than that of Norv for 
OTC (5.8µM)[72] which could be explained by different interactions of the inhibitors 
to the respective enzyme since AOrn binds to XcAOTC in a different orientation from 
those observed in PALO or Norv complexed OTCases[86, 90-92].   
PALAO was proven a much more efficient inhibitor of XcAOTC with a 
calculated Ki of 22.4µM (Figures 24 and 25), although, compared to PALO is ~23 
times less effective (Ki of PALO for OTC is 0.77µM[75]).  The fact that PALO did not 
inhibit the activity of XcAOTC proved one more time that αN-acetylation is essential 
for both substrate and inhibitors recognition. 
Other potential XcAOTC inhibitor tested was pyrophosphate. Pyrophosphate 
showed significant effects over the activity of XcAOTC reducing the Vmax by 40% at 
5mM (Figure 23), unfortunately the inhibitory mechanism could not be determined 
based on the results obtained. 
The fact that ornithine and arginine are precursors for the polyamines 
synthesis (Figure 1) led us hypothesize that, polyamines may regulate the levels of 
ornithine and/or arginine by controlling or regulating the activity of XcAOTC. 
To test this hypothesis I assayed the activity of XcAOTC in the presence of 
several concentrations of putrescine and spermidine (Table 2).  The results showed 
that putrescine did not have an effect over XcAOTC activity, while spermidine 
behave as an activator of the enzyme reducing the Km for AOrn and therefore 
increasing its affinity for this substrate. 
 
 
Arginine biosynthetic pathway in Xanthomonads  
 
The discovery of the AOTC activity of XcArgF’ implied that the following 
enzyme in the arginine biosynthetic pathway (AOD, Figure 2) should be able to 
deacetylate acetylcitrulline efficiently in order to continue the flow of metabolites 
that will produce arginine. 
To corroborate this hypothesis I tested the deacetylase activity of XcArgE 
using acetylcitrulline and acetylornithine as substrates.  The results obtained 
(Figure 26) showed that the rate at which acetylcitrulline was deacetylated by 
XcArgE was comparable to that of acetylornithine deacetylation by the same enzyme.  
These results probed that acetylcitrulline continues the arginine biosynthetic 
pathway by means of ArgE and let us propose a novel pathway for arginine 
biosynthesis occurring in the Xanthomonads family of microorganisms and those 
organisms that possesses an AOTCase. 
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Figure 48:  Brief schematic representation showing the proposed arginine biosynthetic 
pathway for those organisms that contain an AOTC (Panel B) instead of OTC (Panel 
A). The enzymes studied in this work that differ from the canonical arginine biosynthetic pathway 
are highlighted in red. 
The fact that XcArgE is able to deacetylate acetylcitrulline as well as 
acetylornithine implies that a possible regulatory mechanism may occur at the level 
of ArgE in the arginine biosynthetic pathway of organisms containing an AOTC 
instead of OTC, which could control the flow of metabolites towards the polyamines 
or arginine biosynthetic pathways. 
Further studies are necessary to corroborate possible regulatory mechanisms 
of metabolic flow between the arginine and polyamines biosynthetic pathways.  To 
my knowledge such studies are not being performed and could be one of the future 
perspectives that can be extracted from the present Thesis work. 
As part of the research performed in our lab the gene annotated as argB in X. 
campestris has been identified as a bifunctional enzyme that is able to synthesize 
NAG from AcCoA and glutamate and catalyze the ATP-dependent phosphorylation 
of NAG[82]. Qu et al. have characterized both functions of XcNAGS-K[82] and have 
concluded that this new bifunctional enzyme activity is regulated by the final 
product of the pathway, arginine, although the NAGS activity is 25 times more 
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sensitive to arginine than the NAGK activity. 
This recent discovery allows us to re-write the initial part of the proposed 
arginine biosynthetic pathway for Xanthomonads (Figure 48) to accommodate this 
finding (Figure 49). 
 
Figure 49:  Modification of the initial steps of 
the arginine biosynthetic pathway in X. 
campestris  and organisms that contains 
AOTC. 
 
Qu et al.[82], on the basis of phylogenetic trees constructed with the 
sequences from 31 organisms including both bacteria and eukaryotes, speculate that 
the argAB fusion gene arose early in the evolution and underwent gene duplication 
evolving then to the actual mammalian NAGS and fungal NAGK genes.   
Interestingly, the evolutionary tree of the transcarbamylases (Figure 5) 
generated by Naumoff et al.[46] also locate the organisms containing the argF’ gene 
closer to the root than those that contains the canonical argF in the evolution of the 
members of this family of proteins. 
The fact that organisms containing the argF’ gene (which codifies for the 
enzyme characterized in this Thesis, AOTC) also contains the argAB fusion gene 
suggest that this form of arginine biosynthetic pathway could have been present in 
the early stages of the evolution. 
The discovery of the AOTC activity of XcArgF’ expanded our view of the 
possible substrates of some of the transcarbamylases of unknown activity identified 
by Naumoff et al.[46] and by Dr. Morizono. 
 
 
Implications of this new arginine biosynthetic pathway 
found in Xanthomonads  
 
As stated in the Introduction, ornithine is an intermediate in the synthesis of 
the following metabolites: 
a) Arginine 
b) Proline 
c) Putrescine 
d) Siderophores 
e) Peptidoglycan 
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f) Antibiotics 
g) Membrane lipids 
 
In the case of Xanthomonads, AOTC ensures that acetylornithine will 
continue the arginine biosynthetic pathway; therefore factors altering its activity 
will affect the availability of ornithine for other pathways.   
Metals are an important component of the ecosystem where Xanthomonads 
can be found.  Variations in the concentrations of certain metals could be detected by 
the cells, reducing the activity of AOTC, while incrementing the activity of ArgE, 
therefore increasing the concentration of free ornithine inside the cells and 
activating the synthesis of siderophores.  Siderophores are compounds of small 
molecular mass (<1000 Da) that posses a high affinity for Fe2+ and other metals[94], 
and are usually synthesized in situations were there is a deficiency of iron and is 
required for cell survival.  It has been shown that affecting the iron uptake through 
the siderophore FeoB, affects the growth (in planta) and virulence of Xanthomonas 
oryzae pv oryzae[95] in iron limiting situations therefore it would be interesting to 
investigate the possible control of the synthesis of siderophores exerted by the 
regulation of the activities of both AOTC and ArgE in X. campestris pv campestris to 
elucidate a possible mechanism for infections control. 
The importance that the regulation of AOTC activity, in response to different 
environmental situations like heavy rain, temperature and soil pH, has on any of the 
above mentioned pathways is an interesting project that could be studied if a X. 
campestris ArgF’- and/or ArgE- deficient strains can be obtained. 
 
 
Discovery and characterization of the enzymatic activity of 
the protein codified by the gene argF’  in Bacteroides fragilis  
 
The transcarbamylase-like protein codified by the gene argF’ in B. fragilis 
presented the next challenge in this project.  As indicated in the introduction to 
Chapter 4: “Demonstration that a structurally obvious transcarbamylase from 
Bacteroides fragilis, of previously unknown activity catalyzes the 
transcarbamylation of succinylornithine. Functional characterization of this 
transcarbamylase”, the crystal structure of this protein has been known since 
2002[47] unfortunately, its enzymatic activity remained a mystery as well as the 
arginine biosynthetic pathway in this organism. 
Although the BfArgF’ structure is very similar to that of anabolic OTC and 
ATCases (Figure 7) there are several differences in some of the regions of the active 
site, especially at the ornithine binding site, that set the BfArgF’ enzyme apart from 
previously characterized transcarbamylases.  Basically the pocket in which 
ornithine should bind is bigger in BfArgF’ than in other OTCases (Figure 27 and 
Figure 50) making impossible for this enzyme to catalyze the transcarbamylation of 
ornithine or even acetylornithine to produce citrulline or acetylcitrulline (Figure 15). 
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Figure 50: Representation of the binding pockets of human OTCase and BfSOTCase for 
ornithine and succinylornithine respectively. Human OTCase structure is shown in purple 
(transparent) and the residues involved in the binding of the substrates are shown as VDW 
representations. BfSOTCase is shown in green and the residues involved in the binding of the 
substrates are shown as VDW representations. This figure shows how the substrates-binding pocket 
in human OTCase (purple transparent) is smaller and less open compared to the substrates-binding 
pocket in BfSOTCase (green opaque). This figure has been generated using the VMD 1.9 software. 
 
Succinylornithine is an intermediate in the arginine and proline metabolism 
of several organisms as well as in other biosynthetic and catabolic pathways[96, 97] 
and its structure is very similar to that of the compounds used as substrates for OTC 
and AOTC (Figure 28), therefore one of the possible substrates for BfArgF’ is 
succinylornithine.   
To test if BfArgF’ indeed catalyzed the transcarbamylation of 
succinylornithine to produce succinylcitrulline I chemically synthesized this 
compound from ornithine and succinic anhydride. 
In the first attempt to assay the possible succinylornithine transcarbamylase 
activity of BfArgF’ we used the lysate of cells over expressing the protein and the 
results obtained showed a significant amount of activity when succinylornithine was 
used as substrate for the reaction compared to acetylornithine and ornithine (Figure 
29).  These results led us to hypothesize that we had found the activity of BfArgF’ 
and is that of a succinylornithine transcabamylase (SOTC) and therefore yet another 
new member of the transcarbamylases family of enzymes. 
To confirm this hypothesis and to discriminate between possible artifacts and 
real SOTC activity from the over expressed BfArgF’ in the lysates, we purified BfArgF’ 
and tracked the SOTC activity throughout the purification (Figure 30).  The results 
showed that the SOTC activity was detected in those fractions in which BfArgF’ was 
present.  From these experiments we confirmed the initial hypothesis and concluded 
that the transcarbamylase activity of BfArgF’ was that of a succinylornithine 
transcarbamylase, a new member of the transcarbamylases family of enzymes. 
Further prove of the SOTC nature of BfArgF’ was obtained from the NMR and 
LC-MS analyses of the product of the reaction (Figure 31).  These analyses 
confirmed that the product of the reaction was indeed N-succinylcitrulline. 
Once that we proved that BfArgF’ is indeed a SOTC we proceeded to 
characterize its activity by determining the kinetics parameters Km and Vmax for 
both substrates: SOrn and CP.  A summary of the kinetic parameters determined for 
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both substrates of BfSOTC can be found on Table 4.  Although the affinity of BfSOTC 
for CP is on the range of other transcarbamylases[41, 69], its affinity for SOrn is the 
highest among the studied transcarbamylases.  Such a high affinity could be 
explained by an error on the estimation of the Km value for SOrn due to the limited 
amount of concentrations studied.   
The SOrn saturation curves showed that BfSOTC is slightly inhibited by high 
concentrations of this substrate (Figure 33), while CP saturation curves followed a 
Michaelis-Menten kinetic (Figure 34).  Structural insights on the conformational 
changes occurring in BfSOTC upon binding of the substrates provided an explanation 
for the substrate inhibition detected[85].  From the studies performed on the 
crystallographic structure of BfSOTC complexed with its substrates it was possible to 
quantify the domain closure of the enzyme upon binding of the substrates.  In the 
case of BfSOTC when CP and succinylnorvaline were bound, the domain movement 
was of ~5.6°[85] a value comparable to that of E. coli and human OTCases is of 4-
12°[52, 91], while in E. coli ATC is 8.4-12.3°[98] and in XcAOTC is only 2.2°[63].  As 
stated before, the catalytic mechanism of XcAOTC is random which explains the lack 
of substrate inhibition, while in OTC and ATCases is ordered[52, 69, 87, 88] as in 
BfSOTC, differences in the interactions of the substrates to each enzyme can explain 
the differences in the catalytic properties observed between them. 
The reaction catalyzed by BfSOTC is very specific for succinylornithine as has 
been demonstrated in the results presented in this Thesis (Figures 15 and 29), which 
led us to think that succinylation would be required for inhibitors recognition as 
well.  PALO and its acetylated derivative PALAO are two potent inhibitors of OTC 
and AOTC respectively, therefore it was expected that the succinyl derivative of 
PALO αN-succinyl-δN-phosphonoacetyl-L-ornithine (PALSO), would be also a strong 
inhibitor of BfSOTC. 
To test this hypothesis I synthesized PALSO chemically from PALO in the 
presence of succinic anhydride.  BfSOTC activity was assayed in the presence of 
several concentrations of PALSO (Figure 35) and estimated IC50 was 0.45 ± 0.05 µM.  
Although the PALSO preparation had a very high degree of purity (Figure 35), due 
to the lack of purified PALSO we could only estimate the IC50 and not calculate the 
Ki or determine the mechanism of inhibition of this compound over BfSOTC activity. 
 
 
Arginine biosynthetic pathway in Bacteroides fragilis  
 
The fact that BfArgF’ was unable to complement OTC deficient mutants of E. 
coli, while restoring the capacity to synthesize arginine in the B. fragilis arginine 
auxotrophs JDP3a.3 or JDP3a.4[85], along with the discovery of its SOTC activity, 
implies that the pathway by which B. fragilis and, therefore the Bacteroidetes family 
of microorganisms synthesize arginine is different from any organism described 
until now.  We hypothesized that, in Bacteroidetes, arginine is synthesized by a 
pathway that use succinylated rather than acetylated intermediates, and to probe it 
I investigated the initial steps of the pathway. 
There is no gene similar to argA in the whole genome of B. fragilis although 
looking at the genomic organization of the genes involved in the arginine 
biosynthesis in this organism it is possible that the gene denominated argX? (Figure 
37) could encode the enzyme responsible for the synthesis of succinylglutamate if the 
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hypothesis of a succinylated arginine biosynthetic pathway is true. 
I cloned and over expressed the argX gene from B. fragilis, unfortunately its 
activity could not be assayed due to the high rate of spontaneous succinylation of 
glutamate in the presence of Suc-CoA (Figures 38-40). 
Therefore I focused my efforts on the next enzyme of the pathway, ArgB 
(Figure 2).  In the arginine biosynthetic pathway known until now, N-
acetylglutamate kinase (NAGK or ArgB) catalyzes the ATP-dependent 
phosphorylation of NAG, in the second step of the pathway (Figure 2)[9].  In the case 
of B. fragilis, hypothetically, ArgB would catalyze the ATP-dependent 
phosphorylation of N-succinylglutamate (NSG). 
Once again, the substrate of the reaction that I was trying to assay was not 
commercially available therefore I synthesized it chemically from glutamate and 
succinic anhydride.  The degree of conversion was very high (99.95%, based on LC-
MS quantification of the free glutamate present in the sample after the chemical 
reaction was stopped) and the chemically synthesized NSG was used without further 
purification to test the NSGK activity of BfArgB. 
The initial attempts to assay the activity of BfArgB were performed using 
lysates of cell over-expressing the protein (Figure 42) by a colorimetric method and 
showed an significant increase in the color produced in the sample that contained 
chemically synthesized NSG with respect to the other substrates assayed (NAG, 
glutamate, succinylaspartate and aspartate).  These results indicated that, most 
likely, the activity of BfArgB is that of an N-succinylglutamate kinase. 
To probe that NSGK was indeed the activity of the enzyme codified by the 
gene argB in B. fragilis, I purified BfArgB with a degree of purity >95% and assayed 
it in the presence of the same substrates as the lysates.  The results showed that 
NSGK was the preferred substrate since the partial activity detected with NAG and 
succinylaspartate was not distinguishable from the heat-inactivated enzyme controls 
(Figure 43). 
Using the chemically synthesized NSG I proceeded to determine the kinetic 
parameters that characterized BfNSGK using NSG and ATP saturation curves.  The 
Km and Vmax determined for each of the substrates of BfNSGK are summarized on 
Table 5. 
The affinity of the enzyme for the two substrates apparently is lower 
compared to other NAGKs from other organisms that uses use acetylated 
intermediates in their arginine biosynthetic pathway[83, 84], nevertheless 
chemically synthesized and purified NSG should be obtained in order to properly 
determine the kinetic parameters of BfNSGK. Proximity of the substrates would help 
to compensate for the low affinity of BfArgB for them, therefore it is possible that 
ArgB and ArgX from B. fragilis interact with each other in such a way that ArgX 
becomes active and the substrates are easily available to ArgB to continue the 
arginine biosynthesis pathway as is the case of the S. cerevisiae and N. crassa 
enzymes[17]. 
The discovery of the SOTC activity of BfArgF’ implied the existence of a 
succinylated pathway for arginine biosynthesis in this organism.  Complementation 
studies performed by Dr. Malamy provided further evidences that the arginine 
biosynthetic pathway in B. fragilis was different from that of E. coli.  Although the 
enzyme responsible for the synthesis of NSG in B. fragilis remains elusive, we have 
demonstrated that the second step of the arginine biosynthetic pathway in this 
organism, catalyzed by the product of the gene argB requires NSG, confirming the 
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hypothesized succinyl derivatives intermediated pathway for arginine biosynthesis 
in B. fragilis and other organisms that contains SOTC. 
The fact that there is no OAT-like gene in the whole genome of B. fragilis and 
the fact that arginine has no regulatory effects on the activity of BfArgB led us to 
hypothesize that the arginine biosynthetic pathway in B. fragilis and organisms 
with SOTC is linear instead of cyclic.  A schematic representation of the proposed 
arginine biosynthetic pathway occurring in Bacteroidetes is shown in Figure 51. 
 
 
 
Figure 51:  Schematic representation of the proposed arginine biosynthetic pathway 
occurring in Bacteroidetes and other organisms with SOTC (Panel B) compared to that 
occurring in organisms with OTC (Panel A). For clarification, differences between the two 
arginine biosynthetic pathways are shown highlighted in red. 
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Structural insights onto substrate recognition of XcAOTC and 
BfSOTC 
 
Comparison of the crystal structures from XcAOTC and BfSOTC highlighted 
the differences between these two enzymes[86].  Although the tridimensional 
structures are very similar there are several differences in important regions of the 
proteins (Figure 52): 
• The conformation of the 240’s loop is 4 amino acids longer in XcAOTC 
vs. BfSOTC. 
• In the 80’s loop of XcAOTC the NE atom of Trp77 (Trp72 in B. fragilis) 
is displaced 12° relative to the substrate.  The loop movement is 
important for CP binding. 
• Sequence differences around helix H1 significantly shift its position. 
• The major difference between these two structures is an 11 amino 
acids insertion between H7 and B8, which makes the β-sheet core in 
the second substrate domain in X. campestris more similar to the E. 
coli OTC. 
 
 
Figure 52: Comparison of the crystallographic structures of XcAOTC and BfSOTC. 
XcAOTCase strucutre is shown in purple and BfSOTCase structure in green. Differences mentioned 
in the text are indicated by arrows. 
  
From the crystallographic studies of these two enzymes (XcAOTC and BfSOTC) 
it was determined that the residue Glu92 (Pro90 in B. fragilis) was the responsible 
for the specificity of the X. campestris ArgF’ for AOrn[86].  The fact that proline is a 
smaller residue compared to glutamate was hypothesized to help the fitting of 
bulkier acyl groups.  Around the same time, the activity of BfSOTC was discovered 
confirming the hypothesis of a substrate bigger than ornithine or acetylornithine.  
Crystallographic studies of BfSOTC complexed with its substrates and substrates 
analog highlighted the importance of the residue Pro90 (B. fragilis numbering) on 
the specificity of the enzyme[85]. 
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The importance of this residue (Pro90) in substrate recognition has been 
studied using the following mutants[99]: 
 
 XcAOTC mutants: E92S, E92A, E92V and E92P 
 
 BfSOTC mutants: T242L, P90E/T242L 
 
The fact that all of the XcAOTC mutants lost, almost completely, the AOTC 
activity while catalyzing the transcarbamylation of SOrn to SCit and the fact that 
the P90E/T242L mutant of BfSOTC was able to catalyze the transcarbamylation of 
AOrn almost 10 times more efficiently than SOrn[99] confirmed that the residue 
Pro90 (in B. fragilis numeration) or Glu92 (in X. campestris) is the responsible for 
determining the substrate specificity in these two enzymes (XcAOTC and BfSOTC). 
As a consequence of the results discussed above these new transcarbamylases 
activities can be assigned to new genes, based on the presence or absence of 
glutamate and allowed the proposal of the following schematic method for 
classification: 
 
Figure 53:  Schematic classification method proposed for ornithine, 
aspartate, acetylornithine and succinylornithine transcarbamylases 
based on structure-derived amino acid signature motifs. 
Using this classification method Shi et al.[99] proposed the re-annotation of 
several misannotated transcarbamylases in the genomes of organisms that included 
several species of the genus Xanthomonas, Xylella and Flavobacteria among others 
some of which had been confirmed enzymatically. 
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Can NSGKs also be correctly annotated based on the 
genomic sequence? 
 
Despite the fact that E. coli ArgB and B. fragilis ArgB are very similar (47% 
similarity, 27% identity) there are striking differences between the two proteins as 
shown in Figure 54. 
 
 
 
Figure 54: Comparison of the amino acids sequence of E. coli  ArgB with several 
members of the Bacteroidetes family.  Sequences were obtained from the NCBI Protein 
database.  Sequences alignment was performed using ClustalW.  Green boxes indicate residues 
responsible for ATP binding.  Blue boxes indicate residues responsible for NAG binding.  Red boxes 
indicate sequences gaps between E. coli sequence and the other proteins used for the analysis. 
The 4 residues gap before G45 (E. coli numbering) and the 3 residues insert 
after A161 could explain how a bigger pocket is present in this enzyme to 
accommodate the larger NSG (compared to NAG), but crystallographic studies are 
necessary to corroborate this hypothesis. 
Some of the residues identified by Ramón-Maiques et al.[100] as responsible 
for ATP binding (based on the cristal structure of E. coli ArgB liganded to AMPPNP) 
are different in the Bacteroidetes ArgB (S180, D181 and T211, E. coli numbering), 
the relevance of these changes still needs to be determined using site directed 
mutagenesis and enzymatic studies.  
Although, without the proper crystallographic data and the proper enzymatic 
studies it would be hard to distinguish between NSGK and NAGK based on the 
amino acids sequence, we can speculate that the above mentioned gaps and 
insertions combined with the amino acids changes observed in the Bacteroidetes 
ArgBs could be an useful tool for discrimination between these two types of enzymes. 
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Conclusions 
 
 
 
The conclusions of the present thesis work are the following. 
 
 
 
1. The AOTCase from Xanthomonas campestris pv campestris 
characterized in this thesis, catalyzes the formation of a new 
intermediate in a novel arginine biosynthetic pathway found in 
some of the bacteria that do not possess the canonical argF gene. 
 
2. Bacteroides fragilis argF’ gene encodes for another new member 
of the transcarbamylases proteins; N-Succinyl-L-Ornithine 
transcarbamylase (SOTCase). 
 
3. Bacteroides fragilis argB gene encodes for a new enzyme in the 
arginine biosynthetic pathway is these microorganisms, N-
Succinyl-L-Glutamate kinase. 
 
4. The arginine biosynthetic pathway in the Bacteroidetes family 
of microorganisms uses succinylated instead of acetylated 
intermediates in the first part the pathway. 
 
5. The identification and biochemical characterization of the 
transcarbamylases found in X. campestris and B. fragilis 
enables the bioinformatic annotation of these transcarbamylase-
like genes in other organisms. 
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Materials 
Chemicals: 
 
All chemicals utilized in this work were purchased from Sigma-Aldrich or 
Fischer Scientific unless otherwise specified. 
Strains and plasmids: 
 
Tables 6 and 7 contain the cell strains and the plasmids used in the present 
work. 
 
 
Table 6: Cell strains 
Strain Characteristics Purpose Reference 
BL21(DE3) 
F– ompT gal dcm lon hsdSB(rB- 
mB-) λ dST [lacI lacUV5-T7 gene 1 
ind1 sam7 nin5]) 
general purpose 
expression host Studier et al. 1986 
DH5a 
F- endA1 glnV44 thi-1 recA1 relA1 
gyrA96 deoR nupG 
lasmlacZΔacZAΔalacZYA-
argF)U169, hsdR17(rK- mK+), λ– 
non-expression host; 
general purpose cloning; 
plasmid propagation. 
Messelson et al. 
1968 
TOP10 
F- mcrA Δmmrr-hsdRMS-mcrBC) 
φrr-hsdRMS- Δrr-hsd nupG recA1 
araD139 ΔnupG recA1 ar galE15 
galK16 rpsL(StrR) endA1 λ- 
host for general purpose 
cloning and plasmid 
propagation. 
expression host used in 
combination with vectors 
containing BAD 
promoter. 
Invitrogen 
Rossetta2 F- ompT hsdSB(rB- mB-) gal dcm (DE3) pRARE2 (CamR) 
expression host; allows 
expression of genes 
encoding tRNAs for rare 
arginine codons AGA, 
AGG, and CGA, glycine 
codon GGA, isoleucine 
codon AUA, leucine 
codon CUA, and proline 
codon CCC 
EMD Biosciences 
HMS174(DE3) F- recA1 hsdR(rK12- mK12+) (DE3) (Rif R) recA- expression host Novagen 
B. fragilis 
TM4000 Wild type strain of B. fragilis  
Dr. Malamy (Tufts 
University, Boston, 
MA) 
B. fragilis 
TM4000 4.9 B. fragilis ArgE- mutant  
Dr. Malamy (Tufts 
University, Boston, 
MA) 
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Table 7: Plasmids 
Plasmid Purpose Bacterial resistance Reference 
pCRBluntII TOPO Cloning Kanamycin Invitrogen 
pCR4Blunt-TOPO Cloning Ampicillin/Kanamycin Invitrogen 
pET15b Cloning/expression Ampicillin Novagen 
pET21b(+) Expression Ampicillin Novagen 
pET28a(+) Cloning/Expression Kanamycin Novagen 
pJCL7 
Derived from 
pET21b(+) 
containing BfArgB 
Ampicillin This work 
pET21b-BfArgX 
Derived from 
pET21b(+) 
containing putative 
BfArgA 
Ampicillin This work 
pTrc99a-BfArgF-
His 
Derived from 
pTrc99a containing 
BfArgF’ 
Ampicillin Dr. Malamy 
 
Media and growth conditions 
Liquid Media 
 
The rich liquid medium used for the growth of all the strains used in this 
work was the Luria-Bertani (LB) medium.  The following is the composition of this 
media: 
 
  Bactotriptone  10 g 
  Yeast extract  5 g 
  NaCl   5 g 
  H2O   up to 1 liter 
 
Media were sterilized by vapor pressure in the autoclave at 121°C during 20 
minutes. 
Antibiotics were added to the cooled, sterilized media at the concentrations 
specified in Table 8. 
 
Table 8: Antibiotics 
Antibiotic Stock concentration Working concentration Solvent 
Ampicillin (Amp) 60 mg/ml 60 µg/ml H2O 
Kanamycin (Kan) 10 mg/ml 10 µg/ml H2O 
Chloramphenicol (Cam) 35 mg/ml 35 µg/ml Ethanol 
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Solid Media 
 
For the preparation of the solid media, liquid medium (LB) was 
supplemented with bacto-agar to a concentration of 1.5% (w/v). In this case the 
antibiotics were added after sterilization and before the media solidified 
(approximately at a temperature of 50°C). 
 
Plasmid isolation 
 
For plasmids isolation strains containing the plasmid to isolate were grown 
in 3 ml or 100 ml of LB supplemented with the required antibiotic, for mini-prep or 
midi-prep respectively, overnight (o/n) at 37°C under aerobic conditions. The 
cultures were shaken at 250rpm in an Innova 4000 (New Brunswick Scientific) 
orbital shaker. 
For strain conservation 1 ml of the o/n culture was mixed with 1 ml of sterile 
50% glycerol and kept at -80°C. 
 
Protein expression 
 
For protein expression, strains were grown o/n in 50 ml of liquid LB 
supplemented with the required antibiotic, at 37°C and 250 rpm.  The following day, 
1 L of LB supplemented with the required antibiotic was inoculated with 20-40 ml of 
the o/n culture and cells were grown at room temperature (r.t.) until OD600 reached 
0.4-0.6 absorbance units.  When the culture reached the desired OD600, recombinant 
protein expression was achieved by adding IPTG to the medium to a final 
concentration of 0.1-0.2 mM.  The cells were grown o/n under expression conditions. 
Buffers 
Transcarbamylases purification buffers 
 
Table 9 indicates the composition of the buffers utilized for the purification of 
the transcarbamylases utilized in this work. 
 
Table 9: Transcarbamylase purification buffers 
Column Binding buffer Elution buffer 
Nickel column 
50mM NaH2PO4 50mM NaH2PO4 
300mM NaCl 300mM NaCl 
10% Glycerol 10% Glycerol 
10mM b-ME 10mM b-ME 
pH 7.4 250mM Imidazole 
 pH 7.4 
DEAE column 
20mM Tris-HCl 20mM Tris-HCl 
50mM NaCl 500mM NaCl 
1mM EDTA 1mM EDTA 
5mM b-ME 5mM b-ME 
pH 8.0 pH 8.0 
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Transcarbamylases storage buffer 
 
Bacteroides fragilis and Xanthomonas campestris pv campestris 
transcarbamylases were stored in DEAE column binding buffer. 
 
NAGS purification buffers 
 
Table 10 indicates the composition of the buffers utilized for the purification 
of the NAGS-like proteins utilized in this work. 
 
Table 10: NAGS purification buffers 
Column Binding buffer Elution buffer 
Nickel column 
50mM KPO4 50mM KPO4 
300mM KCl 300mM KCl 
10mM Imidazole 500mM Imidazole 
20% glycerol 20% glycerol 
0.006% Triton X-100 0.006% Triton X-100 
pH 7.5  pH 7.5  
DEAE column 
50 mM Tris 50 mM Tris 
50mM NaCl 1M NaCl 
20% Glycerol 20% Glycerol 
10mM b-ME 10mM b-ME 
0.006% Triton X-100 0.006% Triton X-100 
pH 8.0 pH 8.0 
 
NAGS storage buffer 
 
NAGS-like proteins were stored at 4°C in the following buffer: 
 50mM KPO4,  pH 7.5 
 50mM KCl 
 10mM β-ME 
 0.1% Triton X-100 
 20% Glycerol 
 
Tris-Acetate-EDTA (TAE) buffer 
 
50X TAE stock solution was prepared as follows: 
242 g Tris Base (MW=121.1) 
57.1 mL Glacial Acetic Acid 
100 mL 0.5 M EDTA 
Add H2O to a final volume of 1L 
Store at room temperature. 
 
Note: Final (1x) working concentration: 0.04 M Tris-Acetate, 0.001 M EDTA 
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6x DNA loading buffer 
 
0.25% Bromophenol Blue 
0430% Glycerol 
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Methods 
Primer design 
 
Primers were designed using the software package Amplify 3© (Bill Engels, 
University of Wisconsin. http://engels.genetics.wisc.edu/amplify)  
Table 11 shows the primers designed for the completion of the present thesis 
work. 
 
Table 11: Primers  
Primer Sequence (5’-3’) 
BfargBNdeIFW TTTCATATGAAAGAAAAGATGAAGGAAAAACTGAC 
BfragBXhoI TTTCTCGAGTTTTTTTATCCGAGTTCCCCCATCT 
BfargXXhoIFW ATTCTCGAGGTTATTTCTTTCTTGTTCTTTTTTTATGTTA 
BfargXNdeIRV TCACATATGGACACTCAACAAATAGATGTTATGGTAG 
 
Cloning of BfArgB 
 
The sequence flanking argB gene was identified from genomic sequences of B. 
fragilis NCTC9343 using Artemis® software, and used to design the primers 
BfargABNdeIFW and BfragABXhoI that add the restriction sites of NdeI and XhoI 
on the 5’ and 3’ ends of the PCR amplification product, respectively.  A crude lysate 
of B. fragilis TM4000 4.9 (argE-) was used as template for PCR, and argB was 
amplified using Phusion DNA polymerase following manufacturer instructions.  The 
cycling conditions were as follows: 30 s at 98°C for polymerase activation and 40 
cycles for the melting (10 s, 98°C), annealing (15 s, 55°C) and extension (15 s, 72°C), 
followed by an extension step (5 min, 72°C) yielding an unique fragment of the 
desired size (798bp).  The 798bp-long PCR amplification product was cloned into 
pCRBluntII vector (Invitrogen), subcloned into the NdeI and XhoI sites of pET21b 
(Novagen), and sequence verified to produce the pJCL7 plasmid. 
 
Cloning of the putative BfArgA 
 
Cloning of the putative BfArgA (ORF# BF0842 in B. fragilis NCTC9343 strain 
genomic sequence), was performed in a similar way as the cloning of BfArgB but 
using the primers: BfargXXhoIFW and BfargXNdeIRV for amplification. Cloning of 
the BfArgA yielded the expression vector pET21b-BfArgX. 
 
Transformation 
 
One aliquot of 50µl of chemically competent cells (Table 8) were transformed 
with 1µl of the desired plasmid (Table 9) at ~10ng/µl, followed by a 10 minutes 
incubation on ice. After the incubation on ice cells were heat shocked at 42°C for 30 
seconds and immediately were placed on ice.  200µl of S.O.C. medium were added to 
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the transformed cells and then incubated at 37°C and 250 r.p.m. for 1 hour.  After 
incubation at 37°C 10, 25 and 50µl of the transformed cells were plated on LB-agar 
containing the required selection antibiotics (Table 8). 
 
Plasmid DNA purification 
 
Plasmids were purified using the QIAprep Spin Miniprep Kit or the QIAGEN 
Plasmid Midi Kit (QIAGEN) following the manufacturer protocol. 
 
DNA digestion with restriction enzymes 
 
All the restriction enzyme reactions were carried out using enzymes 
purchased from New England Biolabs (NEB) following the manufacturer protocols 
using 0.5 to 1µg of plasmid DNA. When possible, double digestions reactions were 
performed. 
 
DNA electrophoresis 
 
Following PCR amplification and enzymatic restriction reactions, DNA 
samples were separated based on size using horizontal electrophoresis in TAE buffer 
on agarose gels. Agarose gels were prepared using 1x TAE buffer and depending on 
the size of the fragment to identify the composition of the agarose gel varied from 0.9 
to 2% w/v.  10µl of sample were mixed with 2µl of 6x loading buffer prior to the load 
of the sample on the gel. 
Once loaded on the gel samples were separated by electrophoresis at 90 volts 
for 45 minutes, or 100 volts for 60 minutes, depending on the size and composition of 
the gel and the number of samples 
1Kb(+) (Invitrogen) size ladder was used to identify the size of the separated 
fragments. 
 
Sequencing 
 
Purified plasmids and PCR product were sequenced using the services of 
ACTG Inc. (Wheeling, Illinois) and following the company guidelines for sample 
preparation and concentration. 
Sequencing results were analyzed using Sequencher® software package 
(Genes Codes Corporation). 
 
Protein purification 
 
Cells were harvested by centrifugation, suspended in 40 ml of sonication 
buffer (Ni-column buffer A) and lysed by sonication using a Bransonic Sonifier at 
approximately 50% maximal output for 10 minutes on ice.  The lysates were cleared 
by centrifugation at 14,000-x g for 25 minutes.  The supernatant fluid was filtered 
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through a 0.22 µm filter and then loaded at a flow rate of 1 ml/min onto a 5 ml His-
Trap Ni-affinity column (Amersham Biosciences) equilibrated with Ni-column buffer 
A.  The eluted volume was monitored for the presence of proteins by UV-
spectrophotometry at 280 nm. 
Weakly bound or unbound proteins were removed by washing the column 
with the same buffer containing 50 mM imidazole (Ni-column buffer B at 20% 
proportion) until the absorbance at 280 nm returned to baseline.  The imidazole 
concentration was then increased to 250 mM to elute the protein of interest.  
Protein-containing fractions were pooled; dialyzed into DEAE-column buffer A; and 
then loaded onto a DEAE His-Trap column equilibrated with the same buffer 
running at 3.0 ml/min.  A linear gradient of 20 column volumes with DEAE-column 
buffer B as second buffer was used to elute the protein.  The eluted protein was 
dialyzed and stored in DEAE-column buffer A. 
 
Protein concentration 
 
The purified protein was concentrated using a Millipore 30,000 or 100,000-
molecular-weight-cutoff spin filter to > 10 mg/ml and stored at 4°C. 
 
Protein quantification 
 
For all procedures, protein concentration was determined by the Bradford 
method[101] using the Bio-Rad protein assay dye reagent with bovine serum 
albumin (BSA) as standard. 
 
Protein electrophoresis (SDS-PAGE) 
 
SDS-PAGE was used to separate the proteins of each preparation according 
to their molecular weight.  0.7-20ng of total protein were mixed 1:1 with Laemmli 
sample buffer (Bio-Rad) prepared according to the manufacturer’s instructions.  
Samples were then incubated in boiling water for about 10 minutes.  After that, 
samples were loaded onto the appropriate Ready Gel® or Criterion® precast gels 
(Bio-Rad) depending on the number of samples.  Electrophoresis was performed at 
120 volts using a PowerPac® power supply (Bio-Rad) for 1 hour and stained with 
Bio-Safe Coomasie Stain (Bio-Rad) according to manufacturer instructions. 
 
Colorimetric transcarbamylase activity assay 
 
Transcarbamylase activity was measured by using a modification of the 
colorimetric assay to detect an ureido group[64], except that AORn or SOrn replaced 
ornithine. All assays were performed in triplicates at 25°C.  The reaction was 
initiated with CP, allowed to proceed for 5 minutes and then quenched by the 
addition of 1 ml of antipyrine:butadione monoxime color reagent.  Fresh color 
reagent (1 part of 0.8% 2,3-butadione monoxime [wt/vol] dissolved in 5% acetic acid 
[vol/vol] mixed with 2 parts of 0.5% antipyrine dissolved in 9.05 M H2SO4) kept on 
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ice was used to terminate the reactions.  The assay is very sensitive to light; 
therefore, samples were then wrapped in foil and placed on a shaker, also protected 
from light, overnight at approximately 100 rpm.  To develop the final color, the 
samples were uncovered and incubated for 20 minutes at 42°C with illumination. 
The chromophore in the assay produced by commercially synthesized and purified 
ACit has an absorption coeffient that was 93.4% of that of Cit. 
Standard curves of known amounts of ACit were used for quantification of 
the enzymatic activity.  
Initial reaction mixtures to determine the function of the ArgF’ protein from 
Xanthomonas campestris contained 4 mM of AOrn and 4.8 mM CP in 1 ml of a 50 
mM Tris-HCl, pH 8.3 buffer. 
 
Colorimetric NAGS activity assay 
 
ArgB kinase activity was measured using a colorimetric assay described by 
Haas and Leisinger [84], to detect acetylglutamate kinase activity but substituting 
N-acetyl-L-glutamate (NAG) by N-succinyl-L-glutamate (NSG). Succinylglutamyl 
hydroxamate is formed from NSG-phosphate in the presence of ammonium 
hydroxamate.  The 500 µl incubation volume contained 100 mM MES buffer pH 6.0, 
40 mM ATP, 40 mM NSG, 400 mM NH2OH.HCl, 50 mM MgCl2 and 2.5 µg of 
protein. The reaction mixture was incubated for 10 min at 37°C and terminated by 
the addition of 500 µl of 5%(w/v) ferric chloride solution (FeCl3·6H2O) containing 
8%(w/v) trichloroacetic acid and 0.3 M HCl. The absorbance of the hydroxamate–
Fe3+ complex was measured at 540 nm. 
 
Saturation curves 
 
Activity determinations for the kinetic studies were performed by measuring 
the amount of ACit or SCit  formed at 25°C in a 1 ml reaction mixture in the 
presence of 0.2 µg of enzyme as described before.  The rate of catalysis of the 
enzymes was investigated using saturation curves for each of the substrates of the 
enzyme. 
XcAOTCase saturation curves:  In the AOrn saturation curves, CP was kept 
constant at a concentration of 4.8 mM, while the AOrn concentration was varied 
from 0 to 5 mM, the reaction was started by adding CP to the mixture.  Km and Vmax 
were determined from the plots of v vs. [AOrn], and non-linear fitting using the 
Michaelis-Menten equation for enzyme kinetics.  The same procedure was used to 
obtain the kinetics parameters of the enzyme for CP, in this case AOrn 
concentration was kept constant at 5 mM and that of CP was varied from 0 to 1 mM, 
and the reaction was initiated by adding AOrn to the mixture. 
BfSOTCase curves were obtained as the XcAOTCase saturation curves but 
SOrn was the substrate and SCit was used as standard reference. 
In the case of BfArgB the substrates were ATP or NSG and the saturation 
curves were obtained as descrived above. 
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Liquid chromatography mass spectrometry (LC-MS) 
 
Samples were treated with equal volumes of 30% Trichloroacetic acid (TCA) 
and centrifuged for 10 minutes at 14,000-x g to remove the precipitated protein. 10-
20µl of the reaction solution were analyzed using an Agilent LC-MS 1100 (Hewlett-
Packard) and conditions described previously by Caldovic et al.[102], briefly: 
compounds are separated by reverse-phase HPLC (Hewlett-Packard 1100).  The 
mobile phase consisted of 92% solvent A (1ml of trifluoroacetic acid in 1L of water) 
and 8% solvent B (1ml trifluoroacetic acid in 1L of 1:9 water:acetonitrile). The flow 
rate was 0.6ml/min.  Compounds were quantified using the area under the selected 
ion peak extracted after mass spectrometry analysis (1100 MSD, Hewlett-Packard). 
 
Nuclear magnetic resonance (NMR) 
 
Enzymatically synthesized ACit and SCit were analyzed using NMR as 
described in this section. 
Three milligrams of purified ArgF’ protein were transferred into buffer 
containing 50 mM sodium phosphate and 100 mM NaCl, pH 7.4, using three rounds 
of centrifugation with a Millipore Microcon YM30 spin filter according to 
manufacturer’s directions.  A total of 15.4 µg of the buffer-exchanged protein were 
reacted with 4.8 mM CP and 5 mM AOrn or SOrn dissolved in the same buffer at pH 
8.3.  After overnight incubation at 25°C, the enzyme was removed by centrifugation 
through a Millipore Microcon YM30 filter. Two micrograms of CP, AOrn, SOrn and 
chemically synthesized ACit or SCit were dissolved in the phosphate buffer used for 
the assay for use as standards.  The enzymatically and chemically synthesized ACit, 
SCit, SOrn, CP and AOrn were subjected to three rounds of lyophilization and 
resuspension in D2O prior to analysis to suppress the residual proton (1H) water 
signals. 
One-dimensional 1H NMR was performed using a Bruker NMR spectrometer 
(DRX-500; Bruker, Billerica, MA) equipped with a tri-nuclei inverse probe with a Z 
gradient at 500.13 MHz at 25°C ± 0.5°C.  Chemical shifts were calibrated with an 
external reference of 3-trimethylsilyl propanesulfonic acid, sodium salt, set as 0 ppm 
at the same temperature.  NMR line assignments were based on the similarities 
(within 2 Hz) in the one-dimensional 1H chemical shifts between the model 
compounds (chemically synthesized ACit, SCit, SOrn and AOrn) and the 
enzymatically-synthesized product at the same pH, ionic strength and temperature.  
Two-dimensional NMR-correlated spectroscopy (COSY) with solvent presaturation 
was carried out using a Bruker NMR spectrometer (AV-400) fitted with a broadband 
inverse probe with a Z gradient at 400.13 MHz at 25°C.  The relaxation delay was 
2.5 s.  The two-dimensional matrix for COSY was 2000 by 512, yielding digital-free 
induction decay resolutions of 2.1 Hz and 8.6 Hz, respectively.  Linear prediction 
was used for processing of the data, giving a matrix size of 2000 by 1000. 
NMR analyses were performed by Yui-Fai Lam at the University of Maryland 
NMR and EPR Analytical Facility. 
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Ninhydrin reactivity assay 
 
The product of the reaction catalyzed by X. campestris ArgF’ was analyzed 
using the ninhydrin reactivity assay.   
Ninhydrin preferentially reacts with free amino groups to produce a 
detectable product with a maximal absorbance at 570 nm. 10 µg of purified X. 
campestris ArgF were incubated for 5 minutes at 25°C with 5 mM AOrn and 4.8 mM 
CP in a 1-ml volume.  100 µl of the reaction mixture were removed and diluted to 
500 µl with water, and the reaction was terminated with 500 µl of 7% sulfosalicylic 
acid.  900 µl of color reagent were added to the remainder to terminate the reaction 
and for quantification of the product by the colorimetric assay.  The sulfosalicylic 
acid-treated sample was analyzed using a Beckman amino acid analyzer according 
to the manufacturer’s instructions.  Separate injections of AOrn and CP plus enzyme 
at concentrations identical to those used in the enzyme assay as well as Cit and ACit 
were used as controls and standards. 
Amino acid analyses were performed by Crystal Stroud at the Clinical Lab at 
Children’s National Medical Center, Washington DC. 
 
Synthesis of compounds 
 
Acetyl Citrulline synthesis 
 
L-Citrulline (0.1mmols) was dissolved in 1ml of water and incubated with 
0.2mmols of acetic anhydride for 2 hours at room temperature. After incubation the 
solution was neutralized by the addition of 1% (w/v) KOH to pH 7. Purity was 
assessed by LC-MS. 
 
PALAO synthesis 
 
PALO (5.1mg or 0.02mmols) was dissolved in 200µl of water and incubated 
with 0.2mmols of acetic anhydride for 2 hours at room temperature with constant 
stirring. After incubation the solution was neutralized with 2ml of 1% (w/v) KOH. 
Sample purity was assessed by LC-MS. 
 
N-Succinyl-L-Orn synthesis 
 
t-Boc-Ornithine (1.076mmols) was dissolved in 5ml of water. pH was kept 
neutral with 40% (w/v) NaOH while 1.076mmols of succinic anhydride was added. 
Once the pH was neutral the reaction was considered finalized. The Boc group was 
removed by acidification of the sample with trifluoroacetic acid and then 
neutralized. The purity of the sample was assessed by LC-MS. 
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PALSO synthesis 
 
PALO (5.1mg or 0.02mmols) was dissolved in 200µl of water. pH was kept 
neutral with 40% (w/v) NaOH while 0.2mmols of succinic anhydride were added at 
room temperature with constant stirring. Once the pH stabilized the reaction was 
considered finalized and the purity of the sample was assessed by LC-MS. 
 
N-Succinyl-L-Glutamate (NSG) and N-Succinyl-L-Aspartate 
(NSA) synthesis 
 
Glutamic acid (monosodium salt, 0.025 mols) or aspartic acid (0.025 mols) 
was dissolved in 25ml of water.  NaOH was added until fully dissolved.  The solution 
was then incubated with 0.025 moles of succinic anhydride for 24 hours at around 
50°C with constant stirring.  Purity was assessed by LC-MS as described in Section 
2.17.  Quantification of the product formation was obtained by measuring the 
depletion of peaks corresponding to unreacted glutamic acid (148 m/z) using known 
concentrations of glutamic acid as a standard curve by LC-MS. 
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Introducción 
 
 
El aminoácido L-arginina es un componente esencial de todos los organismos 
vivos. Su importancia reside en la gran variedad de funciones que la arginina, así 
como los intermediarios involucrados en su síntesis, tienen en las células, como 
muestra la Figura 1. 
 
 
 
Figura 1: Representación esquemática de las principales 
rutas metabólicas interconectadas con la ruta de 
biosíntesis de la arginina. Sólo se muestran los intermediarios 
más significativos que interconectan las rutas. 
 
Entre las principales funciones de la arginina en la célula se encuentran: 
 
• forma parte de la composición aminoacídica de muchas proteínas 
• precursor de los siguientes compuestos que almacenan energía 
o fosfoarginina, usado en la contracción muscular en 
invertebrados y 
o fosfocreatina, que se encuentra almacenado en el músculo y el 
cerebro en vertebrados 
• metabolito intermediario en el ciclo de la urea 
• precursor de las moléculas de señalización: oxido nítrico, agmatina y 
glutamato en mamíferos 
• y es usada como compuesto de almacenamiento de nitrógeno en 
plantas y cianobacterias 
En numerosos procariotas, hongos y plantas la síntesis de novo de la arginina 
ocurre a partir de glutamato en ocho pasos enzimáticos como se describe en la 
Figura 2. La acetilación de los precursores iniciales en la biosíntesis de la arginina 
permite la separación de ésta ruta metabólica de la biosíntesis de la prolina. 
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Figura 2: Esquema representativo de la ruta de biosíntesis de novo de la 
arginina a partir de L-glutamato.  
 
El primer paso en la ruta de biosíntesis de la arginina es la acetilación del 
grupo α-amino del glutamato. Ésta reacción puede ser catalizada por varias enzimas 
en los procariotas: 
(i) NAGS clásica, inicialmente caracterizada en E. coli y presente en 
los animales capaces de sintetizar arginina de novo. 
(ii) OAT bifuncional, capaz de utilizar AcCoA o AOrn para acetilar el 
glutamato. Ésta enzima se encuentra en los reinos Bacteria, 
Archaea y Eukaryotes. 
(iii) NAGS truncada, perteneciente a la familia de las GNAT, ya sea de 
manera independiente o bien fusionada con la argininosuccinato 
liasa. 
En el caso de los organismos que utilizan la acetilornitina deacetilasa, la 
acetilación del glutamato es, aparentemente, el punto de control en el flujo de 
intermediarios acetilados que conducen a la ornitina. Se dice de ellos que poseen una 
ruta de biosíntesis de la arginina linear. La actividad de la NAGS clásica está 
controlada por un mecanismo de inhibición por retroalimentación ejercido por el 
producto final de la ruta: arginina. Lo mismo ocurre en el caso de los organismos que 
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utilizan la NAGS truncada. El mecanismo por el cual la actividad de las OATs, tanto 
mono como bifuncionales es controlada por la arginina no está demostrado, sin 
embargo éstas enzimas son inhibidas competitivamente por la ornitina, controlando 
así su actividad. 
El segundo paso en la ruta de biosíntesis de la arginina es la fosforilación del 
N-acetilglutamato catalizada por la enzima NAGK (Figura 2). Al contrario que 
ocurre con la acetilación del glutamato, la fosforilación del N-acetilglutamato sólo es 
catalizada por NAGK, indicando la importancia que esta enzima tiene en el control 
de la ruta biosintética de la arginina. 
En organismos tales como E. coli y Micobacterium lacticum entre otros, 
NAGK es insensible a la inhibición por arginina y por lo tanto la reacción catalizada 
por NAGS es la más relevante en el control de la ruta. Sin embargo en aquellos 
organismos en los que la acetilación del glutamato ocurre a partir de la AOrn, y por 
lo tanto poseen una ruta denominada cíclica, la reacción catalizada por NAGK es 
crucial en el control del flujo de metabolitos en la ruta de biosíntesis de la arginina. 
De todos los pasos implicados en la ruta biosintética de la arginina, la 
acetilación de glutamato y su fosforilación han sido los más estudiados dada su 
importancia en la regulación del flujo de metabolitos en ésta ruta. 
Sin embargo, la transcarbamilación de la ornitina constituye otra reacción 
crucial en la ruta de biosíntesis y biodegradación de la arginina como muestra la 
Figura 3. 
 
 
Figura 3: Representación esquemática de la ruta 
de degradación de la arginina por la arginina 
deiminasa. 
 
En la ruta de biosíntesis, la ornitina es transcarbamilada por la enzima 
ornitina transcarbamilasa (OTC, EC 3.2.1.1). OTC pertenece a la familia de las 
transcarbamilasas cuyos miembros son identificados fácilmente basándose 
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únicamente en las homologías a nivel de las secuencias peptídicas que presentan 
todos ellos. Todos comparten el motivo de unión al fosfato de carbamilo, que es un 
sustrato común a todos los miembros de la familia. Los miembros más estudiados de 
la familia de las transcarbamilasas son OTC y aspartato transcarbamilasa (ATC). 
Los estudios sobre la evolución de las transcarbamilasas realizados por 
Labedan y colaboradores revelaron la presencia de ésta actividad en el último 
ancestro común universal (Last Universal Common Ancestor, LUCA), destacando la 
importancia de la reacciones catalizadas por las transcarbamilasas. 
Más recientemente, Naumoff y colaboradores, entre otros, han puesto de 
manifiesto cuan inexacta es la asignación de ciertas actividades enzimáticas 
basándose exclusivamente en las similitudes entre nuevas secuencias genómicas y 
las estudiadas bioquímicamente previamente. El trabajo de Naumoff y colaboradores 
se centró en el caso particular de las transcarbamilasas de putrescina (PTC), 
miembros de la familia de las transcarbamilasas incorrectamente anotadas como 
OTC. La topología del árbol evolutivo generado por Naumoff y colaboradores usando 
las 245 secuencias disponibles en el momento (Figura 4) no difiere de la del árbol 
presentado por Labedan y colaboradores anteriormente.  En su análisis, Naumoff y 
colaboradores introdujeron dos nuevos grupos de transcarbamilasas (PTC y 
transcarbamilasas de función desconocida o UTC). El grupo de las UTC está formado 
por las transcarbamilasas anotadas como OTCasas pero que carecen de la capacidad 
de usar la ornitina como sustrato, como es el caso de la enzima, potencialmente 
transcarbamilasa, presente en el organismo Bacteroides fragilis. 
 
 
Figura 4: Esquema del árbol evolutivo de las transcarbamilasas. Adaptado de Naumoff et al. 
2004. 
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El Dr. Malamy, usando mutagenesis mediada por transposon, demostró que 
en B. fragilis el gen que codifica para la posible ornitina transcarbamilasa está 
directamente involucrado en la biosíntesis de la arginina dado que cuando dicho gen 
no estaba presente en el genoma, el organismo se volvía auxotrofo para la arginina. 
El gen BfargF´ fue clonado y la proteína purificada y cristalizada por el Dr. 
Shi (Figura 5). La estructura tridimensional de la enzima presenta grandes 
similitudes con las estructuras de OTC y ATC, desafortunadamente la actividad de 
esta enzima no pudo ser identificada dado que no catalizaba la transcarbamilación 
de la ornitina. 
 
Figura 5: Representación de la estructura tridimensional del 
monómero the proteína similar a una transcarbamilasa presente en 
B. fragilis .  
 
Usando como referencia la secuencia aminoacídica de la proteína de B. 
fragilis se pudieron identificar proteínas similares a ésta en los genomas de varios 
organismos entre los que se encuentran Xylella fastidiosa, Cytophaga hutchinsonii, 
Xanthomonas campestris, Prevotella ruminicola y Tannerella forsythus. Todas estas 
proteínas identificadas compartían con la de B. fragilis la ausencia del motivo de 
unión a ornitina (SMG), presente en todas las OTCasas. Asímismo, ninguno de los 
genes identificados en estos organismos pudo complementar los mutantes de E. coli 
(argF-, argI-) que carecen de OTCasa. 
La primera actividad que se descubrió de entre las anteriormente 
mencionadas UTC fue la de X. campestris ArgF´. Dr. Morizono descubrió que la 
actividad de XcArgF´ era la de una nueva transcarbamilasa: acetilornitina 
transcarbamilasa (AOTCasa). 
La presente tesis se centra en la caracterización bioquímica de la actividad de 
la enzima XcArgF´ así como en la identificación y caracterización de la actividad 
catalítica de la enzima BfArgF´ y en las implicaciones que la presencia de estas dos 
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enzimas tienen para la ruta de biosíntesis de la arginina en los organismos que las 
poseen. 
A continuación presento el sumario de los resultados obtenidos durante la 
realización del presente proyecto de tesis: “Discovery of novel pathways of microbial 
arginine biosynthesis”. 
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Objetivos de la presente tesis doctoral 
 
1.- Caracterización bioquímica de la enzima ArgF’ de 
Xanthomonas campestris. 
 
• Se investigará la especificidad de la reacción catalizada por XcArgF’. 
• Los productos de la reacción catalizada por XcArgF’ serán 
identificados. 
• Los parámetros cinéticos que caracterizan la reacción catalizada 
por XcArgF’ será determinados. 
• La cinética de la reacción catalizada por XcArgF’ será estudiada en 
presencia de distintos inhibidores específicos. 
 
2.- Diseño y síntesis de posibles sustratos así como de 
posibles compuestos inhibidores. 
 
• Se identificarán los posibles sustratos de la enzima ArgF’ de B. 
fragilis a partir de la estructura cuaternaria de la proteína. Los 
posibles sustratos de dicha enzima serán sintetizados así como los 
posibles sustratos de algunas de las otras enzimas implicadas en la 
biosíntesis de novo de la arginina en estos organismos. 
• Así mismo se sintetizarán los compuestos con posible acción 
inhibitoria basándonos en la especificidad de la actividad 
enzimática de las proteínas ArgF’ de X. campestris y B. fragilis. 
 
3.- Se identificará la actividad de la enzima codificada por 
el gen argF’ en B. fragilis. Dicha actividad será parcialmente 
caracterizada. 
 
• La actividad enzimática de la proteína ArgF’ de B. fragilis será 
identificada. 
• La cinética de la reacción catalizada por la enzima ArgF’ de B. 
fragilis será parcialmente caracterizada. 
 
4.- Se determinarán las implicaciones que la presencia de 
estas transcarbamilasas tienen en la ruta metabólica de la 
biosíntesis de novo de la arginina en los organismos que las 
poseen. 
 
• Se investigará el curso lógico de los metabolitos intermediarios en 
la biosíntesis de la arginina en X. campestris. 
• Se investigarán los pasos iniciales de la ruta biosintética de la 
arginina en B. fragilis que conducen al sustrato de la enzima ArgF’ 
en éste organismo. 

   Resumen en español 
151 
Capítulo 2: “Functional characterization of a novel type of 
transcarbmylase that uses acetylornithine, identified in 
Xanthomonas campestris pv campestris” 
 
Xanthomonas es un género que incluye varios patógenos de plantas. X. 
campestris pv campestris es una bacteria Gram-negativa que ataca a una gran 
variedad de crucíferas importantes para la economía. Entre las especies de 
crucíferas que X. campestris pv campestris es capaz de infectar se encuentran 
Brassica y Arabidopsis causando la enfermedad de la raíz negra. 
Prácticamente todos los genes involucrados en la biosíntesis de la arginina 
han sido identificados en X. campestris y X. axonopodis en base a las homologías que 
las secuencias de dichos genes presentan con los de otros organismos previamente 
secuenciados. No obstante, la secuencia de los genes que codifican para la posible 
OTCasa en estos organismos (argF’), son significativamente diferentes de la 
considerada secuencia canónica para ésta enzima. 
Al comienzo de este proyecto se había identificado la posible actividad de 
éstas enzimas como la de un nuevo miembro de las transcarbamilasas: N-
acetilornitina transcarbamilasa (AOTCasa). 
En este capítulo se presentan pruebas concluyentes demostrando que la 
actividad catalizada por la enzima XcArgF´ es la de una acetilornitina 
transcarbamilasa (AOTCasa) mediante la identificación tanto de los sustratos como 
de los productos de la reacción. Dichas pruebas fueron obtenidas por diferentes 
métodos entre los que se incluyen:  
• La capacidad del producto de la reacción para reaccionar con la 
ninhidrina (Apartado 2.2.1 de la tesis) 
• Análisis por LC-MS y NMR del producto de la reacción (Apartado 2.2.2 
de la tesis) 
La especificidad de la reacción catalizada por la XcAOTCasa ha sido 
demostrada indicando que acetilornitina es el único compuesto que junto con 
carbamilfosfato puede ser transcarbamilado para formar acetilcitrulina (Figura 6). 
 
 
Figura 6: Comparación de la habilidad de diferentes ArgF’ para utilizar ornitina o 
acetilornitina como sustrato. 
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Asimismo se han optimizado las condiciones para el ensayo de esta nueva 
actividad AOTCasa (Apartado 2.3.3 de la tesis). 
Los parámetros cinéticos (Km y Vmax) han sido determinados para ambos 
sustratos (AOrn y CP, Tabla 1). 
 
Tabla 1: Resumen de los parámetros cinéticos calculados para 
ambos sustratos de la reacción catalizada por XcArgF’. 
 
Substrate Km (mM) Vmax (µmols/min*µg) 
CP 0.01 ± 0.0007 50.68 ± 0.48 
AOrn 1.05 ± 0.23 65.05 ± 4.77 
 
Al contrario que ocurre con otros miembros de la familia de las 
transcarbamilasas, XcAOTCasa no está sujeta a inhibición por el sustrato de la 
reacción (AOrn), incluso a concentraciones tan elevadas como 50mM (Figura 7).  
 
 
Figura 7: Estudio de la inhibición por el sustrato AOrn de la 
actividad de la XcAOTCasa. 
 
Estos resultados parecen indicar que la reacción catalizada por XcAOTCasa no 
es crucial en el control de la ruta biosintética de la arginina, sin embargo el echo de 
que la ausencia de este gen confiera auxotrofía para la arginina hace resaltar su 
importancia en la mencionada ruta de biosíntesis. 
Asimismo en este capítulo se demuestra que la acetilación del grupo alfa-
amino no sólo es necesaria para el reconocimiento del sustrato sino que también es 
un requerimiento para los inhibidores, como muestran los resultados obtenidos en 
los estudios de inhibición por norvalina y acetilnorvalina (apartado 2.4.2 de la tesis), 
así como en los estudios con Nδ-fosfoacetil-L-ornitina (PALO) y Nδ-fosfoacetil-L-
acetilornitina (PALAO), Figura 8 (apartado 2.4.3 de la tesis). 
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Figura 8: Estudios de inhibición de la actividad de XcAOTCasa por 
PALO y PALAO (sintetizado químicamente y usado sin posterior 
purificación). 
 
El descubrimiento de ésta nueva actividad enzimática (AOTCasa), implica 
que el producto de la reaccíon catalizada por XcArgF’ (acetilcitrulina) ha de continuar 
la ruta metabólica para sintetizar arginina. De ser cierto la siguiente enzima de la 
ruta debería ser capaz de deacetilar la acetilcitrullina. 
La capacidad de la enzima ArgE de X. campestris para deacetilar 
acetilcitrulina y acetilornitina fue estudiada (apartado 2.5 de la tesis) mediante el 
uso de un analizador de aminoácidos Figura 9. 
 
 
Figura 9: Estudio de la capacidad para deacetilar acetilcitrulina y 
acetilornitina de XcArgE. 
 
Estos estudios han demostrado que la ruta de biosíntesis de novo de la 
arginina en los organismos que poseen una AOTCasa en lugar de una OTCasa 
difiere de la hasta ahora considerada canónica (Figura 2). 
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Basándonos en los resultados expuestos en este capítulo de la presente tesis 
proponemos la siguiente (Figura 10) ruta de biosíntesis de novo de la arginina en los 
organismos dotados de AOTCasa: 
 
 
Figura 10: Representación esquemática de la ruta 
propuesta para la biosítesis de novo  de la arginina 
en organismos dotados de AOTCasa. 
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Capítulo 3: “Demonstration that a structurally obvious trans 
carbamylase from Bacteroides fragilis ,  of previously 
unknown activity catalyzes the transcarbamylation of 
succinylornithine. Funtional characterization of this 
transcarbamylase” 
 
En este capitulo se presentan los resultados que prueban que la actividad 
enzimática de la proteína codificada por el gen argF´ de B. fragilis es la de una 
succinilornitina transcarbamilasa (SOTCasa). 
Para ello se han identificado los posibles sustratos de la enzima basándonos 
en la información obtenida de la estructura cristalográfica de la proteína (apartado 
3.2 de la tesis) y se han sintetizado químicamente dichos sustratos (apartado 3.3 de 
la tesis). 
El primer compuesto sintetizado y ensayado fue la succinilornitina (Figura 
11). 
 
 
Figura 11: Primer ensayo para elucidar la naturaleza del segundo 
sustrato de la proteína BfArgF’. 
 
Aparentemente la succinilornitina podría ser el sustrato de la enzima BfArgF’. 
Los análisis por resonacia magnética nuclear (NMR) y cromatografía liquida 
acoplada a un espectrómetro de masas (LC-MS) confirmaron que el producto de la 
reacción catalizada por BfSOTCasa en presencia de carbamilfosfato y succinilornitina 
es ls succinilcitrullina (apartado 3.4 de la tesis). 
Asimismo se presentan los resultados de la caracterización inicial de la 
enzima BfSOTCasa y se han determinado los parámetros cinéticos para ambos 
sustratos de la reacción (Tabla 2). 
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Tabla 2: Resumen de los parámetros cinéticos calculados 
para ambos sustratos de la reacción catalizada por BfArgF’. 
 SOrn CP 
Km (mM) 12.5 ± 1.5 0.025 ± 0.003 
Vmax (µmol min-1mg-1) 370.6 ± 32.6 141.7 ± 3 
Ksi (mM) 20.4 ± 3.3 n/a 
 
Al contrario que la XcAOTCasa, BfSOTCasa muestra inhibición por el sustrato 
(Figura 12) aunque dicha inhibición es mucho menos pronunciada comparada con 
otros miembros de la familia de las transcarbamilasas. 
 
 
Figura 12: Curva de saturación por succinilornitina de la BfSOTCasa. 
 
Al igual que ocurría con XcAOTCasa, la BfSOTCasa requiere la presencia del 
grupo succinilo unido al extremo alfa-amino tanto para el reconocimiento del 
sustrato (succinilornitina), como de los inhibidores. Ésto ha sido demostrado 
mediante estudios de inhibición por PALO y PALSO (apartado 3.7 de la tesis). 
El descubrimiento de la actividad SOTCasa de la enzima BfArgF´ unido al 
hecho de que la ausencia del gen argF´ en B. fragilis transforma este organismo en 
auxotrofo para la arginina indica que tanto succinilornitina y succinilcitrulina son 
intermediarios en la ruta de biosíntesis de la arginina en Bacteroidetes.  
Lo expuesto en el anterior párrafo implica que la parte inicial de la ruta de 
biosíntesis de la arginina en los organismos que poseen actividad SOTCasa 
transcurre a través de intermediarios succinilados y no acetilados como ocurre en el 
resto de los organismos descritos hasta el momento. 
Esta hipótesis es el punto de partida para los resultados expuestos en el 
siguiente capítulo. 
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Capítulo 4: “The use of N-succinyl-Lglutamate as substrate 
by ArgB of Bacteroides fragilis  supports the existence in this 
organism of an arginine biosynthetic pathway using N-
succinylated intermediates” 
 
En este capitulo se presentan los datos obtenidos en el estudio de la actividad 
enzimática de los dos primeros genes supuestamente involucrados en al biosíntesis 
de la arginina en B. fragilis (argX and argB, Figura 37 de la tesis). 
Ambos genes fueron clonados y las respectivas proteínas expresadas y 
purificadas, desafortunadamente la actividad enzimática de la proteína que 
hipotéticamente catalizaría el primer paso de la ruta, la succinilización del 
glutamato, no pudo ser cuantificada dado que la velocidad de la reacción espontánea 
era similar o superior a la de la reacción en presencia de la proteína codificada por el 
gen BfargX (Figura 13). Posiblemente la enzima necesite unas condiciones diferentes 
a las utilizadas para ser activa, como por ejemplo algún cofactor desconocido de 
momento, o la interacción con otras proteínas. 
 
 
Figura 13: Ensayos iniciales para la determinación de la actividad 
enzimática de la proteína codificada por el gen argX  de B. fragils .  
 
Por consiguiente los esfuerzos se concentraron en el ensayo de la posible 
actividad succinilglutamato quinasa de la proteína codificada por el gen argB de B. 
fragilis. Para poder ensayar esta actividad, el posible sustrato, succinilglutamato, 
fue sintetizado químicamente (apartado 4.4 de la tesis) y dada el alto porcentaje de 
conversión (Figura 41 de la tesis), usado sin posterior purificación en los ensayos 
enzimáticos. 
Como se muestra en la Figura 14, sólo el succinilglutamato puede ser 
utilizado como sustrato por la enzima BfArgB, lo cual demuestra que la biosíntesis de 
la arginina en B. fragilis transcurre a través de intermediarios succinilados y no 
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acetilados tal y como se había hipotetizado tras el descubrimiento de la actividad 
SOTCasa de BfArgF´ (apartado 4.5 de la tesis). 
 
 
Figura 14: Ensayo de la actividad N-succinilglutamato quinasa de la enzima BfArgB’. 
 
Usando el succinilglutamato sintetizado químicamente en el laboratorio, la 
actividad NSGK de BfArgB ha sido caracterizada y se han calculado los parámetros 
cinéticos (Apartado 4.6 de la tesis). Los parámetros cinéticos calculados para ambos 
sustratos de la reacción catalizada por BfArgB’ se resumen en la siguiente tabla 
(Tabla 3): 
Tabla 3: Resumen de los parámetros cinéticos 
calculados para ambos sustratos de la reacción 
catalizada por BfArgB’. 
 Km (mM) Vmax (µmols min-1 mg-1) 
NSG 7.3 ± 0.44 52.1 ± 1.4 
ATP 4.6 ± 0.25 54.7 ± 1.1 
 
Dado que la actividad de la primera enzima involucrada en la ruta de 
biosíntesis de novo de la arginina en B. fragilis no pudo ser ensayada, y por lo tanto 
el posible efecto controlador que la arginina pudiera ejercer sobre ella no se pudo 
determinar, se estudió la posibilidad de que BfArgB’ fuese el punto de control por 
retroalimentación negativa por la arginina en B. fragilis. 
Para ello se seleccionaron las siguientes condiciones para el ensayo 
basándonos en los parámetros cinéticos estimados para la BfArgB’ presentados en la 
anterior Tabla 3: 
• Condiciones de saturación: 40mM NSG y 40mM ATP 
• Condiciones cercanas a la Km: 10mM NSG y 6mM ATP 
• Condiciones de no saturación: 3.6mM NSG y 2.3mM ATP 
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En estas tres condiciones se estudiaron los efectos de varias concentraciones 
de arginina (entre 0 y 50mM). Los resultados obtenidos se muestran a continuación 
(Figura 15). 
 
 
Figura 15: Estudios de inhibición por arginina de la actividad enzimática de 
BfArgB’. 
 
Los resultados anteriormente expuestos, de los estudios de las actividades 
enzimáticas de las proteínas codificadas por los genes argB’ y argF’ nos permiten 
proponer la siguiente ruta metabólica para la biosíntesis de novo de la arginina en 
aquellos organismos dotados de SOTCasa en lugar de OTCasa o AOTCasa (Figura 
16): 
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Figura 16:Representación esquemática de la ruta 
metabólica de biosíntesis de arginina en 
organismos dotados con SOTCasa. 
 
 
 
Los resultados aquí resumidos se discuten en el Capítulo 5 de la tesis: 
“General discussion: Novel pathways of arginine 
biosynthesis.” 
 
 
 
A continuación se exponen las conclusiones obtenidas en el presente proyecto 
de tesis doctoral: 
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Conclusiones: 
 
1. La enzima AOTCasa de X. campestris pv campestris, caracterizada en 
esta tesis, cataliza la formación de un nuevo intermediario en la ruta de 
biosíntesis de la arginina en éste organismo, demostrando la existencia de 
una nueva ruta biosíntetica para la arginina en los organismos dotados de 
AOTCasa y no OTCasa.  
 
2. El gen argF’ de B. fragilis codifica una enzima con actividad N-
succinilornitina transcarbamilasa, otro nuevo miembro de la familia de las 
transcarbamilasas descubierto y descrito en este trabajo. 
 
3. El gen argB de B. fragilis codifica una nueva enzima en la ruta de 
biosíntesis de la arginina en éste microorganismo: N-succinilglutamato 
quinasa. 
 
4. La ruta de biosíntesis de la arginina en los microorganismos 
pertenecientes a la familia Bacteroidetes utiliza intermediarios 
succinilados en lugar de acetilados en la parte inicial de la ruta. 
 
5. La identificación y caracterización bioquímica de las transcarbamilasas de 
X. campestris y B. fragilis permite la identificación de otros genes 
similares, que no codifican para OTCasas, mediante el uso de métodos 
bioinformáticos. 
 
